Investigation of mass spectrometry approaches for aiding fragment-based drug discovery by Chan, Daniel
 
 
Investigation of mass spectrometry approaches for 





Daniel Shiu-Hin Chan 
Christ’s College 
University of Cambridge 
 





This dissertation is the result of my own work and includes nothing which is the outcome of work 
done in collaboration except as declared in the Preface and specified in the text. 
It is not substantially the same as any that I have submitted, or, is being concurrently submitted 
for a degree or diploma or other qualification at the University of Cambridge or any other 
University or similar institution except as declared in the Preface and specified in the text. I 
further state that no substantial part of my dissertation has already been submitted, or, is being 
concurrently submitted for any such degree, diploma or other qualification at the University of 
Cambridge or any other University or similar institution except as declared in the Preface and 
specified in the text. 
It does not exceed the prescribed word limit of 60,000 words, excluding the acknowledgements, 






Investigation of mass spectrometry approaches for aiding fragment-based drug discovery 
The use of mass spectrometry (MS)-based techniques to study protein structure dynamics is a 
relatively new field, with seminal developments such as nanoelectrospray ionization (nano-ESI) 
and traveling-wave ion mobility-mass spectrometry (TWIM-MS) MS being introduced only 
around twenty-five and fifteen years ago, respectively. However, MS methods have not yet found 
widespread use in drug discovery, particularly in fragment-based drug discovery (FBDD).  
The work described in this thesis focuses broadly on the application of MS techniques to aid FBDD 
campaigns. In Chapter 1, an overview of the strengths and limitations of MS in FBDD is presented. 
In Chapter 2, native MS and IM-MS were used to explore the effect of DMSO, a common solvent 
used in fragment screening on protein size and stability in the gas-phase. In Chapter 3, native MS 
was used to study the structure of the EthR-DNA complex, a tuberculosis target, and to screen 
fragments against a protein-DNA interaction for the first time. In Chapter 4, native MS and IM-
MS were used to study the structure and interactions of the antibacterial target CoaB and its 
ligands, including potential fragment inhibitors. In Chapter 5, native MS was used to study the 
protein-protein interaction between Aurora A, an anticancer target, and TPX-2, and its inhibition 
using chemical compounds. In Chapter 6, the overall conclusions and outlook of this project are 
presented. Overall, these studies demonstrate the utility of native MS approaches in providing 
complementary information to other biophysical techniques regarding protein structure and 
interactions in FBDD campaigns. 
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1.1. The search for new drug discovery approaches 
The late 1980’s to mid-1990’s ushered exciting advances in pharmaceutical research and 
development (R&D) around the world. Novel methods and techniques in molecular biology 
furnished high-throughput screening (HTS) platforms that were able to screen compounds at 
rates that were previously unheard of.[1-4] At the same time, new strategies in combinatorial 
chemistry promised to generate exponentially-higher numbers of compounds compared to what 
could be made by a typical bench chemist in a given period of time.[5-7] Unfortunately, after 
disappointing results with the new methodology, people came to the realization that the 
chemical universe was too vast to be empirically explored systematically. Moreover, early 
combinatorial libraries often sacrificed diversity in order to accommodate facile reaction and 
purification methodologies, resulting in the generation of libraries of compounds that lacked 
structural complexity. 
Today, HTS is now seldom conducted on purely combinatorial, unfocused compound databases. 
Instead, both industry and academic researchers have devised a number of new strategies over 
the past few decades to create “privileged” chemical libraries that aim to sample a more 
pharmacologically applicable space within the colossal universe of feasible molecular structures. 
For example, the strategy of drug repurposing or drug repositioning seeks to accelerate drug 
discovery by restricting the screening set to databases of approved drugs.[8-10] In diversity-
oriented synthesis (DIOS), a collection of diverse central scaffolds are decorated with peripheral 
functional groups, producing small libraries of molecules for each central scaffold.[11-13] On the 
other hand, both biology-orientated synthesis (BIOS)[14-15] and the reemerging field of natural 
product-based drug discovery[16-17] seek to harness knowledge from Mother Nature to generate 




1.2. Fragment-based drug discovery (FBDD) 
Fragment-based drug discovery (FBDD) is another strategy that aims to increase the efficiency of 
early-stage drug discovery. FBDD broadly describes the identification of small molecules 
(“fragments”) possessing affinity typically in the 0.1 to 10 mM range and their subsequent 
elaboration into potent ligands.[18] The central thesis of fragment-based methods is that while 
smaller fragment molecules bind only weakly to the target site, they reveal high-quality 
interactions that can be exploited by assembly of the individual fragments into larger 
molecules.[19] Ever since Fesik and co-workers first demonstrated the application of FBDD against 
the FK506-binding protein over 20 years ago,[20] the technique has been successfully applied in 
both academic and industrial medicinal chemistry programmes against a variety of diverse 
targets.[21] The utility of FBDD has been further exemplified by the approval of vemurafenib 
(Zelboraf)[22] targeting the oncogenic kinase BRAF for the treatment of metastatic melanoma, 
and venetoclax (Venclexta) targeting the anti-apoptotic protein Bcl-2 for the treatment of chronic 
lymphocytic leukemia (CLL).[23] Very recently, ribociclib (Kisqali), an orally bioavailable, highly 
selective inhibitor of CDK4/6 developed by an Astex/Novartis collaboration, received approval 
from the United States Food and Drug Administration and the European Commission for the 
treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative 
(HR+/HER2-) advanced or metastatic breast cancer.[24] 
At its core, the fragment-based approach aims to tackle the challenge of the immense chemical 
space of potential drug molecules that has stymied classical combinatorial approaches. While 
Lipinski’s “rule-of-five” (molecular weight < 500 Da, calculated logP < 5, hydrogen bond donors < 
5 and hydrogen bond acceptors < 10)[25] aimed to narrow the universe of small molecules to those 
possessing drug-like characteristics, there still remains an estimated 1060–200 drug-like molecules 
of HTS size (300−500 Da).[26] In contrast, fragments typically obey a “rule-of-three”, with 
molecular weight < 300 Da, calculated logP of < 3, hydrogen bond donors < 3 and hydrogen bond 
acceptors < 3 (Figure 1.1).[27] As there are only about 107 possible molecules composed of up to 
11 atoms of C, N, O, and F that follow the rule-of-three,[28] a significantly larger percentage of the 
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chemical space can be sampled with a smaller fragment library (typically ca. 103 fragments) than 
with a much larger library of ca. 105–106 larger molecules in an HTS campaign. 
 
Figure 1.1 Comparison of potency of leads vs. molecular mass developed from conventional high-
throughput screening and fragment-based drug discovery approaches. Reproduced with permission from 
Scott et al.[18] 
A second fundamental advantage of fragment-based screening is that since the fragment hits are 
individually only weakly binding, they must form very high-quality interactions with the target to 
be detected. Thermodynamically, fragments identified as weakly-binding hits must possess high 
intrinsic binding enthalpy in order to overcome the entropic penalty of binding. Thus, fragments 
are very “atom-efficient” ligands with high ligand efficiency (LE) values, which is calculated as the 
binding energy per mole divided by the number of heavy atoms. Importantly, the minimal 
structural complexity of fragments allows them to effectively probe binding sites and to establish 
geometrically unencumbered, high-quality, and enthalpically-biased interactions, making them 
ideal starting points for further chemical elaboration.[18]  
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1.3. A biophysical cascade for FBDD 
A number of biophysical tools are available for the identification and characterization of weakly-
binding fragments. Due to the low binding affinities generally seen with fragments, the screening 
stage of FBDD requires the use of biophysical techniques significantly more sensitive than the 
methods utilized in HTS.[29] Differential scanning fluorimetry (DSF), also known as the thermal 
shift assay (TSA), is a low-cost and high-throughput technique that can rapidly screen fragments 
for validation. The principle of DSF is based upon measuring the changing fluorescence of an 
exogenous dye as the protein to which it is bound unfolds (or alternatively, the change of 
fluorescence has been attributed to the onset of aggregation).[30] Ligand binding usually stabilizes 
a protein, thereby increasing the melting temperature (Tm) of the protein and producing in a 
positive thermal shift of typically ±0.5 to 2 °C for a weakly binding fragment. However, one 
drawback of DSF is that it is susceptible to false negatives. Many strong binders have been 
observed to cause insignificant thermal shifts, or even negative thermal shifts. 
One-dimensional (1D) ligand-observed 1H nuclear magnetic resonance (NMR) spectroscopy 
methods, such as saturation transfer difference (STD), water-ligand observed via gradient 
spectroscopy (WaterLOGSY) and Carr-Purcell-Meiboom-Gill (CPMG) techniques, are also 
commonly used for fragment screening.[31] When performed in the presence of known ligands, 
ligand-observed NMR experiments can also provide preliminary binding site information as well 
as relative affinity data. Moreover, fragments can be screened in cocktails to expedite the 
validation process, followed by singleton screening to confirm hits. 
More detailed structural information can be obtained using protein-observed two-dimensional 
(2D) NMR experiments, which analyze chemical shift perturbations (CSPs) of protein amide 
signals induced by the ligand.[32] Another method that is commonly utilized for the screening of 
fragment libraries is surface plasmon resonance (SPR).[33] The change of SPR signal when a 
solution of ligand is passed over proteins immobilized on the biosensor surface allows the 
determination of both kinetic and thermodynamic parameters of binding.  
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The fragment binding characterization stage involves determining the energetic and structural 
parameters of ligand binding. Isothermal titration calorimetry (ITC) can be used to determine the 
enthalpy (ΔH), entropy (ΔS), and Gibb’s free energy (ΔG) changes associated with binding, as well 
as the equilibrium dissociation constant (KD) and the binding stoichiometry (n).[34] Meanwhile, X-
ray crystallography provides detailed structural information on the fragment-target interaction, 
by confirming the binding location of the fragment and determining the orientation of the 
fragment within the binding site of the protein.[35-36] Although ITC and X-ray crystallography are 
traditionally considered to be relatively low-throughput methods, it is also possible to use them 
as preliminary screening techniques provided that sufficient automation is available.[34-35] In 
particular, high-throughput fragment screening using X-ray crystallography has been performed 
since 1999 by Astex, who pioneered this approach by integrating computational tools such as 
AutoSolve to efficiently interpret electron density maps for fragment binding, with robotic 
systems that are able to store and automatically manipulate protein crystals.[37] More recently 
(since 2015), the XChem beamline at the Diamond Light Source has also been available for 
fragment screening via X-ray crystallography. A comparison of commonly used fragment 
screening techniques is presented in Table 1.1. 
Table 1.1. A comparison of commonly used fragment screening techniques. 
Technique Principle Advantages Limitations 
DSF  Fragment increases 
stability of protein 
against unfolding 
High-throughput, low-
cost, easy to perform, 
low protein consumption 
Low information content, 
susceptibility to false 
positives and false negatives 
Ligand-
observed NMR 
Change in T2 
relaxation rate 




protein can be unlabeled, 
allows verification of 
protein and ligand purity 
Prone to false positives from 
aggregation, limited to 
fragments that transiently 
bind in the fast exchange 






Ligands induce CSPs 
of amide signals of 
protein 
Determination of ligand 
binding site and KD 
Low-throughput, requires 
large amounts of labeled 
protein, limitations on 
protein size 
SPR Change in refractive 
index at interface of 
an optical biosensor 
induced by ligand 
binding 
Medium-throughput, 
provides both kinetic and 
affinity data, low protein 
consumption 
Requires that protein be 
stable to immobilization on 
surface 
ITC Detection of heat 
change upon ligand 
titration 
Provides thermodynamic 
parameters of binding, 






Diffraction of X-rays 
by crystals of protein-
ligand complexes 
High-resolution 
structural detail of ligand 
binding mode 
Protein must form well-
diffracting crystals, high 
ligand concentration 




In a typical fragment screening “cascade”, the initial primary screening is performed using a high-
throughput and low-cost technique, such as DSF, to rapidly generate a shortlist of hits for further 
testing. The hits are then validated using a secondary screening technique, such as 1D NMR, 
which can additionally provide information on relative binding affinity and binding site 
information if conducted in competition mode. The most promising hits from the validation stage 
are then finally characterized using a combination of ITC and X-ray crystallography. An important 
benefit of this three-stage biophysical cascade is that the binding of the fragments is validated 
with a combination of orthogonal biophysical techniques, which enables confidence in using the 
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fragment hit for further lead optimization.[29] The validated fragment hits can then be 
synthetically elaborated into lead compounds by iterative cycles of synthesis, guided by a synergy 
of structural information, bioaffinity measurement, and rational chemical design (Figure 1.2).[18]  
 
Figure 1.2 Schematic representation of the general workflow of FBDD. Reproduced with permission from 
Scott et al.[18] 
1.4. Mass spectrometry (MS) methods for drug discovery 
While mass spectrometry (MS) is a well-established technique for characterizing biomolecular 
structure and interactions,[38-41] it has been less widely applied for drug discovery.[42-43] Only 
recently have MS approaches been utilized for FBDD.[44-46] MS-based methods have the 
important advantages of high sensitivity, low sample consumption and being label-free. The 
following sections provide an introduction to how MS-based methods can be used to elucidate 
protein-ligand interactions, with a view towards applications in drug discovery.  
1.4.1. Mechanism of electrospray ionization (ESI) 
The mechanism of electrospray ionization (ESI) is well-known.[40] Briefly, a potential difference is 
applied between the aperture of the mass spectrometer and a conducting capillary containing 
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the analyte solution, which causes the analyte solution to be dispersed into fine, charged droplets 
at the tip of the capillary. The droplets evaporate and shrink in size as they pass into the vacuum 
of the mass spectrometer. Droplet fission occurs when the droplet size reaches the Rayleigh limit, 
which is the point where the surface tension holding the droplets together is equal to the 
electrostatic repulsion between the charges on the surface. Successive rounds of evaporation 
and fission occur until the analyte ions are set free in the gaseous state. 
This technique was further refined by the introduction of a miniaturized version of the ESI process 
by Wilm and Mann in 1994.[47] Termed nanoflow-ESI (nanoESI), the use of much narrower spray 
apertures enhances the dispersion of the liquid into nanodroplets with a favorable surface-to-
volume ratio even under very mild combinations of applied voltage, pressure and temperature. 
Importantly, the lower flow rates afforded by nanoESI greatly reduces the consumption of 
protein material (as little as 1 μL of a 1 μM protein solution can suffice for a single experiment), 
which is a very important consideration when protein supplies are scarce and/or expensive. A 




Figure 1.3 A schematic representation of the nanoESI process. Reproduced with permission from 
Konijnenberg et al.[41] 
The precise mechanisms by which gaseous ions are formed from charged droplets are a source 
of active investigation. The three main mechanisms that have been proposed for explaining ion 
formation in ESI are the ion evaporation model (IEM), the charge residue model (CRM) and the 
chain ejection model (CEM) (Figure 1.4).[48] In the IEM, which is considered to be the primary 
mechanism by which low molecular-weight ions are generated, a charged analyte ion 
“evaporates” from the surface of a droplet as a result of internal repulsion (Figure 1.4a). A 
transient solvent bridge is thought to initially tether the departing ion to the parent droplet, until 
it eventually ruptures to release a small gas-phase cluster containing the analyte ion and a few 
solvent molecules. The solvent shell is subsequently lost as the cluster travels through the various 
stages of the mass spectrometer, allowing the free analyte ion to be detected. Globular protein 
ions are widely accepted to be generated via the CRM (Figure 1.4b). In this model, repeated 
fission of larger droplets occurs until the final droplets contain a single analyte ion each. As the 
final solvent shell disappears, the remaining charge of the droplet is transferred entirely to the 
analyte ion. It is important to note that in the initial stages, larger droplets can shed excess charge 
via the ejection of protons or other cations, which accounts for why proteins of different shapes 
and/or sizes can end up with different charge state distributions. Finally, unfolded or disordered 
proteins are thought to yield gaseous ions through the CEM (Figure 1.4c). The exposure of 
hydrophobic residues in unfolded or disordered proteins means that it is unfavorable for them 
to remain within the aqueous interior of the droplet. Thus, unfolded chains migrate to the droplet 
surface and become expelled into the gaseous environment. Stepwise ejection of the remaining 




Figure 1.4 Schematic representation of (a) ion evaporation model, (b) charge residue model and (c) chain 
ejection model for electrospray ionization. Reproduced with permission from Konermann et al.[48] 
1.4.2. Native MS 
Native MS, also known as native state MS or non-denaturating MS, aims to observe biomolecules 
and their complexes in as natural state as possible (i.e., with protein structures and interactions 
preserved) given the constraints of mass spectrometric detection in the gas phase.[55] Due to its 
advantages of low sample consumption and tolerance to salts and buffers, ESI, or more 
specifically nanoESI, is by far the most commonly used ionization technique for native MS. As ESI-
MS is a relatively soft ionization technique, the native conformation of biomolecules as well as 




Given that the ESI process produces analyte ions in the gas phase, how relevant are detected gas-
phase interactions to drug discovery? Enthalpic interactions, which are driven primarily by 
electrostatic or polar interactions, survive or are even strengthened upon transfer from solution 
to the gas phase.[56-57] In contrast, hydrophobic effect interactions are weakened and may not 
survive transfer into the gas phase. This implies that native MS has an inherent bias towards 
identifying ligands that bind predominantly via electrostatic interactions rather than through 
hydrophobic interactions, which is an advantage for drug discovery. Enthalpically-driven leads 
are associated with superior clinical outcomes, whereas leads optimized through entropic or 
hydrophobic interactions often have poorer prospects and suffer an increased probability of 
attrition.[58]  
Despite the fact that interactions that are important for protein folding in solution (such as 
hydrogen bonds with water and the hydrophobic effect) are lost in the gas phase, protein ions 
are able to retain their solution-like protein conformations during ESI because of kinetic 
trapping.[59] In other words, the detected protein conformation might not necessarily be the most 
thermodynamically stable conformation of the gaseous protein ion. However, these other 
conformations are inaccessible by the protein ion in the gas phase (where water and other 
protein refolding catalysts are absent), as the solution-like conformation that the protein ion 
initially adopts after electrospray is located in a local energy minimum that cannot be escaped 
from on the time scale of typical ESI-MS experiments. 
Additionally, and in contrast to structural techniques such as X-ray crystallography and NMR 
spectroscopy, ESI-MS also offers the capability to investigate the interactions that are inherent 
to a particular protein-ligand or protein-protein system in solvent-free or independent 
manner.[42] This is because the gas-phase complex is detected in an isolated environment that is 
free from the effects of buffers, solvent or other known or unknown chemical additives in the 
analyte solution. Coupled with the selectivity and specificity of mass spectrometry analysis, ESI-
MS provides a reproducible environment for reproducible studies on protein structure and 
interactions. However, one limitation is that there are limits to how well an isolated, gas-phase 
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system can mimic the real cellular environment where proteins constantly interacting with the 
surrounding water molecules and other chemical entities in an aqueous environment. 
Native MS has been widely applied to study the stoichiometry and interactions of 
macromolecular assemblies.[60-61] A natural extension of the concept is to use native MS to screen 
for protein-ligand interactions. Hits are readily detected with native MS because the presence of 
a bound fragment will cause the mass/charge (m/z) signal of the protein-ligand complex to be 
higher compared to the free protein. As an example, Figure 1.5a shows the native mass spectrum 
of carbonic anhydrase recorded in negative ion mode.[44] The narrow charge state envelope 
together with the low absolute charge of the ions (from 8– to 10–) indicates that the protein 
remained compacted in the gas phase. In the presence of a cocktail of fragments, shifts to higher 
m/z values are observed due to the formation of protein-ligand complexes (Figure 1.5b). These 
signals are readily deconvoluted because multiplying the m/z shift (Δm/z) and the charge state 
directly gives the molecular weight of the bound ligand. Additionally, evaluating the proportion 
of bound and unbound protein species allows determination of KD values.[62] It is important to 
note that in native MS, the voltages at various stages within the mass spectrometer should be 
minimized as far as possible in order to preserve non-covalent interactions, while still being high 
enough to maintain sufficient desolvation and ion transmission. This also has consequences for 
the resolution of the technique, as the ability to increase m/z resolution (narrower spectral 
peaks) by raising the accelerating voltages must be balanced against the possibility of disrupting 
non-covalent interactions, including both those that are responsible for maintaining the tertiary 
structure of proteins, as well as any quaternary protein-protein interactions or protein-ligand 
interactions. On the other hand, insufficient voltages lead to broader peak shapes due to adduct 
formation with water molecules and salt ions, which hampers the detection of protein-ligand 
binding particularly for small fragments. Besides voltage, gas pressures can also be used to 




Figure 1.5 Native mass spectra of carbonic anhydrase in the (a) absence and (b) presence of a fragment 
cocktail. The formation of protein-ligand complexes causes a shift (Δm/z) in the protein signals, with the 
magnitude of the m/z shift being equal to the m/z of the bound fragment. Reproduced with permission 
from Poulsen.[44] 
A number of studies applying native MS to fragment screening have been described in recent 
years. In 2012, Maple et al. provided one of the first demonstrations of automated fragment 
screening using native MS.[63] To increase throughput, experiments were performed with the 
Triversa NanoMate (Advion),[64-65] a microfluidic chip-based sample injection and liquid handling 
robot. The experimental setup was first validated using lysozyme as a model enzyme, which 
revealed good agreement between KD values for acetylglucosamine oligomers determined by 
native MS and those determined by ITC. Subsequently, the automated native MS screening 
platform was applied to screen a focused phenylpyrazole fragment library against Bcl-xL, an anti-
apoptotic protein that has been implicated in tumorigenesis.[66] Of the fragments screened, 84 
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out of 157 were revealed as hits (KD < 300 μM), and a subset of these were further subjected to 
validation using other biophysical techniques, including STD NMR, 2D NMR and ITC. 
Woods et al. recently described a fragment screening campaign against human carbonic 
anhydrase using native MS in conjunction with SPR and X-ray crystallography.[67] In the first stage 
of this study, a library of 720 fragments were screened against carbonic anhydrase by SPR, and 
the 7 hits that emerged were validated by native MS and X-ray crystallography. Subsequently, a 
focused library of 70 compounds selected based on structural similarity to the fragment hits from 
the first stage, were independently screened using both native MS and SPR.  The second stage 
revealed 37 hit compounds, 24 of which were detected as positive by both native MS and SPR, 
and there was agreement between the two techniques for 58 out of the 70 compounds in the 
library.  
In a recent study, Göth et al. applied native MS to four protein targets, 7,8-dihydro-8-oxoguanine 
triphosphatase (MTH1), lysine-specific demethylase 5B (KDM5B), bromodomain and PHD finger-
containing protein 1 (BRPF1), and E3 ubiquitin-protein ligase (UHRF1), and compared these 
results with those obtained with DSF.[68] For MTH1 and KDM5B, there was good overlap between 
native MS and DSF, with 16 out of 24 stabilizing fragments in DSF also showing as MS hits for 
MTH1, and 8 out of 9 for KDM5B. However, for BRPRF1 and UHRF1 the agreement between the 
two techniques was poor. For BRPRF1, none of the 21 tested fragments qualified as a native MS 
hit despite 11 of these showing thermal stabilization by DSF, while for UHRF1, the only native MS 
hit showed as a non-binder by DSF. Additionally, the researchers observed that the complicating 
issues of charge state distribution shifts and non-specific binding were largely protein-
dependent, highlighting the need to carefully assess the suitability of a protein target (e.g. in 
terms of size or ionization efficiency) before embarking on a fragment-based screening campaign 
using native MS.  
Fragments can also be screened as cocktails in native MS. Vu et al.[69] screened 331 natural 
product-like fragments against Plasmodium falciparum deoxyuridine 5′-triphosphate 
nucleotidohydrolase (PfdUTPase), a potential antimalarial target.[70] Fragments were assessed in 
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cocktails of eight compounds each, revealing securinine and 4-α-hydroxy-allosecurinine as hits. 
The two hits together with five other securinine compounds were subsequently evaluated for 
their ability to inhibit PfdUTPase activity as well as block P. falciparum replication. There was 
good correlation between binding affinities determined by native MS and inhibition of P. 
falciparum growth, although surprisingly, the molecules promoted rather than suppressed 
PfdUTPase activity. In a later study,[71] the same group of researchers applied native MS to screen 
659 natural product-like fragments against P. falciparum Rab11a, a Rab GTPase that regulates 
parasite replication.[72] Using a similar cocktail method as before, 11 fragments emerged as hits 
against PfRab11a.  
Even when native MS is not employed as the primary screen, the technique can still be used to 
aid FBDD campaigns. Our group has recently developed low nanomolar inhibitors of 
Mycobacterium tuberculosis (Mtb) CYP121, a cytochrome P450 enzyme essential for Mtb 
viability,[73] via a fragment-merging strategy. Previous work had shown that azole antifungal 
compounds bind tightly to CYP121, while also inducing significant dissociation of dimeric CYP121 
into its monomeric form, whereas other small molecule inhibitors and the natural substrate (cYY) 
did not affect the oligomeric status of the enzyme.[74] In our study, we tested the binding affinity 
of several lead compounds (250–373 Da) derived from an initial triazol-1-yl phenol fragment (161 
Da) against CYP121 by native MS.[75] The lead compounds bound up to twice per CYP121 dimer, 
while having no effect on the dimer-monomer equilibrium, which was attributed to differences 
in the mode of heme binding between the tested compounds and previous antifungal azoles. 
Additionally, the double-occupancy observed for one of the compounds in X-ray crystallography 
was not detected by native MS, which could indicate that one of the two binding sites in the X-
ray crystal structure of CYP121 is a low-affinity site. Finally, the rank order of binding affinities 
determined by native MS correlated well with affinity data recorded with ITC and UV-Vis optical 
titration. This study highlighted the utility of native MS in confirming ligand binding stoichiometry 
as well as to test for potential changes in protein quaternary structure. 
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1.4.3. Ion mobility-mass spectrometry (IM-MS) 
The separation of ions by ion mobility (IM) is based on the principle that the movement of ions 
through an electric field containing an inert background gas is dependent on the charge, size and 
shape of the ion, as well as other parameters of the drift chamber that are usually considered 
constant for a given set of experimental conditions (see Mason-Schamp equation below). Larger 
ions collide more frequently with the inert gas, and thus move through the ion mobility chamber 
more slowly. Additionally, ions bearing a larger charge will experience a greater electric force and 
move more quickly through the chamber. By measuring the drift time (tD) of an ion of charge z, 
it is possible to determine the collision cross-section (CCS) (Ω) of a protein ion by use of the 




















where kb is the Boltzmann constant, T is the temperature, e is the elementary charge, mI is the 
mass of the ion, mN is the mass of the inert gas, E is the electric field strength, L is the length of 
the drift region, P is the pressure in mmHg, and N is the number density of the neutral gas at 760 
mmHg. Note that in the IM measurement of a protein ion, the mass of the protein has little effect 
on the CCS because the reduced mass of the protein and neutral gas molecule is calculated.  
Coupling IM with MS therefore allows for the three-dimensional evaluation of protein ions in the 
gas phase, with the first dimension being the mass-to-charge ratio of the protein or protein 
complex, the second being the CCS of the ion, and the third being the relative abundance for all 
the ions observed.  
The use of IM-MS to study proteins or protein complexes is a relatively new field. The first 
commercially available mass spectrometer capable of performing IM-MS measurements, the 
SYNAPT HDMS® (Waters), was introduced in 2006.[77] The traveling wave (TW)-type ion mobility 
separator used in this instrument, which employs time-varying electric fields to propel the ions 
through the drift chamber (Figure 1.6), was developed only two years prior in 2004.[78] Compared 
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to the older drift tube (DT)-type ion mobility separator, TW separation improves the transmission 
efficiency of ions through the drift cell, however, direct measurement of CCS is not possible. 
Instead, the drift times measured for the protein ion of interest are calibrated against those 
measured for ions of known CCS values under the same conditions.[42] A calibration dataset for a 
range of denatured peptides and proteins, and native proteins and protein complexes was 
presented by the Robinson and Ruotolo groups in 2010.[79]  
 
Figure 1.6 A schematic representation of the SYNAPT HDMS mass spectrometer. IM-MS is performed in 
the ion mobility separation cell. Reproduced with permission from Konijnenberg et al.[41]  
IM-MS can be used to study the conformational changes of proteins or protein complexes upon 
ligand binding. For example, Hopper and Oldham have used IM-MS to study the effect of ligand 
binding on the conformational stability of proteins such as FK-binding protein, lysozyme and 
myoglobin.[51] Barran and co-workers have shown using IM-MS that the metal-bound form of a 
zinc finger peptide motif is more stable with respect to unfolding compared to the apo-form.[80] 
More recently, Cianférani, Giglione and co-workers have used IM-MS to investigate very small 
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conformational changes in peptide deformylase (PDF1B), a potential antimicrobial target, 
induced by different ligands.[81] Due to the low-throughput nature of this technique, IM-MS is 
best suited for the characterization of hit ligands rather than as a primary screening technique. 
Apart from ligand screening however, IM-MS has found much greater use for the characterization 
of protein conformation and stability, as described in the next section.  
1.4.4. Collision-induced dissociation (CID) and collision-induced unfolding (CIU) 
The internal energy of gaseous protein ions can be increased by raising the acceleration voltages 
at different stages of the mass spectrometer, as a result of more energetic collisions with neutral 
gas molecules. Activated multiprotein complexes can undergo collision-induced dissociation 
(CID), which commonly takes place through the asymmetric charge partitioning mechanism.[49-50] 
In this mechanism, an unfolded monomeric subunit is ejected which carries away a 
disproportionately large amount of charge for its size, leaving behind a “stripped” oligomer of 
relatively lower charge. The exact process of dissociation is thought to depend on various factors 
including the internal energy, charge state, and conformation of the complex, as well as the 
conformational flexibility of the monomers in the complex.[49] In one model, the asymmetry is 
induced by the unfolding of one of the monomers in the complex, presumably the subunit with 
the higher conformational flexibility, upon activation. The activated subunit overcomes the 
dissociation barrier so that further unfolding of the protein is promoted by the repulsive Coulomb 
potential.[50] As the departing subunit increases in surface-to-mass ratio during the separation 
process, protons are driven to the unfolding subunit to reduce overall Coulomb energy, which 
accounts for why the ejected monomer is able to carry away a disproportionate amount of 
charge.   
Moreover, activated protein ions can undergo collision-induced unfolding (CIU).[51-53] CIU can be 
considered to be the gas-phase equivalent of differential scanning calorimetry experiments that 
are performed in solution. The unfolding of protein ions can be tracked by monitoring their sizes 
as a function of collision energy using IM-MS. The collisional activation of proteins or protein 
complexes often yields a collection of partially folded intermediates that are stable on the 
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millisecond time scale, generating a “CIU fingerprint” that is unique for a protein ion under a 
given set of conditions.[54]  Although the data collected by CIU are only indicative of the relative 
and not absolute thermodynamic properties of a protein, they can still provide useful insight into 
the structure, stability and conformations of proteins and their complexes. 
1.4.5. Hydrogen-deuterium exchange (HDX)-MS 
The amide hydrogens of a peptide or protein are labile and exchange with solvent hydrogen or 
deuterium through acid-, base- or water-catalyzed reactions. The rate of exchange is highly 
dependent on the structural environment of the amide as well as the solution conditions. For 
example, an amide hydrogen in a random coil conformation will exchange on the order of 
milliseconds to seconds at pH 7.0 and room temperature, but may exhibit a reduction in exchange 
rate by a factor of as high as 108 if found within the interior of a folded protein.[82] Thus, amide 
hydrogen exchange rates give an indication of the local structure and solvent accessibility of 
different regions of a protein, allowing changes in the structure and dynamics of a protein to be 
monitored indirectly.  
A schematic overview of the HDX-MS process as applied to ligand screening is depicted in Figure 
1.7.[83] In the first stage, “on-exchange” of hydrogen for deuterium takes place when the protein 
is incubated in D2O in either the presence or absence of the ligand. Aliquots of this solution are 
withdrawn at pre-specified time intervals and then quenched by the addition of cold and acidic 
solution. This quench step is essential to preserve the level of deuterium incorporation until MS 
analysis is performed. The partially-deuterated protein is then digested, typically by passing 
through a pepsin column, to generate a collection of small peptides, which are then separated 
chromatographically before MS analysis. The percentage incorporation of deuterium for each 
peptide at each time point can be determined, and a graph of % deuterium uptake against time 
for the given peptide can then be plotted. Further analysis of overlapping proteolytic fragments 
can generate more localized HDX data, sometimes down to single-residue resolution (although 




Figure 1.7. A schematic representation of the HDX-MS process as applied to ligand screening. a) Proteins 
are labelled with D2O either in the absence (upper panel) or presence (lower panel) of ligand. (b) Reaction 
aliquots are quenched at pre-specified time intervals, followed by protease digestion. (c) Peptides are 
separated chromatographically and analyzed by MS. (d) The rate of deuterium uptake for the apo and 
ligand-bound forms are compared for each peptide and differences are mapped onto the crystal structure. 
Reproduced with permission from Marciano et al.[83] 
Comparing the differential deuterium uptake between the apo and ligand-bound forms of a 
protein therefore gives information on the effects of ligand binding on the structure of the 
protein. At the simplest level, the binding of a ligand to a protein should shield the amide protons 
of the ligand-binding site from the deuterated solvent, thereby reducing the % deuterium uptake 
of the binding site residues to them. This can be used to generate an ‘HDX fingerprint’ for each 
ligand, and analysis of these fingerprints can allow for the clustering of ligands into groups that 
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share a comparable binding mode.[84] However, differences in HDX patterns upon ligand binding 
can also result from changes to the protein structure or dynamics in regions that are distant from 
the binding site (i.e., allosteric effects). 
While HDX-MS has been widely employed for studying the structure and dynamics of 
biopharmaceuticals,[85-87] its use for small-molecule ligand screening has received comparatively 
less attention. The primary drawback of HDX-MS is that it is a low-throughput technique, and the 
screening of even as few as one thousand compounds will incur significant expense in both time 
and money. In a recent study, Carson and co-workers used HDX-MS as a secondary screen to 
validate the binding of fragment molecules to vitamin D receptor (VDR), a regulator of calcium 
and phosphorus homeostasis.[88] Interestingly, significant protection of H/D exchange was 
observed for some fragments in helixes 3, 7, and 8 of the ligand-binding domain of VDR, regions 
which were similar to those stabilized by the natural hormone vitamin D3. This study, which was 
the first and to-date only report on the application of HDX-MS to FBDD, showed how this 
technique can be used to identify suitable fragments as starting points for further synthetic 
elaboration. 
1.4.6. Ligand-based MS techniques 
Ligand-based MS approaches have also been employed as a fragment screening technique for 
drug discovery. The general workflow of a ligand-observed MS experiment is shown in Figure 
1.8.[89] In the first step, the protein target of interest is incubated with a cocktail of fragments, 
while in a separate control experiment, the same fragment cocktail is incubated in the absence 
of protein. Next, the target and control samples are subjected to ultrafiltration using a centrifugal 
concentrator. This retains the protein-ligand complexes in the supernatant, while the unbound 
ligands are driven into the filtrate. Note that this step presumes that the protein-ligand 
complexes are stable to centrifugation. The protein-ligand complexes are subsequently 
dissociated by the addition of 90% aqueous methanol, and the released fragments are analyzed 
by liquid chromatography-mass spectrometry (LC-MS). Fragments that are enriched in the target 
sample compared to the control sample are deemed to be binders, as these compounds were 
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retained in the supernatant presumably through binding to the target protein. Measurement of 
the bound fragment concentration moreover enables the calculation of binding dissociation 
constants (KD) for the target-ligand interaction. It is also possible to perform LC-MS analysis on 
the unbound ligand fraction, which is obtained as the filtrate after the ultrafiltration step. In this 
case, fragments that are reduced in intensity in the unbound fraction are deemed to be binders.  
 
Figure 1.8 General workflow of a ligand-observed MS experiment for fragment screening. (a) The target 
protein is incubated with a mixture of fragments. The negative control experiment is performed without 
protein. (b) Ultrafiltration separates the free ligand from the protein-ligand complexes, which are retained 
in the supernatant. (c) The protein-ligand complexes are dissociated using 90% aqueous methanol to 
liberate the ligands. (d) The released ligands are quantified by LC-MS. Fragments that are significantly 
enriched in the target sample compared to the control sample are deemed to be binders. Adapted from 
Chen et al.[89] 
In 2015, Shui and co-workers explored the use of ligand-observed MS for fragment screening.[90] 
Their methodology was first validated using the model enzyme human carbonic anhydrase I 
(hCAI) and reported inhibitors of the enzyme, which showed a close correlation between KD 
values determined from ligand-observed MS with those determined by ITC. The researchers then 
screened 50 randomly selected fragments against hepatitis C virus RNA polymerase NS5B, an 
enzyme that is essential for viral replication.[91] Nine fragment hits emerged from the ligand-
observed MS screening campaign, with KD values determined to be in the range of 0.7 to 9.6 mM. 
Seven of those hits were also shown to bind to NS5B using SPR. In a follow-up study, the 
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researchers integrated ligand-observed MS into a fragment-based lead discovery pipeline.[89] A 
library of 384 fragments was screened against NS5B either all at once, generating 20 fragment 
hits, or in cocktails of about 50 fragments, which yielded 12 fragment hits. Screening of the 
mixture of the latter 12 compounds using a further round of ligand-observed MS validated 10 of 
those hits, which bound to NS5B with KD values of between 1 to 20 mM. Although binding 
affinities were too weak to be determined by SPR, the rank order of SPR response showed 
reasonable correlation with the order determined by ligand-observed MS.  
Instead of ultrafiltration, fragment binders can be separated from non-binders by the use of weak 
affinity chromatography (WAC). In this approach, fragments are passed through a column upon 
which the protein of interest is immobilized. Compounds that bind to the protein are retarded 
within the column and elute at a longer retention time compared to inactive compounds (Figure 
1.9a). In 2011, Ohlson and co-workers first applied WAC to fragment screening.[92] They initially 
validated their methodology using a small collection of 20 known binders of trypsin and thrombin 
as model target proteases. Screening was then performed by passing fragments through the 
column using HPLC, either as singletons or as a mixture. The apparent KD of compounds were  
calculated by dividing the total number of binding sites on the column by the product of the 
adjusted retention time and the flow rate. The results showed that fragment binding could be 
detected over a KD range of 10 to 1000 μM, with good correlation between the KD of compounds 
calculated by WAC with IC50 values determined by an enzymatic assay. Additionally, the issue of 
non-specific binding could be addressed by pre-treating the column with highly-affinity protease 
inhibitors. As these inhibitors saturate the active site, any retardation observed in the presence 
of the protease inhibitor would represent non-specific binding of the compounds to other parts 
of the protein molecule. The net retention time (tR′), which is the difference in retention time for 
a particular compound in the presence and absence of the protease inhibitor, therefore gives an 
indication of the specific component of binding (Figure 1.9b). The Ohlson group later applied 
WAC to high-throughput screening of a commercial fragment library.[93] 590 fragments randomly 
chosen from the TimTec fragment collection were passed through a thrombin column in cocktails 
of 35 to 65 fragments, resulting in 30 initial hits. However, screening of the compounds using an 
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inhibitor-blocked thrombin column revealed that only 1 of the 30 compounds bound specifically 
to the active site. Fragment screening campaigns using WAC have also been conducted by the 
Ohlson group against cyclin G-associated kinase[94] and HSP90[95] In the case of HSP90, good 
overlap was observed between hits revealed by WAC and those identified by NMR and SPR 
experiments. 
 
Figure 1.9. (a) Schematic of WAC. Compounds elute in order of their affinity to the column, with non-
binders eluting first and strong binders eluting last. Adapted with permission from Potterat et al.[96] (b) The 
net retention time (tR′) is calculated by subtracting the retention time of the fragment on the inhibitor-
blocked column (dashed line) from the corresponding retention time on the active column (solid line). 
Adapted with permission from Duong-Thi et al.[92] 
1.4.7. Other MS-based techniques 
The entire field of MS is vast and cannot be satisfactorily reviewed here. Other techniques, such 
as protein footprinting or chemical cross-linking, can be used in conjunction with MS to aid the 
study of protein-ligand interactions.[42] Additionally, matrix-assisted laser desorption/ionization 
(MALDI) is an alternative ionization technique that has also been commonly used in protein MS 
as well as in the emerging field of MS imaging.[97] A summary of the MS-based techniques utilized 
for fragment screening is present in Table 1.2. 
Table 1.2. A comparison of MS techniques used for fragment screening. 
Technique Principle Advantages Limitations 
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Native MS Detection of gas-
phase protein-ligand 
complexes 
generated by ESI 
Low sample consumption, 
medium-throughput, 
provides binding affinity 
and stoichiometry, allows 
verification of protein and 
ligand purity 
Gas-phase species may not 
reflect distribution in 
solution  
IM-MS Gaseous ions are 
retarded by drift gas 
molecules based on 
their collision cross 
section 
Can reveal conformational 
changes 
Low-throughput 
HDX-MS Ligand changes 
deuteration rate of 
protein amide 
residues in solution 
Can reveal ligand binding 
site and allostery 
Low-throughput 
Ligand-
observed MS  
Bound and unbound 




before MS detection 
Medium to high-




method, requires that 
protein be stable to 
centrifugation or 
immobilization on column 
 
1.5. Project aims 
The use of MS-based techniques to study protein structure and interactions is a relatively new 
field and moreover, MS methods have not yet found widespread use in drug discovery, 
particularly in FBDD. At the time this project was initiated, MS methods were not routinely part 
of the biophysical cascade used in FBDD by the Abell research group. With the above 
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considerations in mind, this project broadly aimed to explore whether MS methods, particularly 
native MS, can become a valuable complement to the arsenal of existing biophysical tools 
employed within a FBDD campaign. 
DMSO is common co-solvent used in fragment screening, yet literature studies on its effects on 
protein structure have been conflicting. In Chapter 2, native MS and IM-MS were used to explore 
the effect of DMSO on protein size and stability in the gas-phase, revealing trends that were both 
protein and concentration-dependent. This chapter was published in ChemistrySelect 
(ChemistrySelect, 2016, 1, 5686) and in Analytical Chemistry (Anal. Chem., 2017, 89, 9976). 
CoaBC, an integral member of the bacterial coenzyme A biosynthetic pathway, is a newly 
validated antibacterial target. In Chapter 3, native MS and IM-MS were used to study the 
structure and interactions of CoaBC and its ligands. Additionally, the application of native MS to 
screen fragments against the CoaB subunit was demonstrated. This chapter was published in 
Chemical Communications (Chem. Commun., 2017, 53, 3527) and in Angewandte Chemie 
International Edition (Angew. Chem. Int. Ed., 2017, 56, 7488). 
EthR increases the resistance of Mycobacterium tuberculosis to ethionamide, a second-line anti-
tubercular drug. In Chapter 4, native MS was used to study the structure of the EthR-DNA 
complex, revealing a hitherto unknown 6:1 stoichiometry. Additionally, the use of native MS to 
screen fragments against a protein-DNA interaction was demonstrated for the first time. This 
chapter was published in Biochemical Journal (Biochem. J. 2019, 476, 3125). 
The aberrant activity of Aurora A kinase is implicated in the development of several kinds of 
cancers. In Chapter 5, native MS was used to study the interaction between different Aurora A 
mutants and TPX-2, a cognate binding protein that increases the activity and stability of the 
enzyme. 




2. Insight into effects of DMSO on protein charging, conformation, 
stability and interactions as assessed by native ion mobility mass 
spectrometry 
2.1. Introduction 
Over the last two decades, electrospray ionization-mass spectroscopy (ESI-MS) has emerged as a 
versatile technique to probe protein structure and function.[40, 98-99] The ability of ESI-MS to 
generate macromolecular ions from aqueous solution under relatively soft ionization energies 
has enabled the study of both non-covalent protein-protein and protein-ligand complexes under 
native-like conditions.[40, 60] The interfacing of ESI-MS with ion-mobility (IM) spectrometry, 
termed ion-mobility mass spectrometry (IM-MS), provides an additional dimension of resolution 
whereby ions are separated by their collision cross-section (CCS) as they traverse a chamber of 
neutral gas particles under the influence of an electric field.[42, 61, 100-101]  
Biological screening systems often contain significant quantities (up to 10%) of dimethyl sulfoxide 
(DMSO), particularly where high concentrations of weakly-binding ligands such as fragments are 
used.[29, 102] Interestingly, low DMSO concentrations (<10%) decrease the average charge of 
protein ions generated by ESI, whereas higher concentrations (>10%) of DMSO lead to an 
increase in average charge and also induce a broadening of charge state distributions.[103-107] 
However, the mechanism by which low concentrations of DMSO decrease charge is still under 
debate.[106, 108] Williams and co-workers have attributed the charge-reducing effects of DMSO to 
a “global compaction” of protein structure, as supported by both circular dichroism (CD) and 
hydrogen-deuterium exchange (HDX) experiments of hen egg white lysozyme and equine 
myoglobin in solution.[105] Their results suggested that the proteins underwent compaction at 
concentrations of DMSO up to about 50%, followed by unfolding at higher concentrations.[105] In 
contrast, Tjernberg and co-workers have reported that DMSO concentrations as low as 3% 
induced destabilization, degradation and aggregation of the phosphatase domain of PFKFB1 
(BPase) as revealed by both ESI7-MS and solution assays.[103] Other additives that have been 
reported to reduce charge in ESI include DMF,[108] imidazole,[109] and various solvent vapors.[110]  
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In terms of protein interactions, Zenobi and co-workers reported that DMSO (0.5 to 8%) reduced 
the binding affinities of three different protein-ligand complexes, which was attributed to the 
ability of DMSO to destabilize the protein and perturb the ligand-binding pocket, interfere with 
the ligand, or act as a competing inhibitor.[111] In contrast, Landreh and co-workers found that 3% 
DMSO stabilized the tetrameric state of transthyretin (TTR) and its non-covalent interaction with 
the thyroid hormone thyroxine (T4), as well as the trimeric state of the C-terminal domain of lung 
surfactant protein C (CTC) and its non-covalent interaction with a trivaline peptide.[108] This 
protective effect of DMSO was attributed to a combination of charge reduction and a cooling 
effect from adduct dissociation.[108] 
The resistance of protein complexes to dissociation and unfolding in the gas phase can be studied 
by collision-induced dissociation (CID) and collision-induced unfolding (CIU), respectively. 
Previous studies mainly by the Ruotolo group have explored the effect of various cations and ions 
on the CID and CIU stabilities of model proteins.[112-115] However, to our knowledge, no systematic 
study on the effect of DMSO on protein CID or CIU behavior has yet been reported. 
This chapter aims to clarify whether the supposed compaction of protein structure at low 
concentrations of DMSO is manifested as a change in CCS that can be detected by traveling-wave 
ion-mobility mass spectrometry (TWIM-MS) for four different proteins: avidin, concanavalin A, 
alcohol dehydrogenase and pyruvate kinase. These four tetrameric proteins were chosen due to 
their different molecular weights and roughly globular structures and well-characterized 
behavior in IM-MS. In the second phase of this study, the effect of DMSO on protein stability and 
interactions was investigated by CID and CIU. Avidin and CYP142A1 were chosen as 
representative examples of proteins with quaternary structure or prosthetic groups, respectively. 
Avidin is a well-characterized glycoprotein found in the egg-white of birds and reptiles. The 
protein forms a multiprotein complex that consists of four identical subunits assembled together 
in a dimer of dimers arrangement.[116] In contrast, the Mycobacterium tuberculosis (Mtb) 
cytochrome P450 enzyme CYP142A1 is predominantly monomeric and binds a heme-b prosthetic 
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group. CYP142A1 functions as a cholesterol oxidase and contributes to the ability of Mtb to 
establish a chronic infection.[117-119]   
To our knowledge, this is the first time that native IM-MS has been applied to study the effect of 
DMSO on protein conformation and stability. It was found that DMSO influences the size of 
protein ions not only by its effect on charge state distribution, but also at the level of individual 
charge states. Our work also provides evidence that DMSO influences CID and CIU stability via a 
dual mechanism of charge modulation, as well as via charge state-independent effects. Finally, 
tandem MS/MS experiments showed that DMSO can influence the heme dissociation pathway 
of CYP142A1, and also demonstrate that the protective effects of the heme group on CYP142A1 
stability can be tracked using CIU, a technique that should be broadly applicable to other heme-
containing proteins. Overall, these results provide insight into the charge-reducing mechanism 
of DMSO and may help to reconcile previously conflicting observations regarding this 
phenomenon. 
2.2. Results and discussion 
2.2.1. Effect of DMSO on protein charge and conformation 
2.2.1.1. DMSO exerts opposing trends on average protein charge 
Native mass spectra of avidin (Figure 2.1a), concanavalin A (Figure 2.1b), alcohol dehydrogenase 
(Figure 2.1c) and pyruvate kinase (Figure 2.1d) in the absence of DMSO indicated that their 
quaternary structures were well-preserved, with the tetramer presenting as the predominant 
species in all cases. For concanavalin A, a significant amount of the dimeric protein and a small 
quantity of the monomeric protein were also observed, consistent with previous reports.[104, 120] 
Meanwhile, some non-specific dimerization of tetramers was observed for avidin, while in the 
case of pyruvate kinase, an unknown impurity of around 155 kDa was observed at a lower m/z 






Figure 2.1 nESI-MS spectra of (a) avidin (20 µM), (b) concanavalin A, (c) alcohol dehydrogenase, and (d) 
pyruvate kinase in NH4OAc (200 mM, pH 7.0) containing 0, 0.5, 1, 2, 4, 6, 10 or 20% DMSO. For all spectra 
except concanavalin A (b), only the charge states of the tetramer are indicated. For avidin (a), some non-
specific dimerization of tetramers was observed. For pyruvate kinase (d), an unknown impurity of around 
155 kDa was observed at a lower m/z region relative to the tetramer signals.  
As the concentration of DMSO was increased from 0 to 20%, the charge state distributions of the 
four protein complexes were observed to shift to higher m/z values (lower charge) at low DMSO 
concentrations, followed by a reversal of the trend towards lower m/z values (higher charge) at 
higher DMSO concentrations (Figures 2.2a-d). For example, the abundance-weighted average 
charge of avidin decreased monotonically from 15.5+ to 14.1+ as the DMSO concentration was 
increased from 0% to 4%, followed by an increase to 17.3+ as the DMSO concentration was 
increased to 20% (Figure 2.2a). These opposing trends of DMSO on protein charging are 
consistent with previous reports,[103, 105-106] suggesting that at least two factors are at play here. 
Additionally, peak broadening was observed at higher DMSO concentrations in some cases, 
which might be attributed to formation of DMSO adducts of the protein. 
 
Figure 2.2 Weighted-average charge of (a) avidin tetramers, (b) concanavalin A tetramers, (c) alcohol 
dehydrogenase tetramers, and (d) pyruvate kinase tetramers as a function of DMSO concentration. 
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The minimum average charge for the four proteins occurred at 2 or 4% concentration of DMSO 
(Figures 2.2a-d). Furthermore, concanavalin A dimers and monomers showed similar charging 
behavior in response to DMSO concentration as compared to the tetramers (Figure 2.3a). For all 
of the protein complexes, significant charge state distribution broadening was not apparent until 
DMSO concentrations reached high values (≥10%). At 20% DMSO, the average charge of the 
proteins became greater than their initial values in the absence of DMSO, suggesting the onset 
of global protein unfolding. This could account for the increase in the number of occupied charge 
states at higher DMSO concentrations,[121] as well as the increase of the abundance of dimerized 
avidin tetramers that are presumed to be non-specific (Figure 2.1a). It should be noted that 
because of the higher boiling point of DMSO compared to water, ESI droplets become enriched 
in DMSO (estimated to be 3- to 5-fold in Williams et al.[105]) during the desolvation process, and 
hence the effective DMSO concentration experienced by the gaseous protein ions is likely to be 




Figure 2.3 (a) Relative charge reduction of concanavalin A tetramers, dimers and monomers as a function 
of DMSO concentration. (b) Relative abundance of concanavalin A tetramers, dimers and monomers as a 
function of DMSO concentration. 
A previous report found that 2.5% DMSO induced significant dissociation of the bacterial NAD+ 
synthase from dimeric into monomeric form, possibly via weakening of the hydrophobic 
effect.[122] In comparison, no dissociation of any of the four protein tetramers was observed by 
native MS at any DMSO concentration. Moreover, the tetramer-dimer-monomer equilibrium for 
concanavalin A was not significantly perturbed by the addition of up to 20% of DMSO (Figure 
2.3b). This also contrasts with observations from supercharging experiments, in which the 
addition of as little as 0.5% of m-nitrobenzyl alcohol resulted in significant dissociation of 
concanavalin A dimers into monomers.[104] This suggests that the charge-reducing effects of 
DMSO protect against, or at least do not promote, subunit dissociation in ESI in this case. It has 
also been previously reported that charge reduction of protein complexes using crown ethers 
protected against dissociation.[123] 
2.2.1.2. DMSO exerts opposing trends on average protein size 
CCS values for the protein complexes at various DMSO concentrations were obtained in N2 and 
calibrated with CCSN2 reference values for the proteins under DMSO-free conditions following 
the procedure of Ruotolo and Robinson et al.[76] Experiments were performed at four different 
wave heights (7, 8, 9 and 10 V) to rule out the effect of electric field strength on gaseous ion 
separation. Intriguingly, the abundance-weighted average CCS of the four proteins underwent a 
decrease in value at low DMSO concentrations followed by an increase at higher DMSO levels 
(Figures 2.4a-d), paralleling the trend observed for average charge. For example, the average CCS 
of the avidin tetramer decreased from 4130 ± 10 Å2 at 0% DMSO (DT CCSN2 = 4150 Å2)[79] to 4090 
± 10 Å2 at 2% DMSO, followed by an increase to 4200 ± 30 Å2 at 20% DMSO (Figure 2.4a). While 





Figure 2.4 Weighted-average CCS of (a) avidin tetramers, (b) concanavalin A tetramers, (c) alcohol 
dehydrogenase tetramers, and (d) pyruvate kinase tetramers as a function of DMSO concentration. 
The minimum CCS values for the four proteins occurred at 1 or 2% DMSO (Figures 2.4a-d), which 
are similar to the DMSO concentrations at which minimum charge was reached. At 20% DMSO, 
the average CCS of the proteins became higher than their initial values under DMSO-free 
conditions, which is consistent with preliminary unfolding and the onset of protein supercharging 
at this DMSO concentration. These data would therefore support the idea of global protein 
compaction at low DMSO levels,[105] followed by the onset of protein unraveling at higher 
concentrations. 
2.2.1.3. DMSO affects protein size at the level of individual charge states 
Higher charge states of a protein generally have larger CCSs than lower charge states of the same 
protein, which has been attributed to increased Coulombic repulsion leading to expansion of ions 
in the gas phase, or alternatively, to the transfer of less compact proteins from solution that 
provide greater surface area for charge development in ESI.[124] This poses an interesting 
“chicken-or-egg” question: is the apparent compaction of protein structure at low DMSO 
concentrations a direct consequence of the charge-reducing capability of DMSO in ESI, allowing 
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protein ions to access lower charge states that have decreased internal repulsion and hence 
smaller size (Mechanism A), or is protein compaction an ab initio effect by DMSO in solution that 
in turn decreases the charge developed in ESI (Mechanism B) (Figure 2.5)?  
 
Figure 2.5 Two possible mechanisms for size reduction of protein ions by DMSO. In Mechanism A, DMSO 
decreases charge development during ESI and compaction occurs in the gas phase due to lower internal 
repulsion of ions. In Mechanism B, compaction by DMSO occurs in solution, decreasing the area for charge 
development during ESI. 
To investigate this issue, the relationship between the CCSs for single charge states and DMSO 
concentration was analyzed. If the observed compaction of protein structure was solely due to 
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the ability of DMSO to shift the protein charge state distribution to ions of lower charge, then the 
CCSs of specific charge states should not be appreciably different from each other regardless of 
DMSO concentration. Interestingly, for several of the charge states that are present at a range of 
different DMSO concentrations, their CCSs exhibited the characteristic opposing trends in 
response to DMSO concentration (Figures 2.6a-d) as for average charge and average CCS values.  
 
Figure 2.6 (a) CCS of 13+, 14+ and 15+ charge states of avidin tetramers as a function of DMSO 
concentration. (b) CCS of 17+ and 18+ charge states of concanavalin A tetramers as a function of DMSO 
concentration. (c) CCS of 20+ and 21+ charge states of alcohol dehydrogenase tetramers as a function of 
DMSO concentration. (d) CCS of 27+, 28+ and 29+ charge states of pyruvate kinase tetramers as a function 
of DMSO concentration. 
This behavior was also evident from consideration of the arrival time distributions (ATDs) for 
individual charge states (Figures 2.7a-h), which shift to lower drift times at lower DMSO 
concentrations (indicating protein compaction), followed by a shift to larger drift times at higher 
DMSO concentrations. These observations argue against the hypothesis that the decreased 
Coulombic repulsion afforded by DMSO-induced charge reduction in ESI is the sole factor driving 
the overall compaction of the proteins. This is because if the sole effect of DMSO was to reduce 
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protein charge, then identical charge states of a protein generated at different DMSO 
concentrations should show the same drift time, however our data instead show that DMSO 








Figure 2.7 Arrival time distributions for different wave heights as a function of DMSO concentration for (a) 
avidin 15+, (b) avidin 14+, (c) concanavalin A 19+, (d) concanavalin A 18+, (e) aldehyde dehydrogenase 
21+, (f) alcohol dehydrogenase 20+, (g) pyruvate kinase 29+, and (h) pyruvate kinase 28+ charge states. 
Wave heights are indicated at the top and DMSO concentrations (%) are indicated at the side of the plots. 
It was also observed that in the subcharging regime, lower charge states do not necessarily 
exhibit smaller CCSs than higher charge states at a given DMSO concentration (Figures 2.6a-d). 
This is similar to observations from the Robinson group showing that the lower charge states of 
serum amyloid P component (SAP) and aldehyde dehydrogenase complexes subjected to charge 
reduction by triethylammonium acetate (TEAA) do not show significant changes in CCS compared 
to higher, non-reduced charge states.[125] Moreover, drift tube-ion mobility-MS measurements 
of native-like, non-supercharged proteins suggest that the positive correlation between charge 
and CCS is present only for smaller proteins, whereas for larger proteins or protein complexes, 
this relationship is not apparent.[79, 126] This further suggests that internal repulsion should not 
have a significant effect on the CCSs of the different charge states of the proteins in this study, 
which was performed under non-activating conditions. 
2.2.1.4. Error analysis 
Due to the relatively small deviations in CCS observed in this study, error analysis was performed 
to evaluate the significance of the findings. According to Ruotolo and Robinson et al.,[76] the total 
error (ET) of the calibrated CCSs is given by the sum of ER, ECal and ES, where ER is the standard 
deviation of replicate measurements, ECal is the average error of the calibration curve, and ES is 
the error carried by the protein standards that were used to calibrate the drift times of the 
unknown ions. Each of these errors for this experiment are considered separately below.  
ER: The reproducibility error (ER), as estimated by the relative standard deviation of replicate 
measurements across four different wave heights, was found to be low for each charge state of 
the four proteins across all DMSO concentrations (Table 2.1). The majority of ER values were less 
than 1%, indicating good reproducibility between replicate measurements. The average ER for 
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avidin, concanavalin A, alcohol dehydrogenase and pyruvate kinase across all DMSO 
concentrations were 0.33%, 0.48%, 0.40% and 0.50%, respectively (average 0.43%). 
ECal: The calibration curve R2 values were ≥0.978 for all four wave heights, indicating good 
linearity (Table 2.2). The average calibration curve-based error (ECal) at wave heights 7 V, 8 V, 9 V 
and 10 V were estimated to be 1.41%, 1.24%, 1.21% and 1.19%, respectively (average 1.26%).  
ES: The error in mobilities of the protein calibrants (ES) has been assumed to be ca. 1% by Ruotolo 
and Robinson et al.,[76] or in a more recent paper by the same group, to be <3%.[79]  
Adding all three uncertainty components in quadrature suggests that the total error ET associated 
with the calibrated CCSs in this study is 1.67% (when ES = 1%) or 3.28% (when ES = 3%). While the 
magnitude of these errors are significant in relation to the DMSO-induced CCS changes observed, 
it is argued that two of the three error contributors, namely the calibration-related errors, ECal 
and ES, do not impact the validity of the conclusions of this study. This is because the main 
findings of this study do not rely on comparisons of experimental CCS values with calculated CCS 
values of model structures, for which calibration of measurements is an essential step. Instead, 
the context of this study is such that only the determination of relative changes in CCSs are 
necessary for assessing the effect of DMSO on protein conformation. It is therefore assumed that 
the two calibration-based uncertainties, ECal and ES, are systematic in nature, and thus should 
have no effect on the relative differences in CCS observed in this study. As such, the CCS errors 
in this chapter incorporate only the reproducibility error (ER). 
This argument is bolstered by the arrival time distribution data for selected charge states (Figures 
2.7a-h), which clearly show the opposite trends of DMSO on drift time even at the level of 
individual charge states. Moreover, the trends were broadly consistent for each protein ion 
across the different wave heights. Importantly, these relative differences in arrival time 
distribution, being antecedent to the calibration process, are unadulterated by the calibration-
related uncertainties ECal and ES.  
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Finally, the overall trends in DMSO-induced conformational change were repeatable from 
independently-performed repeat experiments conducted on different days. Taken together, this 
data provides sufficient evidence for the significance of the small, but repeatable changes in 
protein conformation induced by DMSO. 
Table 2.1 Table showing the reproducibility error (ER) as estimated by the standard deviation (%SD) for 
four replicate measurements for each charge state of avidin (AV), concanavalin A (CCA), alcohol 
dehydrogenase (ADH) and pyruvate kinase (PK) at different DMSO concentrations. 
[DMSO] 
/ % 
AV CCA ADH PK 
z %SD z %SD z %SD z %SD 
0 14 0.21 18 0.30 22 0.44 32 0.35 
  15 0.18 19 0.21 23 0.24 33 0.44 
  16 0.25 20 0.40 24 0.22 34 0.60 
  17 0.13 21 0.38 25 0.26 35 0.53 
0.5 13 0.26 16 0.78 20 0.38 26 0.56 
  14 0.46 17 0.26 21 0.28 27 0.60 
  15 0.18 18 0.30 22 0.17 28 0.76 
  16 0.58 19 0.67 23 0.27 29 0.21 
1 13 0.31 16 1.13 20 0.68 26 1.45 
  14 0.16 17 0.91 21 0.40 27 0.54 
  15 0.19 18 0.34 22 0.26 28 0.81 
  16 0.22 19 0.39 23 0.23 29 0.26 
2 13 0.31 16 0.76 20 0.45 26 0.46 
  14 0.16 17 0.01 21 0.06 27 0.49 
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  15 0.19 18 0.45 22 0.31 28 0.28 
  16 0.56 19 0.19 23 0.50 29 0.21 
4 13 0.11 16 0.97 20 1.09 26 0.74 
  14 0.16 17 0.83 21 0.44 27 0.66 
  15 0.18 18 0.34 22 0.40 28 0.46 
  16 0.56 19 0.34 23 0.44 29 0.80 
6 13 0.26 16 0.92 20 0.62 26 1.10 
  14 0.22 17 0.36 21 0.34 27 0.43 
  15 0.25 18 0.47 22 0.26 28 0.28 
  16 0.55 19 0.49 23 0.44 29 0.47 
10 14 0.26 17 1.11 21 0.76 29 0.53 
  15 0.36 18 0.23 22 0.48 30 0.60 
  16 0.60 19 0.43 23 0.22 31 0.28 
  17 0.34 20 0.28 24 0.23 32 0.13 
20 16 0.33 18 0.73 22 1.14 33 0.25 
  17 0.76 19 0.13 23 0.34 32 0.47 
  18 0.64 20 0.36 24 0.39 33 0.25 
  19 0.77 21 0.29 25 0.32 34 0.19 
      22 0.24 26 0.30 35 0.04 
              36 0.86 
              37 0.29 
44 
 
Average   0.33   0.48   0.40   0.50 
 
Table 2.2 Table showing the curve R2 and calibration curve-based error (ECal) at four different wave heights. 
Wave height / V 7 8 9 10 Average 
Curve R2 0.978 0.981 0.981 0.981 0.980 
ECal / % 1.41 1.24 1.21 1.19 1.26 
2.2.1.5. Towards a consistent understanding of protein compaction by DMSO 
The observations above suggest that protein compaction by DMSO may be occurring, at least in 
part, in solution phase (i.e., Mechanism B, Figure 2.5). The compaction effect by DMSO in solution 
has been previously documented for lysozyme by the groups of Voets[127] and Williams[105] on the 
basis of CD, small-angle neutron scattering, Rayleigh scattering and HDX-MS results. This 
compaction of protein structure in solution could then be transferred into the gas-phase for it to 
be detected by TWIM-MS, as was shown in this work. However, while this could potentially 
account for the charge reduction of protein ions at low DMSO concentrations,[105] it is considered 
that this is unlikely to be the only operative mechanism, as the degree of CCS reduction (ca. 1–
2%) was small in comparison to the magnitude of charge reduction (ca. 10%).  
Quantitatively, Marijnissen and co-workers have suggested based on theoretical considerations 
that the charge of a progeny droplet generated during ESI is proportional to droplet surface area 
raised to the power of 3/4.[128] According to the CRM model, the final droplet is not much larger 
than the protein itself. Therefore, as the droplet finally evaporates, the entirety of this charge 
should be transferred to the encapsulated protein.[129] By correlating the average charge of 
proteins observed in ESI-MS with their predicted surface areas from crystal structures, Kaltashov 
and co-workers determined that the charge–surface area relationship followed a power function 
of 0.69 ± 0.02.[129] In our study, plotting a log-log graph of average charge against average CCS for 
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the four proteins under DMSO-free conditions revealed an excellent linear fit (R2 = 0.997), with a 
power constant of 0.78, which was close to the expected value of 3/4 (Figure 2.8a). However, 
log-log plots for the individual complexes under varying DMSO concentrations showed both 
worse fits (R2 = 0.82 to 0.97) as well as much higher power constants of 4.5 to 10.6 (Figure 2.8b), 
suggesting that the DMSO-induced change in CCS, and by extension surface area, is itself 
insufficient to account for the entirety of the change in charge. 
 
Figure 2.8. (a) Relationship between average charge and CCS plotted on a log–log scale for the four protein 
complexes at 0% DMSO, showing the equation and correlation coefficient for a linear trendline. (b) 
Relationship between average charge and CCS plotted on a log–log scale for the four protein complexes at 
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various DMSO concentrations (0 to 20%). Values for avidin, concanavalin A, alcohol dehydrogenase and 
pyruvate kinase are shown as closed circles, open circles, closed triangles and open triangles, respectively. 
Linear trendlines are plotted for each individual protein. 
Instead, other chemical or physical mechanisms, such as gas-phase proton transfer[106] or 
dissociative cooling,[108-109] may account for the observed subcharging of protein ions at low 
DMSO concentrations. Additionally, this does not preclude the possibility that the observed 
differences in CCS might be due to other factors; for example, gaseous ions might, depending on 
the DMSO concentration, vary in their internal energy as a result of different desolvation, leading 
to small changes in drift time. In the specific case of ring-like protein assemblies, initial 
compaction can also be achieved through collision activation,[130] although this mechanism is 
unlikely to be operative for the approximately globular multiprotein complexes considered in this 
work. 
2.2.1.6. Summary 
The precise mechanisms governing the relationships between electrospray conditions, protein 
charge and CCS values are still not completely understood. In particular, a consistent framework 
that accounts for the charge-reducing effects of DMSO in ESI has not yet been fully developed. 
Against this backdrop, this study has provided evidence for the first time of a modest, but 
repeatable, decrease of protein size at low DMSO concentrations. Our data also suggests that 
this compaction is unlikely to be solely attributable to the shift of charge state distribution by 
DMSO, as different charge states of the same protein were also individually compacted by DMSO, 
and also because internal Coulombic repulsion was unlikely to be a dominant factor for these 
systems based on consideration of protein sizes in the subcharging regime. Instead, our results 
lead us to speculate that the previously reported compaction of protein structure by DMSO in 
solution can be adequately maintained upon transfer to the gas-phase, allowing for this 
phenomenon to be detected by TWIM-MS. However, the observed CCS reduction is relatively 
small and is thus unlikely to account for the entirety of charge reduction by DMSO, suggesting 
that alternative subcharging mechanisms are operative. Finally, and in contrast to previous 
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studies with other proteins, no evidence was observed of gross protein denaturation, 
degradation or aggregation (except for some dimerization of avidin) of proteins under study at 4 
°C over the timescale of days even at 20% DMSO. This suggests that the deleterious effects of 
DMSO on protein structure and stability are highly protein-dependent, and further reinforces the 
notion that the DMSO concentration for each biological assay has to be carefully optimized in 
order to ensure that the results are not compromised by unintended effects of DMSO on protein 
binding or activity. 
2.2.2. Effect of DMSO on protein stability and interactions 
2.2.2.1. Charging behavior of avidin and CYP142A1 at high levels of DMSO 
The first part of this chapter presented above investigated the charging behavior of four 
tetrameric proteins under low to moderate (0.5 to 20% v/v) DMSO concentrations. In the next 
phase of the study, avidin and CYP142A1 were subjected to CID and CIU experiments to assess 
the effect of DMSO on protein stability and interactions. In the CID experiments, the effect of 
DMSO on maintaining the tetrameric structure of avidin and the protein-heme interaction of 
CYP142A1 was investigated by monitoring complex dissociation. Meanwhile, the CIU experiments 
investigated the effect of DMSO on the resistance of avidin and CYP142A1 to unfolding, as tracked 
with IM-MS. However, as much higher concentrations of DMSO (up to 60%) would be used for 
these experiments compared to the first phase of the study, the charging behavior under higher 
levels of DMSO first had to be investigated under minimal activation conditions.  
For avidin, concentrations of DMSO higher than 60% could not be examined due to protein 
aggregation, whereas for CYP142A1 the maximum DMSO concentration that could be tested was 
40%. The tetrameric state of avidin was well-preserved at concentrations up to 60% DMSO (Figure 
2.9a). At 50 and 60% (v/v) DMSO, a small amount of monomeric avidin ions (16 kDa) could be 
detected centered around the 9+ charge state. This result suggests that high concentrations of 




Figure 2.9 (a) Native mass spectra of avidin in the presence of 0, 4, 10, 20, 30, 40, 50 or 60% DMSO.  (b) 
Native mass spectra of CYP142A1 in the presence of 0, 4, 10, 20, 30, or 40% DMSO.  
For CYP142A1, the native mass spectra showed that CYP142A1 exists predominantly in 
monomeric form (Figure 2.9b), consistent with the reported X-ray crystal structure,[117] and was 
centered around the 12+ charge state in the absence of DMSO. The observed mass of 47.2 kDa 
matched well with the theoretical mass of the construct (47178 kDa) used in this experiment. The 
protein remained monomeric as the DMSO concentration was increased to 40%. However, signals 
of individual charge states were broadened, which could be attributed to the adduction of small 
molecules (e.g. solvent or ions) to the protein at higher DMSO concentrations. Moreover, 
CYP142A1 fully retained its heme moiety even at 40% DMSO, in contrast to a previous ESI-MS 
study of myoglobin in which 90% of heme was already lost at 20% DMSO.[105] To our knowledge, 
this is the first reported study of CYP142A1 by native MS. 
The opposing trends of DMSO on average protein charge was also evident (Figure 2.10). However, 
very high DMSO concentrations (50% for avidin and 40% for CYP142A1) decreased average charge 
slightly, similar to previously observed for lysozyme and myoglobin.[105] Intriguingly, the average 
charge of CYP142A1 reached at 30% or 40% DMSO was still lower than under DMSO-free 
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conditions (Figure 2.10b), in contrast to avidin where supercharging was observed from 10% of 
DMSO (Figure 2.10a). To our knowledge, CYP142A1 is the first protein that has been reported to 
remain charge-reduced at such high DMSO concentrations. In the first part of this chapter, avidin, 
concanavalin A, alcohol dehydrogenase and pyruvate kinase were supercharged at DMSO 
concentrations greater than 10 or 20%. Meanwhile, the onset of supercharging was around 20% 
DMSO for lysozyme and myoglobin,[105] while for BPase both supercharging and protein 
denaturation were evident at as little as 3% of DMSO.[103]  
 
Figure 2.10 (a) Average charge and CCS of avidin as a function of DMSO concentration. (b) Average charge 
and CCS of CYP142A1 as a function of DMSO concentration. 
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2.2.2.2. Effect of high levels of DMSO on avidin and CYP142A1 size 
IM-MS was performed to assess the effect of DMSO concentration on the size of avidin and 
CYP142A1 ions. The weighted-average CCS of CYP142A1 at 0% DMSO was within 2% (see Section 
2.3.3.) of the theoretical CCS predicted from the X-ray crystal structure (PDB: 2XKR),[117] 
suggesting that CYP142A1 retained its native structure in the gas phase. The abundance-
weighted average CCS of avidin tetramers decreased from 4080 Å2 without DMSO to 4010 Å2 at 
4% DMSO (Figure 2.10a), while for CYP142A1 the CCS decreased from 3450 Å2 without DMSO to 
3240 Å2 at 20% DMSO (Figure 2.10b). This is consistent with the compaction of protein structure 
at low DMSO concentrations as shown previously by IM-MS (vida infra) or solution-phase 
techniques.[105, 127]  
Increasing the DMSO concentration beyond 4% led to an increase in average CCS for avidin, 
initially mirroring the trend for average charge (Figure 2.10a). However, the two trends deviated 
at higher DMSO concentrations, with CCS continuing to rise as the DMSO concentration was 
increased beyond 40%, even while average charge decreased. The maximal CCS of avidin 
tetramers (4240 Å2) was reached at 60% DMSO. This CCS was 4% larger than the average size of 
ions in the absence of DMSO (4080 Å2), and 6% larger than the compacted avidin ions at 4% 
DMSO (4010 Å2). For CYP142A1, the change in average CCS of CYP142A1 ions generally paralleled 
the trend for charge, except that the minimum CCS (3240 Å2) was reached at 20% DMSO, instead 
of at 4% DMSO for minimum charge (Figure 2.10b). Moreover, the average CCS at 40% DMSO 
(3350 Å2) was still 3% lower than that in the absence of DMSO, suggesting that the overall 
structure of CYP142A1 was still compacted even at the highest DMSO concentration used. Since 
electrospray droplets become enriched (estimated to be 3 to 5-fold[105]) in DMSO as they shrink, 
this suggests that CYP142A1 may remain compacted at DMSO concentrations even higher than 
40% during transfer from solution phase to gas phase. The reason for the remarkable gas-phase 
stability of CYP142A1 under such high DMSO concentrations is not known. 
To investigate whether the change in CCS at higher DMSO concentrations could be related to the 
conformational changes of individual ions, the CCS of individual charge states were plotted 
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against DMSO concentration. For avidin, the CCS of individual avidin charge states decreased to 
a minimum in the presence of 4% DMSO, then became larger as the concentration of DMSO was 
increased (Figure 2.11a). In contrast, individual charge states of CYP142A1 were compacted by 
DMSO, with minimum CCS values being reached at 20% DMSO for all charge states (Figure 2.11b). 
These data therefore suggest that DMSO could induce expansion or compaction of avidin and 
CYP142A1 ions, respectively, even at the level of individual charge states. We propose that the 
increase in average CCS of avidin induced by high levels of DMSO (Figure 2.10a) could arise from 
a combination of two factors. Firstly, the supercharging effect of DMSO allows avidin ions to 
access higher charge states that are also larger due to increased Coulombic repulsion. Secondly, 
DMSO causes expansion in the size of individual charge states, which is presumably related to its 
denaturing ability, since DMSO is known to stabilize unfolded conformations of proteins via 
binding to hydrophobic and aromatic residues.[131] Conversely, DMSO is proposed to reduce the 
average CCS of CYP142A1 (Figure 2.10b) both as consequence of its ability to shift the charge 
state distribution of CYP142A1 to lower charge, as well as its ability to compact protein structure 




Figure 2.11 DMSO modulates the CCS of individual charge states in the gas phase. CCS of (a) avidin 
tetramers and (b) CYP142A1 as a function of DMSO concentration for each individual charge state. 
2.2.2.3. DMSO modulates the CID stability of avidin  
While several research groups have studied the effect of DMSO on the stability of non-covalent 
interactions by ESI-MS,[108, 111] no systematic study had been performed on the effect of high 
concentrations of DMSO on the CID stability of protein structure and interactions in the gas 
phase. In this study, avidin tetramers underwent CID at higher trap collision voltages (CV) to 
generate highly-charged, unfolded monomers together with “stripped” trimers via the 
asymmetric charge partitioning mechanism (Figure 2.12a). As the CV was increased, the 
proportion of tetramer dissociation also increased. Moreover, higher charge states of avidin 
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became depleted first compared to lower charge states, which could be attributed to the greater 
Coulombic repulsion experienced by higher charge states, as well as the fact that at any given 
voltage, higher charge states will be accelerated to a greater energy than lower charge states. 
When DMSO was added, the overall CID pathway did not change and similar distributions of 
monomers and trimers were produced. However, dissociation was facilitated by higher DMSO 
concentrations. For instance, in the absence of DMSO, 77% of the tetramer was preserved at a 
CV of 60 V, whereas with 60% DMSO, only 17% of the tetramer remained intact at the same CV 
(Figure 2.12b). Plotting the abundance of the tetramer as a function of CV (Figure 2.12c) reveals 
that DMSO concentrations higher than 4% promoted tetramer dissociation. The Figure 2.12c 
inset presents CID50 values (the CV needed to dissociate 50% of tetramers) as a function of 
DMSO concentration. The CID50 of avidin tetramers increased from 66.5 to 78.1 V (+11.6 V) as 
the DMSO concentration was raised from 0 to 4%, indicating a protective effect against 
dissociation and is consistent with the observed compaction. However, further increases in the 
DMSO concentration led to a decrease in CID50, with the minimum CID50 value of 53.6 V being 
reached at 50% DMSO, corresponding to a decrease of 12.9 V compared to in the absence of 
DMSO. Taken together, our data show that high concentrations of DMSO have a significant 
destabilizing effect on the CID of avidin. Only at 4% DMSO, where the average charge of the avidin 




Figure 2.12 DMSO influences the CID stability of avidin. Native MS spectra of avidin in the presence of (a) 
0% or (b) 60% DMSO at different trap CVs. The abundance of the tetramer (%Tet) at each CV is indicated. 
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(c) Abundance of tetramer as a function of trap CV at each DMSO concentration. The inset shows the CID50 
as a function of DMSO concentration. 
Generally, the CID50 values of avidin were inversely related to average protein charge. That is, 
DMSO concentrations that produced higher average charges of the avidin tetramer also gave 
lower overall CID50 values. This was expected as higher charge state ions possess more collision 
energy at any given CV, and are also inherently less stable due to increased Coulombic repulsion 
compared to lower charge state ions. Therefore, it was also of interest to determine whether the 
destabilization of avidin tetramers by DMSO was due solely to the ability of DMSO to shift the 
charge state distribution of avidin tetramers towards higher charge, or whether DMSO also 
exerted destabilizing effects on individual ions that are independent of its effect on charge state 
distribution. To address this, the CID50 values for the individual charge states were plotted as a 
function of DMSO concentration (Figure 2.13a). Interestingly, DMSO also promoted the 
dissociation of individual charge states. Note that when comparing between individual charge 
states, the concept of collision energy can be used which is calculated by multiplying the charge 
of the ion by the collision voltage. The collision energy more accurately reflects the energy 
available for dissociation and unfolding of a particular charge state compared to collision voltage. 
For example, the CID50 of the 16+ charge state was lowered from 1043 to 954 eV (–89 eV) when 
the DMSO concentration was raised from 0 to 60%, while for the 17+ charge state a reduction 
from 1020 to 923 eV (–97 eV) in CID50 was observed upon increasing DMSO concentration from 
20 to 60%. This is in contrast to previously reported results from Landreh and co-workers, where 
3% DMSO had no effect on the CID stability of the 16+ charge state of TTR.[108] However, our 
study used relatively high concentrations of DMSO, compared to the 3% DMSO used for TTR. 
Indeed, the protective effect of 4% DMSO against dissociation could not be detected at the level 
of individual charge states in our study (Figure 2.13a). Taken together, the overall reduction in 
the CID stability of avidin at high DMSO concentrations could be attributed to two, possibly 
interrelated, mechanisms. First, DMSO shifts the charge state distribution of avidin tetramers 
towards ions of higher charge, which have lower intrinsic stability against dissociation. Second, 
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DMSO may also exert a destabilizing effect against individual charge states, presumably as a 





Figure 2.13 (a) CID50 and (b) CIU50 values of avidin tetramers as a function of DMSO concentration for 
individual charge states. (c) Collision energy difference (CID50 – CIU50) of avidin tetramers as a function 
of charge state at different DMSO concentrations. Note that (b) and (c) are discussed in Section 2.2.2.5. 
2.2.2.4. DMSO influences the stability and heme dissociation pathway of CYP142A1 
The influence of DMSO on the CID behavior of CYP142A1 was also investigated. Figures 2.14a 
and 2.14b show CID spectra (without selection) of CYP142A1 at 0 and 30% DMSO, respectively. 
CYP142A1 holoenzyme underwent CID to release the apoenzyme and also the free heme-b ion 
at m/z 616 Da ([M]+) together with an ammonia adduct of heme-b at m/z 633 Da ([M+NH3]+). The 
CYP142A1 peaks also generally became sharper at higher CV, consistent with the dissociation of 
buffer and/or DMSO molecules from the protein. Interestingly, DMSO had a protective effect 
against heme loss. For instance, only 20% of CYP142A1 ions retained heme at 140 V in the 
absence of DMSO (Figure 2.14a), whereas in the presence of 30% DMSO, the proportion of the 
holoenzyme was 37% (Figure 2.14b). Among all DMSO concentrations tested, heme dissociation 
occurred earliest at 0% DMSO (Figure 2.14c), with a CID50 value (the CV needed to dissociate 
50% of holoenzyme) of 118 V (Figure 2.14c inset). The highest stability of the holoenzyme was 






Figure 2.14 DMSO influences the CID stability of CYP142A1. Native MS spectra of CYP142A1 in the presence 
of a) 0% or b) 30% DMSO at different trap CVs. The proportion of holo-CYP142A1 (%Holo) at each CV is 
indicated. c) Proportion of holo-CYP142A1 as a function of trap CV at each DMSO concentration. The inset 




As with avidin dissociation, it was also of interest to explore whether DMSO could protect against 
dissociation of the heme group in a manner that is independent of its effects on charge state 
distribution. To study this issue further, tandem MS/MS (precursor ion selection) was performed 
to study the dissociation pathways of individual charge states. In the absence of DMSO, 
CYP142A1 ions exhibited two heme dissociation pathways: charge stripping and charge retention 
(Figure 2.15a). In the charge stripping pathway, the holo-CYP142A1 N+ ion dissociates into the 
heme monocation and the (N – 1)+ ion of the apoenzyme. This is the anticipated dissociation 
pathway for CYP142A1 because the protein is isolated in the ferric (3+) oxidation state, and 
therefore would be expected to dissociate the (Fe(III)heme)+ ion.[132] In contrast, in the charge 
retention pathway, the liberated apoenzyme has the same charge as the initial holoenzyme, 
which is presumed to occur via the dissociation of a neutral heme species, possibly a heme-
acetate adduct.[133] However, at 30% DMSO, the charge retention pathway is eliminated and only 
the charge stripping pathway is observed (Figure 2.15b). It was reasoned that the much higher 
concentration of DMSO (ca. 4.2 M) relative to acetate (200 mM) causes the anionic acetate to be 
displaced from heme in the initial solution through the formation of a cationic (heme-DMSO)+ 
adduct,[134-135] thereby eliminating the charge retention pathway which requires the release of a 






Figure 2.15 DMSO influences the dissociation pathway of CYP142A1. Tandem MS/MS of CYP142A1 at (a) 
0% DMSO and (b) 30% DMSO with selection of the 12+ holoenzyme (left panel) or 11+ holoenzyme (right 
panel) as the precursor ion (indicated by a filled red circle). The trap CV and proportion of holo-CYP142A1 
(%Holo) at each CV is indicated. (c) Proportion of holo-CYP142A1 as a function of trap CV at 0 or 30% DMSO 
for 11+ and 12+ charge states. The inset shows the CID50 for the 11+ and 12+ charge states at 0 and 30% 
DMSO. 
In contrast, avidin tetramers exhibited only a minor amount of charge stripping before 
dissociation (Figure 2.16), as indicated by the weak intensity of the (N – 1)+ when the N+ ion was 
selected as the precursor ion. 
 
Figure 2.16. Tandem MS/MS of avidin (a) 17+, (b) 16+ and (c) 15+ tetramer charge states at 0% DMSO 




The MS/MS data also confirmed that higher charge states of CYP142A1 dissociated heme more 
easily than lower charge states, as expected (Figures 2.14c and 2.17a). Moreover, DMSO 
conferred a protective effect against heme-b loss even at the level of individual charge states. 
For instance, the CID50 values of the 11+ and 12+ charge states increased from 1297 ± 13 eV to 
1421 ± 18 V (+124 eV) and from 1277 ± 17 eV to 1354 ± 16 eV (+77 eV) respectively as the DMSO 
concentration was raised from 0 to 30% (Figure 2.14c inset). Taken together, these data suggest 
that DMSO protects against heme loss both by shifting the charge state distribution of CYP142A1 
towards ions of lower charge, which have higher intrinsic stability to dissociation, as well as by 
enhancing the stability of individual charge states. The latter effect could be linked to the 
compaction of CYP142A1 ions by higher DMSO concentrations, that is, more compact 




Figure 2.17 (a) CID50 and (b) CIU50 values of the CYP142A1 holoenzyme as a function of DMSO 
concentration for individual charge states. (c) Collision energy difference (CID50 – CIU50) of the CYP142A1 
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holoenzyme as a function of charge state at different DMSO concentrations. Note that (b) and (c) are 
discussed in Section 2.2.2.5. 
2.2.2.5. DMSO modulates the CIU stability of proteins 
A number of studies have investigated the effect of various solution additives on the CIU stability 
of different proteins. The Ruotolo group have shown that both anions[112] and cations[113] can 
have dramatic effects on both CIU and CID stabilities. It was postulated that anions stabilize 
proteins through dissociative cooling-type mechanisms, whereas cations increase stability by 
forming multidentate interactions within proteins to tether together non-contiguous protein 
regions.[114] Robinson, Ruotolo and co-workers have found that TrisH+ also increased CIU 
stability, which was attributed to an evaporative cooling mechanism or alternatively to the 
binding of TrisH+ to critical regions of the protein so as to replace solvent contacts that are 
needed for maintaining native-like conformations.[115] However, to our knowledge, the effect of 
DMSO on the CIU stability of proteins has not yet been reported in the literature.  
Figure 2.18a shows CIU fingerprints for the 14+ to 17+ charge states of the avidin tetramer in the 
absence of DMSO. At least three less compact conformations in addition to the native 
conformation were observed at 0% DMSO for the 15+ charge state of avidin, which was similar 
to previously reported.[114-115] Higher charge states of the avidin tetramer unfolded at lower CV, 
which can again be attributed to increased Coulombic destabilization. Unfolding pathways for 
the avidin tetramer were broadly similar in the presence of 50% DMSO (Figure 2.18b). However, 
lower voltages were needed to unfold avidin ions of a given charge state at 50% DMSO compared 
to in the absence of DMSO. For instance, the CIU50 (energy needed to deplete 50% of the most 
compact conformation) value of the 15+ ion of the avidin tetramer decreased from 786 ± 11 eV 
in the absence of DMSO to 744 ± 17 eV (–42 eV) with 50% DMSO (Figures 2.18c and 2.13b). 
However, the decreases in CIU50 induced by DMSO are comparatively smaller than the 
reductions of CID50 described previously (shown for representative charge states in Table 2.3), 




Figure 2.18 DMSO decreases the CIU stability of avidin, as indicated by an increased ease of unfolding as 
collision energy is increased. CIU fingerprints of avidin tetramer charge states in the presence of (a) 0% or 
(b) 50% DMSO. (c) CIU50 values for the 15+, 16+ and 17+ charge states at 0 and 50% DMSO. Error bars 




Table 2.3. CID50 and CIU50 values of selected avidin and CYP142A1 charge states. Errors represent the 
standard deviation of duplicate results. 
Avidin 16+ 
[DMSO] / % CID50 / eV CIU50 / eV CID50 – CIU50 / eV 
0 1043 ± 12 682 ± 17 361 ± 29 
10 1038 ± 17 675 ± 14 363 ± 31 
20 1062 ± 28 658 ± 15 404 ± 40 
30 1038 ± 20 661 ± 8 377 ± 28 
40   997 ± 22 687 ± 20 290 ± 42 
50 1022 ± 15 648 ± 14 372 ± 29  
60   954 ± 17 641 ± 13 313 ± 31 
CYP142A1 11+ 
[DMSO] / % CID50 / eV CIU50 / eV CID50 – CIU50 / eV 
0 1297 ± 22 650 ± 15 647 ± 37 
4 1381 ± 15 654 ± 11 727 ± 26 
10 1405 ± 18 697 ± 17 708 ± 35 
20 1416 ± 27 694 ± 15 722 ± 42 
30 1421 ± 19 696 ± 9 725 ± 28 
40 1418 ± 18 709 ± 14 709 ± 32 
The collision energy differences between CID50 and CIU50 (CID50 – CIU50) were invariably 
positive (Figure 2.13c), indicating that all charge states of the avidin tetramer undergo unfolding 
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before dissociation, consistent with the asymmetric protein dissociation hypothesis. The 
magnitudes of these differences were comparable to a previous CID/CIU study on avidin by 
Ruotolo and co-workers.[136] Moreover, at DMSO concentrations between 0 and 30%, the 
collision energy difference generally increased with charge state, similar to previous 
observations.[136] As both CID and CIU values decrease with charge, this suggests that Coulombic 
repulsion has a larger destabilizing effect on unfolding compared to dissociation (i.e., unfolding 
is more charge-driven compared to dissociation). However, the collision energy differences were 
generally reduced at high DMSO concentrations (≥40%). For example, the collision energy 
difference for the 16+ charge state of avidin was decreased from 404 ± 40 eV at 20% DMSO to 
313 ± 31 eV at 60% DMSO. This observation is consistent with the greater ability of DMSO at 
promote dissociation compared to unfolding of individual charge states, as noted above.  
CIU fingerprints for the 10+ to 13+ charge states of the CYP142A1 holoenzyme at 0 and 30% 
DMSO are shown in Figures 2.19a and 2.19b, respectively. As with avidin, CYP142A1 
holoenzymes transitioned through progressively more extended conformers as the CV was 
increased, with the exception of the 10+ ion which exhibited only two conformational states 
(compact and extended) over the range of CV tested. Unlike with avidin, however, DMSO 
increased the stability of CYP142A1 ions against unfolding. For instance, the CIU50 value of the 
11+ holoenzyme increased from 650 ± 15 eV at 0% DMSO to 696 ± 9 eV (+46 eV) at 30% DMSO 
(Figures 2.19c and 2.17b). Thus, and in similar fashion to its effect on CID stability, it is proposed 
that DMSO increases the stability of CYP142A1 holoenzymes against unfolding both by reducing 
the average charge of the ions, as well as by increasing the CIU stability at the level of individual 
charge states. However, as  for avidin the increases in CIU50 induced by DMSO are relatively small 
compared to the increases of CID50 described above (Table 2.3). Figure 2.17c plots the collision 
energy differences between CID50 and CIU50 for different charge states of the CYP142A1 
holoenzyme. As with avidin, CYP142A1 holoenzymes generally unfold before dissociating, and 
the collision energy differences at lower charge states were also reduced. This is consistent with 





Figure 2.19 DMSO increases the CIU stability of CYP142A1, as indicated by an increased resistance to 
unfolding as collision energy is increased. CIU fingerprints of CYP142A1 holoenzyme charge states in the 
presence of (a) 0% or (b) 30% DMSO. (c) CIU50 values for the 10+, 11+ and 12+ charge states at 0 and 30% 
DMSO. Error bars represent the standard deviation of duplicate results. 
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The unfolding behavior of the ejected CYP142A1 apoenzyme was also tracked. CIU fingerprints 
of the apoenzymes were similar in the absence (Figure 2.20a) or presence of 30% DMSO (Figure 
2.20b). At 30% DMSO, the 9+ apoenzyme was ejected in a compact state (CCS = 3060 Å2) that did 
not unfold even at the highest CV tested. The ejected 10+ apoenzyme was also initially compact 
(CCS = 3180 Å2), but transitioned to an extended conformation (CCS = 3620 Å2) at voltages beyond 
90 V. These CCS values are similar to those for the compact and extended states of the 10+ 
holoenzyme at the same CV (CCS = 3200 Å2 and 3640 Å2 respectively), indicating that the loss of 
the heme group did not have a major effect on the size of either the compact or extended 
conformations of CYP142A1. The 11+ to 13+ charge states of the apoenzyme were ejected in 




Figure 2.20 CIU fingerprints of CYP142A1 apoenzyme charge states in the presence of (a) 0% or (b) 30% 
DMSO. (c) CIU50 values for the 10+ holoenzyme and apoenzyme at 0% and 30% DMSO. Error bars 
represent the standard deviation of duplicate results.  
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2.2.2.6. Monitoring the protective effect of the heme group using CIU 
The heme prosthetic group is known to stabilize the structure of heme-containing proteins, 
including cytochrome P450s.[137] Using ultraviolet photodissociation (UVPD) mass spectrometry, 
Brodbelt and Cammarata showed that the cleavage of holo-myoglobin was suppressed in regions 
that interact with heme, indicating that the heme had a protective effect against 
fragmentation.[138] Williams and co-workers found that the heme group protected against the 
DMSO-induced unfolding of myoglobin by solution-phase HDX-MS experiments.[105] Intriguingly, 
the stabilizing effect of the heme group on the unfolding stability of CYP142A1 could also be 
monitored by CIU. For instance, at 0% DMSO, the CIU50 value for the 10+ holoenzyme was 947 
± 3 eV, but this decreased to 852 ± 2 eV (–95 eV) for the 10+ apoenzyme (Figure 2.20c). Similarly, 
at 30% DMSO the CIU50 value for the 10+ holoenzyme (1079 ± 20 eV) was 204 eV higher than for 
the 10+ apoenzyme (875 ± 14 eV). These results indicate that the heme group substantially 
stabilizes the CYP142A1 holo-enzyme in the gas phase. However, while high DMSO 
concentrations protected against the unfolding of the holoenzyme, it had little effect on the 
unfolding stability of the corresponding apoenzyme (Figure 2.21). 
 
Figure 2.21 CIU50 values of the 10+ charge state of the CYP142A1 holoenzyme and apoenzyme as a 




Native nESI-IM-MS has been used to study the effect of DMSO on the dissociative and unfolding 
stability of avidin and Mtb CYP142A1. To our knowledge, this is the first systematic study of the 
effect of DMSO on protein CID and CIU in the literature. There are a number of general 
conclusions from our work.  
Evidence has been provided that suggests a dual mechanism for the ability of DMSO to modulate 
the CID and CIU stability of proteins. DMSO not only shifts the charge state distributions of 
proteins to higher or lower charge states, which vary in intrinsic stability due to differences in 
electrostatic repulsion, but also modulates stability via effects at the level of individual charge 
states.  
The data also show that the effects of DMSO on protein structure and interactions are highly 
protein-dependent, which has implications for the design of biological assays where DMSO is 
frequently employed as a co-solvent. While DMSO concentrations higher than 4% facilitated the 
dissociation and unfolding of the avidin tetramer, CYP142A1 exhibited remarkable stability in the 
presence of up to 40% DMSO, which protected the enzyme from both heme loss and unfolding. 
To our knowledge, CYP142A1 is the first protein that has been reported to remain charge-reduced 
at such high DMSO concentrations in native MS. However, compared to previous work with 
ions,[112-114] the stabilizing effects of DMSO on CYP142A1 are comparatively weaker. This could be 
due to the fact that as DMSO is neutral, it interacts relatively weakly with protein, and hence less 
energy is removed when DMSO adducts dissociate from the protein. 
Additionally, it was established using tandem MS/MS experiments that DMSO could modify the 
heme dissociation pathway of CYP142A1. In the absence of DMSO, CYP142A1 can dissociate 
either the positive (Fe(III)heme)+ ion or the neutral (Fe(III)heme)-acetate adduct, resulting in 
charge stripping and charge retention, respectively. However, DMSO is hypothesized to displace 
acetate, such that only the charge stripping pathway is observed in the presence of DMSO. Finally, 
we have demonstrated that the protective effects of the heme group on the gas-phase stability 
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of CYP142A1 can be assessed using CIU. It is envisaged that this approach could be broadly 
applied to study the stabilizing effect of heme or other prosthetic groups on other proteins in the 
gas phase.   
2.3. Experimental 
2.3.1. Materials and methods 
Avidin (egg white), concanavalin A (Canavalia ensiformis), alcohol dehydrogenase 
(Saccharomyces cerevisiae) and pyruvate kinase (rabbit heart) were obtained from Sigma-Aldrich 
(UK). Mtb His6-tagged CYP142A1 was provided by our collaborator Kirsty McLean in the Munro 
group.[117] Protein samples were exchanged into 200 mM ammonium acetate (pH 7.0) solution 
using Micro Bio-Spin 6 chromatography columns (Bio-Rad, UK) and diluted to a final 
concentration of 20 μM before analysis. 
2.3.2. Mass spectrometry 
Nanoelectrospray ionization-ion mobility-mass spectrometry (nESI-IM-MS) was performed on a 
Synapt HDMS mass spectrometer (Waters, UK) modified for studying high masses (32k 
quadrupole) and equipped with a traveling-wave (TW) IM device. 2.5 μL of protein solution was 
injected into a gold-coated borosilicate emitter (Thermo Scientific, UK) for sampling. Typical 
conditions were: capillary voltage 1.5 kV, cone voltage 50 V,  trap collision voltage 20 V, trap DC 
bias 35 V, transfer collision voltage 12 V, source temperature 20 °C, backing pressure 3–4 mbar, 
trap pressure 3–4 × 10–2 mbar, IM (N2) pressure 5–6 × 10–1 mbar and TOF pressure 7–8 × 10–7 
mbar.  
IM-MS spectra were acquired as above except that the instrument was run in mobility TOF mode. 
The traveling wave velocity was 250 ms−1 and four wave heights (7, 8, 9, and 10 V) were used. 
These wave heights were selected to ensure that the ions arrived within the time course of these 
IM experiments. The reported CCS values were an average of the data recorded over all of the 
wave heights.  
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To promote CID and CIU, the trap collision voltage was raised in 5 V increments from 20 to 100 V 
for avidin and in 10 V increments from 20 to 150 V for CYP142A1. To record CIU, the instrument 
was operated in mobility TOF mode using an IM wave velocity of 250 ms–1 and a wave height of 
10 V without precursor ion selection. Avidin, concanavalin A, alcohol dehydrogenase and 
pyruvate kinase were used as calibrant ions for CCS determination. 
2.3.3. Data processing 
Mass spectra were calibrated externally using a solution of cesium iodide (100 mg mL–1). Data 
acquisition and processing were performed using MassLynx 4.1 (Waters) and DriftScope 2.5 
(Waters). CCS calibration was performed as previously described.[76]  
For CID analysis, the measured peak heights were used and all charge states were taken into 
account. CID50 values were calculated from non-linear curve fitting using Origin 9.1 (OriginLab). 
Unless otherwise stated, all CCS values are quoted as N2 values. CID50 and CIU50 values are 
quoted as mean ± standard deviation of at least two independent experiments. For the CIU 
experiments, PULSAR[53] was used to calibrate CCS values, visualize CIU fingerprints and calculate 
CIU50 values. Tim Allison (University of Oxford) is acknowledged for assistance with PULSAR. 
As algorithms for CCS calculation from X-ray crystal structures are parameterized for helium 
collision gas,[139] the corresponding CCS(He) of CYP142A1 was also determined by calibration of 
the drift times with helium CCS values in order to enable comparison between the experimental 
result and the theoretical CCS. The experimental CCS(He) of CYP142A1 was 3140 Å2, which is 
within 2% of the theoretical CCS(He)calc value of 3090 Å2, where CCS(He)calc = 1.14 × CCS(He)PA × 
(Mexp/MPDB)2/3 and CCS(He)PA is the CCS calculated from the X-ray crystal structure of CYP142A1 
(PDB: 2XKR)[117] using the projection approximation (PA) algorithm implemented in DriftScope, 
Mexp is the mass of His6-tagged CYP142A1 (47178 Da) used in the experiment and MPDB is the 
mass of the CYP142A1 construct (45015 Da) in the reported crystal structure. The coefficient of 
1.14 in the above calculation is an empirically determined scaling factor that takes into account 
75 
 



















3. Structural insights and fragment screening against the EthR-DNA 
interaction using native mass spectrometry 
3.1. Introduction 
Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (Mtb) that exerts 
an enormous burden on human health and wellbeing worldwide. The World Health Organization 
(WHO) has estimated that in 2017, TB killed 1.3 million people, while another 10 million people 
became infected.[140] Moreover, around 23% of the world population, or about 1.7 billion people, 
are estimated to be latently infected.[140] Progress against TB has been challenged by the rise of 
multidrug resistant (MDR) and extensively drug-resistant (XDR) Mtb strains. 3.5% of new cases 
and 18% of previously treated cases have MDR-TB, and of those, an estimated 8.5% are XDR-
TB.[140]  
Ethionamide is a second-line drug used for the treatment of MDR-TB. Mechanistically, 
ethionamide is a prodrug that is activated in vivo by EthA, a flavin-containing monooxygenase 
enzyme in Mtb, to form an ethionamide-NAD adduct.[141] This adduct inhibits the 2-trans-enoyl 
reductase enzyme InhA, which in turn leads to the inhibition of the Mtb type II fatty acid synthase 
system (FAS II).[142] However, the potency of ethionamide is reduced by EthR, which is a 
transcriptional repressor of ethA expression.[143] This suggests that inhibitors of EthR activity 
could function as ethionamide boosters,[144] allowing for lower dosages of the drug to be used. A 
number of EthR inhibitors have shown ethionamide potentiating activity in cellular or even in 
vivo models of TB infection.[144-147] 
EthR belongs to the TetR/CamR repressor protein family, whose members show high sequence 
homology between their N-terminal DNA-binding domains, and is expected to bind to the DNA 
major groove via its helix-turn-helix (HTH) motif.[148] Using DNase footprinting assays, Baulard 
and co-workers showed that EthR recognizes a 55-bp operator sequence within the ethA-R 
intergenic region.[143] Subsequent surface plasmon resonance (SPR) analysis suggested that up to 
eight units of EthR could bind cooperatively to a 62-bp sequence (DNA62) encompassing the 
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operator site (Figure 3.1).[143] There are numerous X-ray crystal structures of the EthR dimer in 
complex with various small-molecule ligands,[149-150] but the structure of the EthR-DNA complex 
has not yet been solved. 
 
Figure 3.1 Sequence of the ethA-R intergenic region. The positions of the DNA sequences used in this work 
are shown. The two arrows in the DNase protected region indicate direct repeats.   
Native ESI-MS is an ideal technique for the study of the interactions and stoichiometries of 
macromolecular complexes.[40, 151] A large body of work has established that the native structure 
and composition of biomolecular complexes can be adequately maintained as solution species 
are transferred into the gas phase during the electrospray process. However, compared to the 
application of ESI-MS for multi-protein complexes, fewer studies on protein-DNA complexes have 
been reported.[152-155] Analysis of protein-DNA complexes containing large DNA sequences using 
positive-ion native MS is complicated by the heterogeneity of cation adduction and as well as 
difficulties with achieving a stable electrospray.[153, 155]   
Meanwhile, fragment-based approaches have been applied to develop EthR inhibitors. Willand 
and co-workers started from a 4-iodo-N-prop-2-ynylbenzenesulfonamide fragment that was 
initially identified using an in situ click chemistry approach.[156] Subsequent fragment elaboration 
furnished analogues that disrupted the EthR-DNA interaction and boosted ethionamide activity 
in Mtb-infected macrophages with sub-micromolar potency.[157] Our group has previously 
employed DSF (also known as the thermal shift assay) to screen a 1250-member fragment library 
against EthR, with fragments showing ΔTm ≥ 1 °C at 10 mM concentration being classed as a 
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hit.[158] Fragment merging and linking strategies subsequently generated improved analogues 
with low-micromolar IC50 values against the EthR-DNA interaction.[158-159] While the use of 
nanoelectrospray ionization-mass spectrometry (nESI-MS) to study biomolecular assemblies has 
been well-documented,[40, 151] native MS is a relatively underutilized technique especially in 
fragment screening for drug discovery.[44-45, 63, 67, 160] 
In this chapter, native MS was used to provide structural insights into the EthR-DNA interaction. 
Our results indicate that up to six subunits of EthR are able to bind to its operator, instead of the 
eight subunits that had been previously reported. Moreover, the first demonstration is provided 
of the use of native MS for screening fragments against a protein-DNA interaction. Hits were 
validated using surface plasmon resonance and X-ray crystallography, resulting in the 
identification of two new fragments that disrupt the EthR-DNA interaction in vitro and that bind 
to the hydrophobic channel of the EthR dimer. 
3.2. Results and discussion 
3.2.1. Structural insights into the EthR-DNA interaction 
3.2.1.1. Optimization of MS conditions for detecting EthR-DNA complexes 
Histidine-tagged  EthR was expressed in this project in excellent yield and purity following a 
literature procedure.[158] Mass spectra were obtained by nano-electrospray ionization (nESI) from 
a hybrid quadrupole time-of-flight (qTOF) SYNAPT HDMS (Waters) instrument. The native MS 
spectrum of EthR alone confirmed the dimeric nature of EthR in solution, with the charge state 
distribution being centered around the 13+ state (Figure 3.2a). The observed mass of dimeric 
EthR (50,475 ± 97 Da) was consistent with the theoretical mass of the dimer of the construct 





Figure 3.2 Native MS reveals the formation of EthR4-DNA and EthR6-DNA complexes. MS spectra of (a) 
EthR alone showing that the protein exists predominantly as the dimer, (b) DNA62 alone, and (c) a mixture 
of EthR and DNA62 in a 8:1 ratio, showing the formation of both EthR4-DNA62 and EthR6-DNA62 complexes. 
The native mass spectrum of DNA62 alone showed that while DNA62 existed primarily in its 
expected duplex state centered around the 10+ charge state, a fraction of the DNA was single-
stranded (DNAss62), which could be due to an excess of one of the two complementary 
oligonucleotides (Figure 3.2b). DNA m/z signals were generally broad, which could be a result of 
the large amount of cations that must be adducted to the polyanionic DNA in order for the nucleic 
acids to be detected in positive-ion mode.[161]  
Previous reports had described difficulties with achieving a stable electrospray with samples 
containing protein-DNA complexes.[153, 155] Optimization experiments were therefore carried out 
80 
 
to investigate the effect of various parameters on the EthR-DNA interaction. Due to the sensitivity 
of protein-DNA interactions to ionic strength,[162] the effect of NH4OAc concentration was first 
investigated. A concentration of 200 mM of NH4OAc was found to provide the most optimal 
conditions for detecting the EthR-DNA complex by native MS (Figure 3.3). At 20 or 50 mM of 
NH4OAc, only a small proportion of EthR-DNA complexes were formed and a significant fraction 
of free protein and DNA remained. On the other hand, at 500 mM of NH4OAc, the signals of the 
EthR-DNA complex broadened and became were hard to resolve. Higher concentrations of ions 
are also expected to weaken protein-DNA interactions by shielding electrostatic interactions. 
Therefore, a concentration of 200 mM NH4OAc was used for further investigation. 
 
Figure 3.3 Native mass spectra of EthR (20 μM) and DNA62 (2.5 μM) in NH4OAc (pH 7.0) of concentration 
(a) 20 mM, (b) 50 mM, (c) 200 mM, (d) 500 mM. 
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Next, the effect of the addition of Mg2+ ions was investigated. Mg2+ is thought to play an 
important role in the structure and function of nucleic acids, including regulating the binding of 
proteins to DNA. For example, a citrate-Mg2+ moiety aided the binding of the dimeric aconitase 
repressor AcnR, which like EthR is a transcriptional repressor of the TetR/CamR family, to 
DNA.[163] However, the addition of 500 µM of Mg2+ (as magnesium acetate) did not significantly 
increase the proportion of protein-DNA complexes (Figure 3.4). Higher Mg2+ concentrations were 
not examined because non-volatile ions exert a detrimental effect on the quality of native mass 
spectra. The presence or absence of Mg2+ ions also did not influence the extent of EthR-DNA 
formation in an SPR assay performed by our collaborator Sherine Thomas in the Blundell group 
(data not shown). 
 
Figure 3.4 Native mass spectra of EthR (20 μM) and DNA106 (2.5 μM) in NH4OAc (200 mM, pH 7.0) in the 
(a) absence and (b) presence of Mg2+ ions (500 μM). 
The time course of EthR-DNA complex formation was also monitored by native MS. The data 
showed that equilibrium was reached within 5 min, as no significant change in the proportion of 




Figure 3.5 Native mass spectra of EthR (20 μM) and DNA106 (2.5 μM) in NH4OAc (200 mM, pH 7.0) after 
incubation for (a) 5 min, (b) 10 min, and (c) 40 min. 
For native MS, the protein is required to be buffer-exchanged into a volatile buffer such as 
NH4OAc before analysis. However, there was no significant change in the spectra when EthR and 
DNA were incubated and then buffer-exchanged together using centrifugal concentrators, versus 





Figure 3.6. Native mass spectra of EthR (20 μM) and DNA62 (2.5 μM) in NH4OAc (200 mM, pH 7.0). In (a), 
buffer-exchanged protein was incubated with DNA before measurement. In (b), protein was incubated 
with DNA, and the mixture was buffer-exchanged before measurement. 
3.2.1.2. Investigating the stoichiometry of the EthR-DNA interaction 
Under the optimized conditions, EthR (20 μM) and DNA62 (2.5 μM) were mixed together in an 8:1 
ratio and subjected to nESI-MS. Surprisingly, instead of the expected EthR8-DNA62 complex, only 
the EthR6-DNA62 complex (192,473 ± 44 Da), centered around the 24+ state, and the EthR4-DNA62 
complex (140,604 ± 23 Da), centered around the 22+ state, were detected (Figure 3.2c). The 
observed masses are about 1% higher than the theoretical masses of 189,555 and 139,099 Da for 
the EthR6-DNA62 and EthR4-DNA62 species, respectively, which can be attributed to the adduction 
of weakly-bound molecules or ions. The EthR6-DNA62 and EthR4-DNA62 complexes are presumably 
formed by the assembly of three or two EthR dimers, respectively, onto the DNA. In contrast, no 
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protein-DNA complexes were observed by native MS when EthR was mixed with a random 55-bp 
sequence (DNAR55) in a 8:1 or 12:1 ratio (Figure 3.7), indicating that the complexes formed 
between EthR with its operator DNA62 were specific.  
 
Figure 3.7 Native mass spectra (a) DNAR55 (2.5 μM) and (b) a mixture of EthR (20 μM) and DNAR55 (2.5 μM) 
in an 8:1 ratio, and (c) a mixture of EthR (30 μM) and DNAR55 (2.5 μM) in a 12:1 ratio. All spectra were 
recorded in NH4OAc (200 mM, pH 7.0).  
The proportion of EthR and DNA62 was varied in order to investigate whether alternative protein-
DNA complexes could be formed at different protein to DNA ratios. At a 6:1 or 7:1 ratio of EthR 
to DNA62, the EthR4-DNA62 and EthR6-DNA62 complexes were detected as the major and minor 
species, respectively, and some free DNA could also be observed (Figure 3.8a,b). The relative 
intensity of free DNA62 in the native mass spectra was much higher than expected for a slight 
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excess of DNA over protein, which could be due to the greater ionization efficiency of DNA 
compared to the protein-DNA complex, as has been previously reported.[152] Additionally, there 
could be uncertainty in the protein-DNA ratio due to variability in the absorbance measurements 
of DNA on the NanoDrop spectrophotometer. As the proportion of EthR was increased to 8:1, 
the EthR6-DNA62 complex became the predominant protein-DNA species, and only free protein 
could be detected (Figure 3.8c). Even at a 12:1 ratio of EthR to DNA62, the EthR6-DNA complex 
was the largest species detected and no evidence of non-specific binding giving rise to higher 





Figure 3.8 Native mass spectra of a mixture of EthR and DNA62 in a (a) 6:1 ratio, (b) 7:1 ratio, (c) 8:1 ratio 
or (d) 12:1 ratio. The concentration of DNA62 was held at 2.5 µM. All spectra were recorded in NH4OAc (200 
mM, pH 7.0). The protein-DNA peaks have been magnified by 2× for clarity. 
A small amount of the EthR5-DNA62 complex was also sometimes observed (Figure 3.9), which 
could presumably be formed from the association of a monomeric EthR subunit with a EthR4-
DNA62 complex. However, the relatively low abundance of the EthR5-DNA62 complex and the 
EthR3-DNA37 complex (see below) compared to complexes containing an even number of EthR 
subunits suggests that their biological relevance may be relatively minor. An alternative 
interpretation is that these odd-numbered species may represent transient intermediates during 
protein-DNA complex formation. 
 
Figure 3.9 Native mass spectra of a mixture of EthR (20 μM) and DNA62 (2.5 μM) in NH4OAc (200 mM, pH 
7.0). 
The stoichiometric heterogeneity of the protein-DNA species observed by native MS could 
possibly account for the difficulties in obtaining an X-ray crystal structure of the EthR-DNA 
complex thus far. A longer 106-bp DNA sequence (DNA106) encompassing the entire ethA-R 
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intergenic region also gave rise to EthR6-DNA106 and EthR4-DNA106 complexes when incubated 
with EthR (Figure 3.10), however the quality of the native mass spectra was reduced. Generally, 
it was found in this investigation that longer DNA sequences gave lower-quality spectra in native 
MS compared to shorter DNA sequences. 
 
Figure 3.10 Native mass spectra (a) EthR (20 µM), (b) DNA106 (2.5 μM) and (c) a mixture of EthR (20 μM) 
and DNA106 (2.5 μM). All spectra were recorded in NH4OAc (200 mM, pH 7.0). 
Next, EthR was incubated separately with the DNA duplexes DNA37 and DNA36 (Figure 3.1), and 
native mass spectra of the resulting complexes were recorded. In the SPR experiments reported 
previously,[143] each DNA37 duplex bound to an average of 4.5 EthR molecules, whereas with 
DNA36, protein-DNA binding was greatly decreased. In native MS, a mixture of EthR (15 μM) and 
DNA37 (2.5 μM) produced mostly the EthR4-DNA37 complex, centered around the 19+ charge 
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state, along with some of the EthR2-DNA37 complex and a small amount of the EthR3-DNA37 
complex (Figure 3.11a). With DNA36, mainly EthR2-DNA36 complexes were formed, along with a 
small amount of the EthR4-DNA36 complex (Figure 3.11b). Furthermore, significant quantities of 
both unbound protein and DNA were detected, which is consistent with the greatly diminished 
binding capacity of EthR to DNA36 as observed by SPR. 
 
Figure 3.11 Native MS showing reduced stoichiometry of EthR with the shorter DNA37 and DNA36 
sequences. MS spectra of (a) EthR and DNA37 in a 6:1 ratio, showing the formation of mainly EthR4-DNA37 
complex, some EthR2-DNA37 complex, and a trace of EthR3-DNA37 complex, and (b) EthR and DNA36 in a 6:1 
ratio, showing formation of mainly EthR2-DNA36 complex and some EthR4-DNA36 complex. 
A collision-induced dissociation (CID) experiment was also performed to investigate whether the 
EthR-DNA complex could be dissociated in the gas phase. Increasing the collision energy of ions 
through raising the trap/transfer voltage led initially to sharpening of the protein-DNA signals 
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accompanied by degradation of free DNA species (Figure 3.12). As collision energy was raised 
further, degradation of protein-DNA complexes could also be observed. However, at no point did 
any new protein-DNA stoichiometries appear that could be assigned to dissociation products of 
the initial protein-DNA complexes. When the experiment was performed in MS/MS mode with 
precursor ion selection, the precursor protein-DNA ion decreased in intensity as the collision 
energy was increased but no recognizable daughter species could be observed (data not shown). 
This suggests that the energy needed to dissociate the EthR subunits from the complex is greater 
than the energy needed to degrade the EthR-DNA complex, so that only degradation is observed 
in this experiment. 
 
Figure 3.12 CID spectra of EthR-DNA106. Collision energy was raised from 30 V to 180 V by adjusting both 
the trap and transfer voltages. 
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3.2.1.3. EthR dimers bind to separate sites on DNA 
To further investigate the EthR-DNA interaction, DNA62 was split into two half-sites, the left-hand 
site (DNAL31) and the right-hand site (DNAR31) (Figure 3.1). Each site contained one copy of an 
imperfect direct repeat that was thought to be responsible for the EthR-DNA binding 
interaction.[143] When EthR (15 μM) was incubated with DNAL31 (2.5 μM), only EthR2-DNAL31 
complexes were formed (Figure 3.13a). On the other hand, mainly EthR4-DNAR31 complexes were 
observed with DNAR31, along with a small amount of EthR2-DNAR31 and EthR3-DNAR31 species 
(Figure 3.13b). As before, the significant quantities of both unbound protein and DNA that are 





Figure 3.13 Native MS showing recapitulation of the EthR6-DNA complex from two independent half-sites. 
MS spectra of (a) EthR and DNAL31 in a 6:1 ratio, showing formation of mainly EthR2-DNA complex, and (b) 
EthR and DNAR31 in a 6:1 ratio, showing formation of mainly EthR4-DNA complex, along with a small 
amount of EthR2-DNA and EthR3-DNA complexes. (c) When EthR was mixed with both DNAL31 and DNAR31, 
a small amount of the putative EthR6-DNAL31-DNAR31 complex was formed. 
Intriguingly, when EthR was incubated with both DNAL31 and DNAR31 at the same time, a small 
amount of higher-order species could be detected that could be putatively assigned as the EthR6-
DNAL31-DNAR31 complex (189,872 ± 23 Da) (Figure 3.13c). This complex could be formed from the 
association of the EthR2-DNAL31 complex with the EthR4-DNAR31 complex in solution. This 
interaction appears to be asymmetric, as homodimeric (EthR2-DNAL31)2 or (EthR4-DNAR31)2 
species were not detected when EthR was treated with DNAL31 or DNAR31 separately. Additionally, 
DNAL31 and DNAR31 do not directly associate with each other in the absence of EthR (Figure 3.14), 
indicating that some kind of communication must exist between EthR and the DNA in order to 




Figure 3.14. Native mass spectra of (a) DNAL31 (2.5 µM), b) DNAR31 (2.5 μM) and (c) a mixture of DNAL31 
(2.5 μM) and DNAR31 (2.5 μM). All spectra were recorded in NH4OAc (200 mM, pH 7.0). The theoretical 
masses of DNAL31 and DNAR31 are 19032 Da and 19031 Da respectively. 
3.2.1.4. Isothermal titration calorimetry of the EthR-DNA interaction 
The EthR-DNA interaction was also investigated using isothermal titration calorimetry (ITC). EthR 
was titrated into DNA62, generating a complex, non-sigmoidal binding isotherm (Figure 3.15) that 
was analyzed using AFFINImeter software (S4SD). The experiment was performed twice. In the 
first experiment, the concentration of EthR dimer was 418 μM and the concentration of DNA62 
was 10.7 μM. In the second experiment, the concentration of EthR dimer was 548 μM and the 
concentration of DNA62 was 15.7 μM. A stoichiometric equilibrium binding model was designed 
that assumed the stepwise formation of the EthR6-DNA complex from free EthR dimers and 
DNA62, proceeding through EthR2-DNA and EthR4-DNA intermediates (i.e., EthR2 + DNA62 ⇌ EthR2-
DNA62 ⇌ EthR4-DNA62 ⇌ EthR6-DNA62). Fitting of the data to this model revealed a 
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stoichiometry of 2.9 ± 0.1 EthR dimers per duplex of DNA62, which is consistent with the native 
MS data. The binding affinities of the first and second dimers to DNA62 were identical within 
experimental error (KD(1) = 3.8 ± 0.8 μM, KD(2) = 3.6 ± 0.6 μM). The third EthR dimer binds to DNA62 
with weaker affinity (KD(3) = 10 ± 3 μM). The EthR-DNA62 binding affinities derived from ITC in this 
work are about an order of magnitude weaker than those previously determined by SPR for the 
EthR-DNA106 interaction (average KD = 146 nM).[143] 
 
Figure 3.15 ITC data for the titration of EthR into DNA62 showing the thermogram (upper panel) and 
binding isotherm (lower panel). Integrated data were fit with a stoichiometric equilibrium binding model. 
Moles of EthR are given as the dimer. ITC data were fit to an equilibrium binding model that assumes the 
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stepwise formation of the EthR6-DNA complex from EthR dimers, as indicated in the lower panel along with 
the associated equilibrium dissociation constants for the binding of the first (KD(1)), second ((KD(2)) and third 
(KD(3)) EthR dimer to the DNA. 
The calculated thermodynamic parameters indicate that the binding of the first EthR dimer to 
DNA is entropically favorable (TΔS = +12.1 ± 0.4 kcal mol–1) but enthalpically unfavorable (ΔH = 
+4.7 ± 0.4 kcal mol–1) (Figure 3.16). The favorable increase in entropy may be due to the release 
of counter cations or solvent molecules that were associated with the DNA.[162] However, the 
enthalpic penalty of binding stands in contrast to that observed for most major groove-binding 
proteins.[164] This suggests that significant structural rearrangement takes place in EthR and/or 
the DNA to accommodate binding of the first EthR dimer. Similar to what has been observed with 
the related TetR/CamR family repressor QacR,[165] which binds to DNA as a dimer of dimers, this 
structural rearrangement could then present the DNA in a conformation that readily accepts the 
second dimer. Indeed, binding of the second EthR dimer is driven almost entirely by enthalpy (ΔH 
= –6.2 ± 0.6 kcal mol–1) with only a minor entropic component (TΔS = –1.3 ± 0.6 kcal mol–1). The 
third dimer binds via a combination of favorable enthalpic (ΔH = –2.1 ± 0.6 kcal mol–1) and 




Figure 3.16 Thermodynamic parameters of the EthR-DNA62 interaction as determined by ITC. ΔG, ΔH and 
–TΔS values are shown for the binding of the first, second and third EthR dimers with DNA. Moles of EthR 
are given as the dimer. Error bars represent the standard deviation of duplicate results. 
The discrepancy in the stoichiometry of the EthR-DNA complex as determined by native MS and 
ITC versus the previous SPR analysis[166] may be a consequence of the correction that was applied 
to the SPR data. In that experiment, a correction factor of 0.73 was applied to the response of 
DNA, reflecting the different molar refractive indices of DNA versus proteins.[167] However, more 
recent work has shown that proteins and nucleic acids behave similarly in SPR, and so there may 
have been no need for this correction factor.[168] When this is taken into account, the previous 
SPR data instead suggest that each DNA62 duplex binds to 6.3 His6-EthR molecules, while each 
DNA37 duplex binds to 3.3 His6-EthR molecules, both numbers being consistent with the present 
study. 
The reverse titration of DNA62 into EthR was also attempted, but this gave a poorly defined 
isotherm that reached completion very quickly. This could be due to the fact that the titration of 
DNA62 into EthR would create a very large excess of protein to DNA in the sample cell, strongly 
favoring the formation of 6:1 EthR-DNA complexes. Instead, the forward titration of EthR into 
DNA62 allows the system to transition progressively through intermediate complexes (e.g. 2:1 or 
4:1), generating more gradual isotherms for analysis.   
3.2.1.5. Summary 
In conclusion, structural insights into the interaction between EthR and its operator have been 
obtained by native MS. While EthR was observed to exist as a dimer in solution as expected, the 
interaction of EthR with the full-length operator produced EthR6-DNA and EthR4-DNA complexes. 
The stoichiometry of the EthR-DNA complex was confirmed by ITC, which also revealed 
thermodynamic parameters that were consistent with a cooperative mode of binding. This study 
also highlights the capability of native MS to provide structural information on macromolecular 




3.2.2. Fragment screening against the EthR-DNA interaction using native MS 
3.2.2.1. Validation of native MS assay to screen EthR-DNA interaction disruptors 
Previous results have suggested that six subunits of EthR bind to its DNA operator sequence with 
micromolar affinity.[169] As fragments are weakly binding, they would not be able to significantly 
disrupt the EthR-DNA interaction at concentrations that are compatible with native MS (typically 
≤1 mM). Therefore, screening was performed against a partial protein-DNA complex that was 
formed between four subunits of EthR and DNAR31, that encompasses only about half of the full-
length DNA operator sequence (DNA62) (Figure 3.1).[143] It was reasoned that the use of this lower-
affinity EthR4-DNAR31 complex would increase the sensitivity of the assay towards detecting weak 
fragments.  
To validate this hypothesis, dose-response experiments were performed with the 
thienyloxadiazole BDM31381 (IC50 = 0.52 μM by SPR)[144] against both the partial EthR4-DNAR31 
complex (Figure 3.17a) and the native EthR6-DNA62 complex (Figure 3.17) by native MS. The 
results showed that BDM31381 disrupted the partial EthR4-DNAR31 complex with about 4-fold 
higher potency compared to the native EthR6-DNA62 complex (IC50 values of 0.4 μM and 1.6 μM, 
respectively) (Figure 3.17). This result suggests that the EthR4-DNAR31 complex is more susceptible 
to dissociation by small molecules, which should improve the sensitivity of the assay for the 





Figure 3.17 Inhibition of (a) EthR-DNAR31 and (b) EthR-DNA62 complexes by BDM31381 (0–100 μM) as 
determined by native MS. Charge states corresponding to the EthR dimer (EthR2), DNA duplex (DNAR31 or 
DNA62), tetramer-DNA complex (EthR4-DNAR31 or EthR4-DNA62) and hexamer-DNA complex (EthR6-DNA62) 
are indicated on the mass spectra. (c) Plot of normalized abundance of the EthR-DNA complex against 
BDM31381 concentration. Estimated IC50 values: 0.4 μM against EthR4-DNAR31 and 1.6 μM against EthR6-
DNA62.  
EthR possesses a long hydrophobic channel that is known to bind a wide variety of molecules, 
including even adventitious components of crystallization buffers such as hexyl octanoate[149] or 
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1,4-dioxane.[150] The binding of molecules to this site can trigger a conformational change of the 
EthR homodimer into a conformation that is incompatible with DNA binding.[149] Given that the 
screening of fragment molecules often entails the use of significant quantities of DMSO at the 
high concentrations of compounds that are used, DMSO might be able to enter the EthR ligand 
binding site and interfere with DNA binding. Our results showed that the EthR4-DNAR31 complex 
was disrupted by >50% at DMSO concentrations at or above 4%(v/v) (Figure 3.18). Therefore, a 
concentration of 2% DMSO was selected as a compromise between preserving the stability of the 
EthR-DNAR31 complex and raising the upper limit of fragment concentration that could be used. 
At 2% DMSO, the abundance of the EthR4-DNAR31 species was decreased by about 12%. 
 
Figure 3.18 Effect of DMSO concentration (0–6% v/v) on EthR-DNAR31 complex formation as determined 
by native MS. (a) Charge states corresponding to the EthR dimer (EthR2), DNA duplex (DNAR31) and 
tetramer-DNA complex (EthR4-DNAR31 or EthR4-DNA62) are indicated on the mass spectra. (b) Plot of 
normalized abundance of the EthR-DNA complex against DMSO concentration. 
3.2.2.2. Fragment screening of EthR-DNA disruptors by native MS 
The automated nESI-MS screening of a fragment library has been reported by several groups, 
which is typically achieved with the aid of a liquid handling and sample infusion robot.[63, 67, 160] 
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However, without access to such automation, a smaller library of 80 fragments was employed to 
demonstrate the proof-of-concept of the use of native MS for screening fragments against a 
protein-DNA interaction. Of the 80 fragments, 7 could not be screened because they were not 
sufficiently soluble at 500 μM in 200 mM NH4OAc buffer containing 2% DMSO. The 73 remaining 
compounds were screened at 500 μM against the EthR4-DNAR31 complex by native MS. Figure 
3.19a and Figure 3.19b respectively show the histogram and bar chart of EthR4-DNAR31 disruption 
values for the screened compounds.  
 
Figure 3.19 Fragment screening against the EthR-DNA interaction by native MS. (a) Histogram and (b) bar 
chart of disruption values of the EthR4-DNAR31 complex by fragments. The hit threshold (>50% disruption) 
is indicated by a dashed line. Error bars represent the standard deviation of duplicate results. (c) Native 
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mass spectra of the EthR4-DNAR31 complex in the presence of the fragment hits (1–8). Fragments were 
tested at 500 μM in NH4OAc buffer (200 mM) containing 2% DMSO. 
Eight fragments (compounds 1–8, Figure 3.20) disrupted the EthR4-DNAR31 interaction by more 
than 50% and were deemed as hits, giving an overall hit rate of 11%. The mass spectra for the 
EthR-DNA complexes in the presence of hit fragments are displayed in Figure 3.19c. Hits were 
retested once for confirmation. The entire native MS screening campaign for the 73 fragments 
utilized only about 0.2 mg of protein and 0.04 mg of total compound, highlighting the important 
advantage of low sample consumption requirement for this technique. 
 
Figure 3.20 Chemical structures of fragment hits identified by native MS (1–8) and DSF (5–11). Native MS 
hits were defined as compounds that disrupted the EthR-DNAR31 complex by >50% at 500 μM while DSF 
hits increased Tm by an average of at least 0.75°C at 500 μM. Molecular weight (MW) as well as IC50 and 
binding efficiency index (BEI) values calculated from the native MS assay are presented for the two most 
potent fragments, 4 and 7.   
A DSF assay was also conducted on the 73 fragments in parallel to allow for a comparison between 
native MS and DSF. The same concentration of fragment (500 μM) and DMSO concentration (2%) 
was used. Each fragment was tested twice and fragments that were able to raise the melting 
temperature of EthR by an average of at least 0.75 °C (1.5 times the standard deviation of vehicle 
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control Tm values) were classed as hits (Figure 3.21a). Figure 3.20b shows the individual ΔTm 
values of EthR in the presence of the fragments. Seven (compounds 5–11, Figure 3.20) passed 
this threshold, resulting in a hit rate of 9.6%, with four of these (compounds 5–8) also appearing 
as hits in the native MS assay. Screening the entire set of 73 fragments once by DSF consumed 
about 2 mg of protein and 0.4 mg of total compound, which are about 10 times the amounts used 





Figure 3.21 Fragment screening against EthR by DSF. (a) Histogram and (b) bar chart of EthR ΔTm values 
in the presence of the fragments. The hit threshold (ΔTm ≥ 0.75 °C) is indicated by a dashed line. Error bars 
indicate the standard deviation of duplicate results. Fragments were tested at 500 μM in Tris buffer (200 
mM Tris-HCl pH 8.5, 150 mM NaCl) containing 2% DMSO. 
The 11 fragments that appeared as hits in at least one of the primary assays were passed to the 
fragment validation stage, which was performed by our collaborator Sherine Thomas in the 
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Blundell group using SPR as previously described.[158-159] In the SPR assay, the ability of 
compounds to disrupt the binding of EthR to a biotinylated 106-bp DNA sequence (DNA106) 
encompassing the operator region is measured. The same fragment (500 μM) and DMSO (2%) 
concentrations were used to maintain consistency between the different techniques. The most 
potent compound in the SPR assay was fragment 4, showing 49% disruption of the EthR-DNA106 
interaction at 500 μM, followed by fragment 7 with 47% disruption (Figure 3.22a). In general, 
fragments that appeared as hits in both assays (5–8) or in native MS only (1–4) showed higher 
disruption of the EthR-DNA106 interaction in SPR compared to fragments that appeared as hits in 
DSF only (9–11). This suggests that native MS was a better predictor of activity in the SPR 
experiment compared to the DSF assay, which is not surprising because the native MS assay tests 
for disruption of the EthR-DNA interaction, whereas the DSF assay tests only for binding to EthR. 
A reasonably high rank correlation (R = 0.75) was observed between native MS and SPR disruption 
values, indicating good correlation between these two techniques (Figure 3.22b). 
 
Figure 3.22 Fragment validation by SPR and native MS. (a) Disruption of the EthR-DNA interaction for the 
fragment hits (500 μM) as measured by SPR. (b) Scatterplot showing rank correlation between native MS 
and SPR disruption values.  
Further validation for the two most potent fragments was provided by both SPR and native MS 
dose-response experiments. In the SPR experiment performed by our collaborators, 4 and 7 
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showed IC50 values of 460 and 610 μM respectively against the EthR-DNA106 interaction (Figure 
3.23a). 
 
Figure 3.23 (a) Dose-response curves for fragments 4 and 7 against the EthR-DNA106 interaction by SPR. 
Estimated IC50 values: 460 μM for 4 and 610 μM for 7. (b) Dose-response curves for fragments 4 and 7 
against the EthR-DNAR31 complex by native MS. Estimated IC50 values: 150 μM for 4 and 190 μM for 7. 
Meanwhile, in the native MS assay, 4 and 7 disrupted the EthR4-DNAR31 complex with IC50 values 
of 150 and 190 μM respectively (Figure 3.23b). Note that these IC50 values are only estimates 
because the peak intensities were not adjusted for differences in response between protein and 
protein-DNA complexes. Native mass spectra for the EthR4-DNAR31 complex with different 
concentrations of fragment 4 and 7 are shown in Figure 3.24a and Figure 3.24b respectively, 





Figure 3.24 Dose-response experiment for (a) fragment 4 and (b) fragment 7 against the EthR-DNAR31 
complex by native MS. b) Dose-response curves for fragments 4 and 7 against the EthR-DNAR31 complex by 
native MS. Estimated IC50 values: 150 μM for 4 and 190 μM for 7. 
Binding efficiency index (BEI) values (where BEI = pIC50 / MW in kDa)[170] for 4 (203 Da) and 7 (178 
Da) were calculated to be 18.8 and 20.9 using the native MS data, suggesting that they are more 
ligand-efficient than the optimized lead compound BDM31381 (359 Da, BEI = 17.7) and might 
represent fertile starting points for fragment elaboration. To our knowledge, the 
dihydronaphthlen-1-one core of 4 and the benzothiophene core of 7 have not previously been 
encountered in reported inhibitors of EthR. 
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3.2.2.3. Validation of hit fragments using X-ray crystallography 
EthR exists as a homodimer in solution, and each monomer is comprised of nine α-helices. The 
first three α-helices of each monomer comprise the DNA-binding “head”, and the two heads of 
the dimer must be in close proximity in order for EthR to bind to DNA. However, the binding of 
inhibitors to a lipophilic channel within the protein forces the DNA-binding heads to move apart 
by around 18 Å, resulting in a conformation that is incompetent for binding to DNA. EthR 
inhibitors are therefore allosteric inhibitors of EthR activity. 
The binding of the hit fragments to EthR was further validated using X-ray crystallography by our 
collaborator Dr. Vitor Mendes in the Blundell group (Table 3.1). As expected, both fragments 
bind to the EthR hydrophobic channel. Fragment 4 (PDB: 5MXK) forms hydrogen bonds with side 
chains of Asn176 and Asn179 but also has π-interactions with Phe110 and Trp207 (Figure 3.25a). 
In contrast, fragment 7 (PDB: 5MWO) binds to two different sub-sites in the EthR channel (Figure 
3.25b), a characteristic also previously observed with other fragments in EthR.[157-159] Fragment 7 
forms an extended network of π-interactions with Phe114, Phe110, Trp138 and Trp145 in binding 
mode “A” and with Trp103, Trp145, Trp207 and Tyr148 in binding mode “B”. Binding mode B also 




Figure 3.25 X-ray crystal structures of (a) EthR:4 (PDB: 5MXK) and (b) EthR:7 (PDB: 5MWO) complexes. 
Fragment 7 binds EthR with two different binding modes (“A” and “B”) occupying distinct parts of the 





In conclusion, the first application of native MS for fragment screening against a protein-DNA 
complex has been demonstrated. The sensitivity of the native MS assay was enhanced by 
screening the fragments against a partial, weaker-affinity EthR-DNA complex. The native MS 
screening campaign consumed about 10 times less protein and compound compared to DSF, a 
frequently used primary screen for EthR inhibitors. Fragment hits were validated using SPR, and 
the results showed that native MS was a better predictor of in vitro EthR-DNA disruption activity 
compared to DSF. Two new fragment scaffolds, a dihydronaphthlen-1-one and a 
benzothiophene, have been identified that disrupted the EthR-DNA interaction with sub-
millimolar potency. X-ray crystallography revealed that both fragments bind to the hydrophobic 
channel of EthR, thus providing a structural basis for their disruption of the EthR-DNA interaction. 
3.3. Experimental 
3.3.1. Materials and methods 
BDM31381 was synthesized by group member Brendan McConnell following a literature 
method.[144] HPLC or PAGE-purified oligonucleotides were purchased from Sigma-Aldrich. Duplex 
DNA samples were prepared by reconstituting oligonucleotides in NH4OAc (200 mM, pH 7.0), 
heating complementary oligonucleotides at 95 °C for 10 min followed by slow cooling to room 
temperature, and then buffer-exchanging once more into NH4OAc (200 mM, pH 7.0). The 
sequences of the oligonucleotides used were (F and R denote forward and reverse 
complementary sequences, respectively): 
 DNA106F: 5'- CGG TCA TGG ATC CAC GCT ATC AAC GTA ATG TCG AGG CCG TCA ACG AGA 
TGT CGA CAC TAT CGA CAC GTA GTA AGC TGC CAG GGT GAC CAC CTC CGC GGC CAG TCA 
G -3' 
 DNA106R: 5'- CTG ACT GGC CGC GGA GGT GGT CAC CCT GGC AGC TTA CTA CGT GTC GAT 




 DNA62F: 5' - GAT CCA CGC TAT CAA CGT AAT GTC GAG GCC GTC AAC GAG ATG TCG ACA 
CTA TCG ACA CGT AG - 3' 
 DNA62R: 5' - CTA CGT GTC GAT AGT GTC GAC ATC TCG TTG ACG GCC TCG ACA TTA CGT 
TGA TAG CGT GGA TC- 3' 
 DNA37F: 5'- ATC AAC GTA ATG TCG AGG CCG TCA ACG AGA TGT CGA C-3' 
 DNA37R: 5'- GTC GAC ATC TCG TTG ACG GCC TCG ACA TTA CGT TGA T -3' 
 DNA36F: 5' -  GTA ATG TCG AGG CCG TCA ACG AGA TGT CGA CAC TAT - 3' 
 DNA36R: 5' - ATA GTG TCG ACA TCT CGT TGA CGG CCT CGA CAT TAC - 3' 
 DNAL31F: 5' - GAT CCA CGC TAT CAA CGT AAT GTC GAG GCC G - 3' 
 DNAL31R:  5' - CGG CCT CGA CAT TAC GTT GAT AGC GTG GAT C - 3' 
 DNAR31F: 5' - TCA ACG AGA TGT CGA CAC TAT CGA CAC GTA G - 3' 
 DNAR31R: 5' - CTA CGT GTC GAT AGT GTC GAC ATC TCG TTG A - 3' 
3.3.2. Protein expression and purification 
The Mycobacterium tuberculosis ethR gene was cloned into a PHAT5 expression vector[171] having 
BamHI and EcoRI restriction sites by our collaborator Dr. Vitor Mendes in the Blundell group.  
Expression and purification of His6-EthR protein was performed in this project by following the 
protocol described in our previous work.[158] Escherichia BL21 (DE3) strain (Novagen) containing 
the above plasmids were grown overnight at 37 °C in LB media for the primary culture. 25 mL of 
this culture was used to inoculate 1 L each of fresh LB media containing ampicillin (100 μg/mL) 
and was grown at 37 °C at 220 rpm until the culture reached an optical density (A600nm) of 0.6-
0.8. The expression of the recombinant construct was induced by IPTG (0.5–1 mM) and   the 
culture was further allowed to incubate at 37 °C for 3 h. The cells were harvested by 
centrifugation (4200 g, 20 min at 4 °C) and resuspended in lysis buffer [50 mM Hepes (pH 7.5), 
150 mM NaCl] supplemented with EDTA-free protease inhibitor cocktail (Roche). The 
resuspended cells were lysed by sonication (Brason) using 10 pulses of 35% amplitude at intervals 
of 30 s each and the lysate was clarified by centrifugation (26,000 g for 1 h at 4 °C). The 
supernatant was passed-through a pre-equilibrated (with lysis Buffer) 5 mL HiTrap IMAC Fast 
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Flow column (GE Healthcare), charged with Ni2+, at a flow rate of 3 mL/min. The column was 
washed with 50ml of wash buffer [50 mM Hepes (pH 7.5), 150 mM NaCl and 20 mM Imidazole] 
and the bound protein was eluted using elution buffer [50 mM Hepes (pH 7.5), 150 mM NaCl and 
250 mM imidazole]. The protein thus obtained was further subjected to size-exclusion 
chromatography (Superdex 200 16/60, GE Healthcare) and fractions containing pure, 
homogeneous EthR protein were pooled and concentrated (4500 g at 4 °C) using 10 kDa Amicon 
Ultra® centrifugal concentrators. 
3.3.3. Mass spectrometry 
Spectra were recorded on a Synapt HDMS mass spectrometer (Waters) modified for studying 
high masses (32k quadrupole). Mass spectra were calibrated externally using a solution of cesium 
iodide (100 mg mL–1). EthR and DNA samples were exchanged into NH4OAc (200 mM, pH 7.0) 
solution using Micro Bio-Spin 6 chromatography columns (Bio-Rad). For complexes, buffer-
exchanged EthR and DNA were incubated together at the indicated concentrations for at least 
15 min at room temperature before measurement. 2.5 μL of sample solution was injected into a 
borosilicate emitter (Thermo Scientific) for sampling. Instrument conditions were optimized to 
enhance ion desolvation while minimizing dissociation of macromolecular complexes. Typical 
conditions were capillary voltage 1.8–2.0 kV, sample cone voltage 100 V, extractor cone voltage 
1 V, trap collision voltage 30 V, trap DC bias 35 V, transfer collision voltage 30 V, source 
temperature 20 °C, backing pressure 5 mbar, trap pressure 3–4 × 10–2 mbar, IM (N2) pressure 5–
6 × 10–1 mbar and TOF pressure 7–8 × 10–7 mbar. Data acquisition and processing were performed 
using MassLynx 4.1 (Waters).  
In the fragment screening campaign, the vehicle control experiment (2% DMSO) was performed 
eight times to establish the baseline for the assay. The responses (percentage of intact EthR4-
DNAR31 complex) showed a standard deviation of 12%, indicating acceptable precision. To 
calculate IC50 values, the native MS data were fit using nonlinear regression to a dose-response 
curve with variable slope on GraphPad Prism v5.00. 
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3.3.4. Isothermal titration calorimetry (ITC) 
EthR and DNA62 were separately buffer-exchanged into a system of Tris-HCl (10 mM, pH 7.5), 
NaCl (200 mM), MgCl2 (2 mM) and EDTA (0.1 mM) using Vivaspin 500 centrifugal concentrators 
with a 10K MWCO (Sartorius). EthR was titrated into DNA62 in the reaction cell using a MicroCal 
Auto-iTC200 isothermal titration calorimeter (Malvern). The titration experiment was performed 
at 25 °C, and consisted of 20 injections of 2 μL every 120 s, with stirring at 1000 rpm. Data were 
fitted to a bespoke model (EthR2 + DNA62 ⇌ EthR2-DNA62 ⇌ EthR4-DNA62 ⇌ EthR6-DNA62) and 
analysed using the AFFINImeter software (S4SD). Global fitting of independently conducted ITC 
experiments was performed to improve the robustness of the fit. The experiment was performed 
twice. In the first experiment, the concentration of EthR2 was 418 μM and the concentration of 
DNA62 was 10.7 μM. In the second experiment, the concentration of EthR2 was 548 μM and the 
concentration of DNA62 was 15.7 μM Eva Muñoz (AFFINImeter) is acknowledged for helpful 
discussion on the ITC analysis. 
3.3.5. Differential scanning fluorimetry (DSF) 
DSF measurements were carried out using a Bio-Rad CFX Connect machine with a 96-well 
reaction module. Samples (50 μL each) containing 20 μM EthR, 150 mM NaCl, 20 mM Tris-HCl pH 
= 8.5, 2.5× SYPRO orange, 2%v/v DMSO and 500 μM fragment were prepared in 96-well plates. 
The 96-well plates were heated linearly from 25 °C to 95 °C using a temperature increment of 0.5 
°C every 30 seconds. Melting curves represent plots of the fluorescence emission intensity at λmax 
490/575 nm of each sample against temperature. Melting temperatures (Tm) were determined 
as the temperatures at which the minima on the negative first derivatives of the melting curves 
occurred. 
3.3.6. Surface plasmon resonance (SPR) 
The SPR assay was carried out by our collaborator Sherine Thomas in the Blundell group using a 
BIAcore T100 instrument as described previously.[158] The assay was designed to measure the 
interaction of EthR with the experimental 106-bp ethA promoter DNA sequence (DNA106), 
112 
 
immobilized via biotin-streptavidin linkage onto an SA Series S Sensor Chip (BIAcore). DNA from 
pUC19 (113-bp) was used as a control against non-specific binding. The experimental and control 
DNA fragments were produced as described previously.[143-144] Biotinylated experimental and 
control DNA were immobilized to the chip surface to achieve stable fixation levels of 152 and 150 
resonance units (RU) respectively.  
For screening, the EthR/fragment solution (1.5 μM EthR and 0.5 mM concentration of fragment 
made up in running buffer (2 mM MgCl2, 10 mM Tris-Cl pH 7.5, 0.1 mM EDTA, 200 mM NaCl, 
2%(v/v) DMSO) was flowed over the chip at 20 μL/min for 90 s. The dissociation time was 120 s. 
To determine binding levels, the response of the control channel at steady state was subtracted 
from that of the experiment channel. The chip was regenerated between samples using 0.03% 
w/v SDS in running buffer (passed at a flow rate of 20 μL/min for 30 s). For IC50 calculations, the 
SPR response of EthR binding to the immobilized DNA was measured at various concentrations 
of compound. The resulting RUs were used to fit the data using nonlinear regression to a dose-
response curve with variable slope using GraphPad Prism v5.00. IC50 values were calculated as 
the compound concentrations necessary to inhibit 50% of the maximal interaction between EthR 
and its DNA operator sequence. 
3.3.7. X-ray crystallography  
Crystallization of EthR was performed by our collaborator Dr. Vitor Mendes in the Blundell group 
using the sitting-drop vapor diffusion method at 25 °C. A drop consisted of 1.0 μL of reservoir 
solution (1.7–2.1 M ammonium sulfate, 0.1 M MES-Na (pH 6–7), 5–15%(v/v) glycerol and 7–
12%(v/v) 1,4-dioxane) and 0.5–1.0 μL of protein solution (20 mg/ml EthR, 0.5 M NaCl, 15 mM 
Tris/HCl pH 8.0 and 10%(v/v) glycerol).[158] Compounds (100 mM in DMSO) were mixed with 
mother liquor (1.9 M ammonium sulfate, 0.1 M MES-Na pH 6.5 and 12.5%(v/v) glycerol) to a final 
concentration of 10 mM. EthR crystals were washed free from 1,4-dioxane by placing them in 
1,4-dioxane free mother liquor for a few hours. The washed EthR crystals were then transferred 
to the fragment-containing solutions and incubated for 16 h. Crystals were cryoprotected by 
passing them briefly through mother liquor containing 20%(v/v) of ethylene glycol and then flash-
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frozen in liquid nitrogen. X-ray crystallographic datasets were collected at the Diamond Light 
Source (Harwell, UK). X-ray datasets were indexed and integrated using autoPROC,[172] XDS[173] 
and Mosfilm. The scaling of datasets was carried out using SCALA/AIMLESS software.[174] 
Structures were solved using the molecular replacement method with PHASER,[175] included in 
the PHENIX software package[176] (PDB: 1T56 was used as search probe). Structures were further 
refined with PHENIX[176] to satisfactory level of R/Rfree using maximum-likelihood restrained 
refinement. Ligand restrain files were prepared with PHENIX elbow software. Every structure was 
modelled manually in Coot[177] (including ligand and essential water molecules). Images of X-ray 
crystal structures in figures were prepared using PyMOL (http://www.pymol.org). 
Table 3.1 X-ray crystallography data collection and final refinement statistics. 
Ligand# 4  7 
PDB ID 5MXK 5MWO 
Data collection*   
Space group P41212 P41212 
Cell parameters:    
Resolution range [Å] 121.2 – 1.93 121.93  – 1.96 
No.  of observations   
Rmerge 0.148 (1.415) 0.193 (1.479) 
CC1/2 0.999 (0.668) 0.998 (0.389) 
I/σ(I) 13.7 (1.8) 11.9 (2.0) 
Completeness [%] 95.0 (100.0) 98.2 (100.0) 
Multiplicity 12.6 (12.4) 12.8 (12.9) 
Refinement   
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Refinement program PHENIX PHENIX 
Resolution [Å] 60.59 – 1.93 86.22 – 1.96 
No. reflections 18531 18489 
Rwork/Rfree [%] 18.6/22.3 20.1/25.9 
RMS deviations   
Bonds [Å] 0.006 0.007 
Angles [˚] 0.736 0.795 
Ramachandran   
Favoured [%] 98 98 
Outliers [%] 0 0 








4. Application of native mass spectrometry to the characterization 
and targeting of the bacterial coenzyme A biosynthetic pathway 
4.1. Introduction 
Coenzyme A (CoA) is a ubiquitous and essential cofactor that is synthesized from pantothenate 
(Pan, also known as vitamin B5) through a conserved pathway consisting of five enzymatic 
steps.[178] In the second step, phosphopantothenoylcysteine synthetase (PPCS) catalyzes the 
Mg2+-dependent conversion of 4′-phosphopantothenate (PPan) and L-cysteine into 4′-
phosphopantothenoylcysteine (PPC) using either CTP (in bacteria) or ATP (in eukaryotes) for 
activation.[179] In bacteria, PPan is first coupled with the α-phosphate of CTP to give an acyl 
cytidylate intermediate, 4′-phosphopantothenoyl cytidylate, with the concomitant release of 
pyrophosphate (PPi) (Figure 4.1a). The CMP-activated acyl group is then transferred to the amino 




Figure 4.1 (a) Conversion of PPan into PPC catalyzed by PPCS and proceeding through an acyl cytidylate 
intermediate. (b) Structures of CoaB inhibitors previously reported. 
Bacterial PPCS, also referred to as CoaB, is usually fused to the next enzyme of the CoA 
biosynthetic pathway, phosphopantothenoylcysteine decarboxylase (PPCDC, also referred to as 
CoaC in bacteria) to form the bifunctional CoaBC protein (coaBC gene product, previously known 
as dfp).[180] The bacterial CoaBC enzyme has been proposed to be a dodecamer based on gel 
filtration experiments[181] and by analogy with the related flavoprotein EpiD, for which the X-ray 
crystal structure has been solved.[182] 
The CoaB domain crystallizes as a homodimer and the residues responsible for dimerization are 
conserved in all domains of life.[183] Dimerization is largely mediated by a dimerization domain 
comprising two antiparallel β-sheets (Thr198 to Asn210 and Ala278 to Lys306 in Escherichia coli).[184] 
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The latter region, which contains the highly conserved Lys298-X-Lys-Lys (X = Ile in E. coli) motif, 
reaches out to the other protomer as a partially disordered loop that is situated near the entry 
of the neighboring active site, with Lys298 contacting the γ-phosphate of CTP.[184] 
Kinetic and structural studies have indicated that the nucleobase binding sites of bacterial CoaB 
enzymes are substantially different from the corresponding human enzyme,[185] rendering CoaB 
as a promising antimicrobial target.[178] The bacterial CoaB enzyme has a strict requirement for 
CTP, in contrast to human PPCS which uses ATP about four times more efficiently than it does 
CTP (based on kcat/Km).[186] In E. coli CoaB (EcCoaB), the nucleotide binding pocket is quite rigid 
and shows strong shape complementarity to the cytosine moiety.[184] In contrast, human PPCS 
has an enlarged and also more flexible nucleotide binding pocket that confers preference for ATP, 
but that still can accommodate the smaller CTP molecule.[185] Recently, Mizrahi and co-workers 
have established the essentiality of CoaBC in a murine model of Mycobacterium tuberculosis 
infection.[187] Silencing of coaBC was bactericidal regardless of whether knockdown was initiated 
at infection or during either the acute or chronic stages of infection, demonstrating that CoaBC 
is needed for Mtb to grow and persist in mice. 
The first CoaB inhibitors were reported by Dotson and co-workers in 2009.[188] These compounds 
are structural mimics of the acyl cytidylate intermediate that forms during catalysis, except with 
the reactive acyl-phosphate moiety of the natural intermediate replaced by either a stable 
phosphodiester or sulfamate isostere (Figure 4.1b). These compounds are non-competitive, 
slow-onset and tight-binding inhibitors that exhibit nanomolar IC50 and Ki values against the CoaB 
enzymes of E. coli, Enterococcus faecalis, and Streptococcus pneumonia, as well as up to 1000-
fold selectivity over human PPCS. More recently, Burkart, Strauss and co-workers have 
characterized the natural product CJ-15,801, an antibiotic effective against drug-resistant strains 
of Staphylococcus aureus, as the precursor to a tight-binding inhibitor of CoaB activity.[189] CJ-
15,801 structurally resembles Pan (differing only because it has a trans-substituted double bond 
in the β-alanine moiety), and it can be phosphorylated by the S. aureus Pan kinase (PanK) to 
furnish a PPan-like compound (Figure 4.1b) that binds to the CoaB domain. Subsequent 
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cytidylylation by CoaB generates a tight-binding structural mimic of the native acyl cytidylate 
intermediate with nanomolar potency against the E. coli CoaB domain as well as against S. aureus 
CoaBC.[189] However, despite the CoaB enzyme being characterized over ten years ago, no non-
mimetic inhibitors of CoaB have yet been reported in the literature. A better understanding of 
the structure and interactions of CoaB could aid the development of therapeutic compounds 
against this promising antimicrobial target. 
In this work, native nESI-IM-MS experiments were conducted to provide structural insights into 
the E. coli PPCS (CoaB) domain. Our results indicate that CoaB exists in an equilibrium of 
monomers and dimers in solution, with dimer formation being favoured by the presence of CTP. 
Equilibrium titration experiments suggest that the binding of CTP to CoaB is cooperative, and also 
confirm the preference for E. coli CoaB for CTP over ATP. IM-MS analysis characterized the size 
and unfolding profiles of the EcCoaB monomer and dimer in the gas phase. Finally, native MS was 
used to screen a small library of sulfonamide compounds against E. coli CoaB, revealing a new 
class of small-molecule, non-mimetic inhibitors of CoaBC.  
4.2. Results and discussion 
4.2.1. Structural insights into the E. coli CoaB domain 
4.2.1.1. Native MS 
Although the bifunctional EcCoaBC enzyme has been suggested by size exclusion 
chromatography to exist as a dodecamer,[181] the isolated CoaB domain crystallizes as a 
homodimer.[183] Strauss and Begley have shown that the product of the PPCS (CoaB) reaction is 
released from EcCoaBC before it returns to a different active site for transformation by PPCDC 
(CoaC).[190] Therefore, the functional significance of the CoaB-CoaC fusion is not currently 
apparent. As the isolated CoaB domain of E. coli is fully functional,[183] in this study we have used 
the isolated CoaB domain as a surrogate for CoaBC in binding and mechanistic studies. The 
dimeric EcCoaB enzyme (56 kDa), being far smaller than the dodecameric EcCoaBC protein (ca. 
500 kDa), is much more amenable to native MS analysis, and easier to express and purify. Doubly-
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His6-tagged EcCoaB, containing residues 182 to 406 of the EcCoaBC, was overexpressed and 
purified in a high yield from E. coli culture. Protein identity and purity were assessed by 
denaturing LC-MS (Figure 4.2) and SDS-PAGE analysis. 
 
Figure 4.2 (a) Denaturing LC-MS mass spectrum of EcCoaB. (b) Deconvoluted LC-MS mass spectrum of 
EcCoaB. 
Typical buffers used for protein expression and purification are incompatible with ESI-MS owing 
to ion suppression as well as the formation of extensive protein-ion adducts. Therefore,  EcCoaB 
was first buffer-exchanged into 200 mM ammonium acetate (NH4OAc) before native MS analysis. 
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The native mass spectrum of E. coli EcCoaB alone showed that EcCoaB existed as a mixture of 
monomeric and dimeric species (Figure 4.3a). The EcCoaB monomer, centered around the 10+ 
charge state, had an observed mass of 28002 ± 24 Da which was close to the theoretical mass of 
the protein (without its N-terminal methionine, 27942 Da) and the mass observed by denaturing 
LC-MS (27942 Da, Figure 4.2). Meanwhile, the EcCoaB dimer, centered around the 15+ charge 
state, had an observed mass of 55999 ± 42 Da, which was also close to the theoretical mass of 
55883 Da for two molecules of CoaB. The masses of the EcCoaB monomer and dimer observed 
by native MS are slightly higher than the theoretical masses presumably due to the adduction of 
weakly-bound buffer or water molecules to the protein under the soft ionization conditions 
employed.  
 
Figure 4.3 The dimerization of EcCoaB is concentration-dependent. Native mass spectra of EcCoaB in 200 
mM NH4OAc at (a) 60 μM, (b) 50 μM, (c) 40 μM, (d) 30 μM and (e) 20 μM, with monomer (M) and dimer 
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(D) charge states indicated. The theoretical mass of the monomer (without its N-terminal methionine) is 
27942 Da.  
 
Non-covalent interactions in native MS can be affected be the concentration of NH4OAc buffer 
used.[191] In this study, the effect of NH4OAc concentration on the appearance of the EcCoaB 
native mass spectrum was investigated. At 50 mM NH4OAc, higher-order species corresponding 
to trimers, tetramers, pentamers and hexamers of EcCoaB were observed (Figure 4.4a). 
However, the abundance of the higher-order species (trimers and above) was greatly diminished 
at 200 mM NH4OAc (Figure 4.4b) or 500 mM NH4OAc (Figure 4.4c), suggesting that the oligomers 
were caused by the non-specific aggregation of EcCoaB. This finding is similar to a recent native 
MS study on CK2 kinase in which the oligomerization state of the protein was also found to be 
dependent on  ionic strength.[192] The proportion of monomer and dimer species was similar at 
200 and 500 mM NH4OAc. However, the electrospray became more difficult to maintain at 500 





Figure 4.4 The ionic strength affects the oligomerization status of EcCoaB. Native mass spectra of EcCoaB  
(30 μM) in 200 mM NH4OAc at (a) 50 mM, (b) 200 mM, (c) 500 mM. 
4.2.1.2. Determination of the affinity of the EcCoaB dimerization 
The peak intensities of the different species in the mass spectrum are often considered to be 
proportional to the concentration of those species in solution. However, this assumes that the 
probability of ions being ionized, transmitted, and detected is the same for all species, which may 
not be true for the monomer and dimer of EcCoaB given their different sizes. A more accurate 
equilibrium dissociation constant can be determined by taking into account the fact that the 
response factors, which are the products of efficiencies of all the processes affecting the signal 
intensities of the ions, may be different for different species. In this study, the method of Zenobi 
and co-workers[193] (based on an earlier work by Gabelica et al.[194]) was used to fit the equilibrium 
association constant (Ka) of the EcCoaB monomer-dimer equilibrium (equation 1) as well as the 
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ratio (R) between the individual dimer (RD) and monomer (RM) response factors (equation 4) from 
the measured peak ion intensities of the dimer (ID) and monomer (IM) according to equation 5 
(see Section 4.3.4. for equations).  
To derive R and Ka, the native mass spectrum of EcCoaB was recorded at different concentrations 
of the enzyme (Figure 4.3a-e). The results show that as the concentration of protein was 
decreased, the relative abundance of the EcCoaB dimer declined in proportion to the monomer, 
consistent with the monomer and dimer being in equilibrium with each other and not just co-
existing. Using nonlinear regression on equation 5, R and Ka were determined to be 1.8 and 3.5 × 
104 M–1 (corresponding to Kd = 29 μM), respectively (Table 4.1). Figure 4.5 shows a graph of 
experimental IM/ID values against total EcCoaB monomer concentration (M0) as well as the fitting 
curve derived from nonlinear regression of equation 5. The value of R (1.8) is within the range of 
0.5 to 6.7 for biomolecules reported in the literature.[193] It should also be noted that the decrease 
in apparent dimer formation could also partially be attributed to the reduction of non-specific 
artefactual oligomers that arise due to droplet crowding.  
 
Figure 4.5 Plot of the ratio (IM/ID) of the monomer (IM) and dimer (ID) peak intensities (filled circles) against 
the total concentration of EcCoaB monomer (M0) (see Figure 4.3 for titration experiment). The solid line 
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represents the fitting curve obtained by non-linear regression of the data using equation 5, from which R 
and Ka were determined to be 1.8 and 3.5 × 104 M–1, respectively. The dashed lines represent the 95% 
confidence interval of the regression curve. 
Gabelica and co-workers emphasized that a very high quality data set from the titration 
experiment is required to obtain precise fitting values.[194] However, similar to observed by 
Zenobi and co-workers,[193] the IM/ID values showed significant scatter around the fitting curve. 
Therefore, the confidence intervals that were obtained by fitting the data using unconstrained 
values of R and Ka were relatively broad (Table 4.1, Entry 1). More precise Ka values may be 
obtained by first constraining the choice of R. With reference to Zenobi and co-workers,[193] the 
fitted Ka values when R was restricted to 1, 2 or 4, were determined to 8.6 × 104, 2.9 × 104 and 
1.1 × 104 M–1 respectively (Table 4.1, Entries 2–4). The Ka values decrease with R as expected 
because increasing the value of R (the ratio of response factors between the dimer and the 
monomer) decreases the estimated dimer to monomer concentration ratio. 
Table 4.1 R and Ka values obtained by nonlinear regression of equation 5, using data obtained from the 
EcCoaB titration experiment (Fig. 2). The corresponding Kd values (where Kd = Ka–1) are shown to aid 
interpretation. 95% confidence intervals determined by the Monte Carlo method are shown in 
parentheses. 
Entry R Ka / × 104 M–1 Kd / μM 
1a 1.8 (0.9–3.0) 3.5 (1.6–5.4) 29 (19–63) 
2 1 8.6 (7.7–9.3) 12 (11–13) 
3 2 2.9 (2.7–3.1) 34 (32–37) 
4 4 1.1 (1.0–1.2) 91 (83–100) 
aR was unconstrained. This gave broader confidence intervals for both R and Ka. In entries 2–4, R was 
constrained to 1, 2 or 4 respectively to generate more precise estimates for Ka. 
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There is evidence that the interconversion between the monomeric and dimeric forms of EcCoaB 
is fairly rapid, occurring within the timescale of minutes. First, passage of an EcCoaB solution 
through a Vivaspin 50 kDa molecular-weight cut-off (MWCO) centrifugal concentrator did not 
lead to significant changes in monomer-to-dimer ratio in either the concentrator compartment 
or in the filtrate (data not shown). This indicates that the EcCoaB dimer (56 kDa) retained in the 
concentrator could readily dissociate into monomers, while the monomer (28 kDa) that passed 
through the membrane into the filtrate could easily reassemble into dimers. Secondly, a gel 
filtration experiment performed by Kupke using a different EcCoaB construct (EcCoaB′, 26 kDa) 
indicated a single peak with an apparent molecular weight of 42 kDa.[183] Although gel filtration 
is a comparatively low-resolution technique for determining molecular masses, the substantial 
difference between the observed mass and the expected mass (52 kDa) of the EcCoaB′ dimer 
might indicate that EcCoaB′ was in fact eluting as a mixture of monomers and dimers in rapid 
equilibrium. 
4.2.1.3. Influence of solution pH on the EcCoaB protein-protein interaction 
Since pH governs the strength of many protein-protein interactions, it was of interest to 
determine the influence of solution pH on the dimerization of the EcCoaB domain. The native 





Figure 4.6 Lowering of pH disrupts EcCoaB dimerization and partially unfolds the protein. Native mass 
spectra of EcCoaB (30 μM) in 200 mM NH4OAc at (a) pH 7, (b) pH 5, and (c) pH 3, with monomer (M), dimer 
(D) and unfolded monomer (U) charge states indicated. For clarity, charge states for the unfolded 
monomer are not assigned in (c). The molecular masses of the aggregates in (c) were unable to be 
assigned. Note the change in x-axis scale in the higher m/z region. 
The results show that the native mass spectra of EcCoaB at pH 7 (Figure 4.6a) and pH 5 (Figure 
4.6b) were broadly similar, except for a slight decrease in EcCoaB dimer abundance and the 
appearance of higher charge states of the monomer (13+ and 14+), suggesting the partial 
unfolding of the protein. However, the appearance of the spectrum was dramatically changed at 
pH 3 (Figure 4.6c). The dimer completely disappeared, and instead, a series of highly-charged 
monomeric EcCoaB ions were observed accompanied by the appearance of aggregates in the 
higher m/z region. All of these features are indicative of the chemical denaturation of EcCoaB. As 
the protein unfolds, its surface area increases which allows for a greater accumulation of positive 
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charge on the molecule during the electrospray process. The exposure of interior lipophilic 
residues could also allow the protein to interact via hydrophobic interactions to form higher-
order aggregates. Additionally, the lowering of the pH is likely to disrupt polar interactions that 
are important for dimerization,[184] leading to the disruption of the EcCoaB protein-protein 
interface even while some of the monomer remains natively folded (as indicated by the intact 
charge envelope encompassing the 9+ to 12+ charge states of the monomer in Figure 4.6c). This 
suggests that the tertiary structure of the EcCoaB monomer is relatively more resistant to acid-
induced denaturation than the quaternary interactions between the protomers in the dimer. 
4.2.1.4. Ion mobility-mass spectrometry of EcCoaB 
IM-MS experiments were performed to investigate the structural characteristics of EcCoaB in the 
gas phase. CCS values for individual charge states of the EcCoaB monomer and dimer at either 0 
or 5%(v/v) DMSO are presented in Table 4.2. To ensure that the CCS values reflect the dimensions 
of the folded state, IM-MS experiments were recorded at a collision voltage (20 V) that precedes 
the onset of unfolding (see below) in order to minimize protein unfolding, which would impact 
CCS values. CCS values generally increase with charge state, which could be due to the increased 
internal electrostatic repulsion of protein ions at higher charge. At 0% DMSO, the average CCS 
values of the two lowest (most native-like) charge states of the EcCoaB monomer and dimer ions 
are 2430 and 3985 Å2, respectively. For comparison, the theoretical CCScalc of the EcCoaB dimer 
calculated from the X-ray crystal structure (PDB: 1U7U)[184] was 4258 Å2. This suggests that the 
EcCoaB dimer remains natively folded in the gas-phase. 
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Table 4.2 CCS values of EcCoaB monomer and dimer ions as determined by IM-MS at 0 and 5%(v/v) DMSO. 
The average CCS values of the two lowest (most native-like) charge states of the monomer and dimer are 
also presented. Errors in CCS are estimated to be 3%.[61, 79] 
Monomer Dimer 
 0% DMSO 5% DMSO  0% DMSO 5% DMSO 
Charge CCS / Å2 Charge CCS / Å2 
8+ - 2307 11+ - 3674 
9+ 2358 2407 12+ - 3747 
10+ 2502 2542 13+ - 3841 
11+ 2755 - 14+ 3938 3945 
12+ 3028 - 15+ 4031 - 
   16+ 4199  
   17+ 4442  
Average 2430 2357  3985 3711 
In the presence of 5%(v/v) DMSO, the charge state distributions of both the EcCoaB monomer 
and dimer shifted to lower charge states (Figure 4.7). This is accompanied with a compaction of 
the protein structure (Table 4.2), and is consistent with previous studies on the effects of DMSO 
on protein size both in solution and in the gas phase.[105, 127, 195] However, the relative abundance 




Figure 4.7 DMSO shifts charge state distributions of EcCoaB to lower charge states. Native mass spectra 
of EcCoaB (30 μM) in 200 mM NH4OAc in the presence of (a) 0% or (b) 5% DMSO(v/v). 
4.2.1.5. Collision-induced unfolding of EcCoaB 
The use of collisional activation to generate unfolding plots (or “fingerprints”) is a recently 
developed technique that has been used to study the gas-phase stability of proteins.[52-53] 
Collision-induced unfolding (CIU) fingerprints are obtained by recording the native mass spectra 
of a protein at incrementally higher acceleration voltages within the collision cell of a mass 
spectrometer. As protein ions unfold through collisions with neutral gas molecules, changes in 
their CCS can be tracked as a function of collision voltage, allowing the quantitation of a protein’s 
resistance to unfolding in the gas phase. CIU IM-MS experiments have been used, for example, 
to evaluate the stabilizing effects of ligands on protein stability,[53] to differentiate between Type 
I and Type II kinase inhibitors of Abl kinase,[196] or to characterize differences between complexes 
formed between Aurora kinase C and different mutants of INCENP.[197] 
The CIU fingerprints for EcCoaB monomeric (Figure 4.8a) and dimeric (Figure 4.8b) ions are 
complex and reveal multiple unfolding transitions over the range of collision voltages tested. For 
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instance, for the 9+ state of the monomer, the native-like protein (N, CCS ≈ 2400 Å2) initially 
transitions into a partially unfolded intermediate form (I, CCS ≈ 2800 Å2+) at moderate collision 
voltages, then shifts into a more extended form (E, CCS ≈ 3100 Å2+) as the collision energy is 
increased further. It is assumed that E represents the most unfolded form of the monomeric 9+ 
ion as populations with larger CCS values were not observed even as the collision voltage was 
increased to 150 V, at which point protein degradation also began to occur (data not shown). The 
CIU50 values of the native-like (N) and intermediate (I) forms of the monomeric 9+ ion (i.e. the 
collision voltage needed to deplete 50% of the population of the conformation) were determined 
to be 34 and 62 V, respectively. For the other monomeric and dimeric EcCoaB charge states, 
multiple intermediate species were observed in the CIU plots, indicative of complicated unfolding 
pathways for those ions. The observation that the CIU unfolding profiles for monomeric and 
dimeric EcCoaB are broadly similar suggests that an asymmetric unfolding mechanism might be 




Figure 4.8 CIU IM-MS reveals gas-phase unfolding transitions of EcCoaB. CIU fingerprints of indicated 
charge states of the EcCoaB (a) monomer (M) and (b) dimer (D). For the 9+ state of the monomer, native-
like (N), intermediate (I) and extended (E) forms of the protein are labeled. 
CIU plots for EcCoaB monomeric 9+ and 10+ states are broadly similar in the presence of 5% 
DMSO(v/v) (Figure 4.9a) compared to the respective plots in the absence of DMSO. The 8+ state 
of the monomer, accessible only via charge reduction conditions with DMSO, did not unfold even 
at the highest collision voltage of 80 V tested (although we do not preclude the possibility that 
the monomer unfolds at an even greater voltage). The greater CIU stability of lower charge states 
is known[136, 195] and can be attributed to the lesser internal electrostatic repulsion experienced 
by proteins of lower charge. For the EcCoaB dimer in the presence of DMSO, the 11+ state did 
not unfold, while the 12+ and 13+ states underwent one and three unfolding transitions 




Figure 4.9 CIU IM-MS of EcCoaB in the presence of 5% DMSO. CIU plots of indicated charge states of the 
EcCoaB (a) monomer (M) (8+ to 10+) and (b) dimer (D) (11+ to 13+) with 5% DMSO(v/v). 
4.2.1.6. Summary 
In conclusion, native nESI-IM-MS has been conducted to provide structural insights into the 
EcCoaB domain. While EcCoaB crystallizes as a dimer, our experiments demonstrate that in 
solution, an equilibrium exists between the monomer and dimer. The gas-phase unfolding 
behavior of monomeric and dimeric EcCoaB ions was studied by IM-MS, revealing complex CIU 
fingerprints for most charge states. 
4.2.2. Assessing EcCoaB-ligand interactions by native MS 
4.2.2.1. Interaction of EcCoaB with CTP 
Since EcCoaB utilizes CTP to activate the carboxylate group of PPan, the interaction between CTP 
and EcCoaB was studied by native MS. Interestingly, the addition of 50 μM CTP to EcCoaB (25 
μM) (Figure 4.10b) increased the proportion of dimeric EcCoaB compared to in the absence of 
CTP (Figure 4.10a). With CTP present, the KD value for the monomer-dimer equilibrium was 
estimated to be 4 μM, which is substantially lower than corresponding KD value of 29 μM 
determined in the absence of CTP. This result indicates that CTP stabilizes the dimeric form of 
EcCoaB, and is consistent with the observation that CTP contacts both subunits of the dimer in 




Figure 4.10 EcCoaB selectively binds CTP over ATP, and CTP stabilizes the dimer. Native MS of EcCoaB (25 
μM) in the (a) absence, or presence of (b) CTP (50 μM) or (c) ATP (50 μM). In (a), the monomer (M) and 
dimer (D) charge states are indicated. In (b) and (c), the number of ligands bound to each monomer or 
dimer species is indicated. 
A titration experiment was performed to assess the effect of adding different concentrations of 
CTP. The results showed that the proportion of dimer was further increased at higher 
concentrations of CTP (Figure 4.11a-e). At 200 μM CTP, only a small amount of the monomer 




Figure 4.11 Titration of CTP into EcCoaB reveals non-specific binding at higher CTP concentrations. Native 
mass spectra of EcCoaB (30 μM) in the presence of (a) 0 μM, (b) 30 μM, (c) 50 μM, (d) 100 μM and (e) 200 
μM of CTP. In (a), the monomer (M) and dimer (D) charge states are indicated. In (b)–(e), the number of 
CTP molecules bound to each monomer or dimer species is indicated. 
At 50 μM CTP, 66% of the EcCoaB monomer was unbound while 34% was singly-bound by CTP 
(Figure 4.10b). In contrast, the majority of the dimer was observed in singly-bound (32%) or 
doubly-bound (38%) states. This can be rationalized on the basis of the fact that the CTP-binding 
site of EcCoaB is formed from residues from both subunits of the dimer (Figure 4.12).[184] 
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Therefore, the binding affinity of CTP for the monomer would be expected to be weaker than to 
the dimer. 
 
Figure 4.12 The CTP binding pockets of the EcCoaB dimer are formed from residues of both protomers.  
Protomer A and B of the CTP-bound EcCoaB dimer (PDB ID: 1U7W)[184] are shown in blue and green, 
respectively, with CTP shown with its carbons in cyan.  
4.2.2.2. Accounting for non-specific binding 
A small amount (17%) of the EcCoaB dimer was bound to three molecules of CTP (Figure 4.10b). 
As each dimer only has two CTP-binding sites, this suggests that the third molecule of CTP is 
bound non-specifically to the protein. The observation that non-specific binding is observed at 
only a mild excess of CTP over protein (50 μM of CTP vs. 25 μM of EcCoaB) could possibly be 
accounted for by the fact that electrostatic interactions, which are presumed significant between 
the doubly-anionic CTP molecule and the positively-charged EcCoaB protein, are generally 
thought to be strengthened in the gas phase. In previous studies, a high degree of non-specific 
binding has also been observed in native MS experiments between creatine kinase and ATP,[198] 
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or between GroEL and ATP.[199] With EcCoaB, non-specific binding was even more pronounced at 
higher CTP concentrations, with up to four CTP molecules bound per dimer at 200 μM of CTP, 
and two molecules of CTP bound per monomer (Figure 4.11e).  
A number of methods have been developed to tackle the issue of non-specific binding in native 
ESI-MS experiments. van der Rest and co-workers[198] developed a deconvolution method that 
modeled the specific binding as a binomial distribution and the non-specific binding as a Poisson 
distribution (originally proposed by Klassen and co-workers).[200] Alternatively, Guan and co-
workers have modeled the non-specific component as a power-law distribution,[201] while in yet 
another approach, the group of Sharon and Horovitz have modeled all non-specific sites with a 
single binding constant.[202] 
In this study, to isolate the effect of non-specific binding in this system, the interaction between 
EcCoaB and ATP was monitored using native MS. The native mass spectrum of EcCoaB with ATP 
(50 μM) is shown in Figure 4.10c. As expected, ATP showed substantially reduced ability to 
increase the proportion of EcCoaB dimer compared to with CTP. While the presence of 50 μM 
CTP lowered the Kd value for the monomer-dimer equilibrium from 29 μM to 4 μM (see above), 
the presence of an equivalent amount of ATP only reduced the Kd value to 19 μM, which is within 
the 95% confidence interval for the Kd value for the apo protein (19 to 63 μM). This indicates that 
ATP does not stabilize the EcCoaB dimer as effectively as CTP, presumably because it is too large 
to enter into the nucleobase binding pocket of the enzyme. Moreover, ATP showed weaker 
binding to the dimer compared to CTP, as reflected by the lower proportion of ligand-bound 
protein for ATP compared to CTP at the same concentration. Based on the findings of Strauss et 
al.,[180] which showed that EcCoaB enzyme activity was not promoted even at ATP concentrations 
as high as 10 mM, we assumed that EcCoaB-ATP complexes observed by native MS were non-
specific. With this assumption, the specific binding component of CTP can be estimated by 
subtracting the occupancy of ATP from the occupancy of CTP at each site of the protein. Applying 
this method to the data shown in Figure 4.10 revealed that the specific binding constant of CTP 
to the monomer is 380 μM, while the average specific binding constant of CTP to the two sites of 
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the dimer was 70 μM. The latter affinity is composed of a specific binding constant of 580 μM for 
the first CTP molecule to the dimer, and a specific binding constant of 9 μM for the second CTP 
molecule to the dimer, which indicates some degree of positive cooperativity in the binding. The 
average specific binding constant (70 μM) is also consistent with the KM value of EcCoaB for CTP, 
which has been reported to be 48 μM.[189] 
4.2.2.3. Screening of EcCoaB inhibitors by native MS 
 Due to its ability to detect protein-ligand interactions, native MS is finding increasing use as a 
drug screening technique, including for fragment-based drug discovery (FBDD).[44-46] In line with 
the continuing interest within the Abell research group in the application of FBDD methods to 
develop new antimicrobial compounds, native MS was applied to screen a small library of 
fragment-sized sulfonamide compounds against EcCoaB. These analogues were designed based 
on the structure of the sulfonamide fragment 1, which was identified as a hit against Mtb CoaBC 
using a combination of differential scanning fluorimetry and ligand-based NMR studies. The 
library analogues 2-11 (synthesized by Dr. Jeannine Hess and Robert Starley, Abell research 
group), retain the sulfonamide core of fragment 1, but have simpler aromatic motifs in place of 




Figure 4.13 Structures of sulfonamide compounds 1-11 examined in this work. 
Additionally, the structure-activity relationships (SAR) around the phenyl substituent attached to 
the sulfonamide nitrogen atom was investigated by the installation of a carboxyl group and/or a 
bromine atom at various positions of the ring (except for compound 9, which carries a 2-
methoxypyridin-3-yl substituent in place of the phenyl ring). All of the library compounds (with 
the exception of naphthalene compound 11) have either 19 and 20 heavy atoms, putting them 
close to the upper limit in size of typical fragment-sized molecules.  
To minimize non-specific binding, the compounds were tested at a concentration of 30 μM with 
EcCoaBC at 15 μM, giving only a 2:1 excess of ligand to protein. The native mass spectra of 
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EcCoaBC incubated with the compounds 1-11 in the presence of 1% (v/v) DMSO are shown in 
Figure 4.14. In general, the compounds did not increase the ratio of the dimer to the monomer, 
indicating that unlike CTP they do not stabilize the EcCoaB dimer. This result is not surprising as 
the compounds are significantly smaller than CTP and thus less likely to be able to simultaneously 
contact both subunits of the dimer, even if they were binding to the CTP-binding site. 
 
Figure 4.14 Screening of sulfonamide compounds 1-11 against EcCoaB by native MS. In each experiment, 
the protein concentration was 15 μM and the ligand concentration was 30 μM. For the screening hits 




The native MS screen revealed five hits (compounds 4, 5, 6, 9 and 11) that bound to EcCoaB, as 
indicated by the appearance of additional peaks corresponding to the mass of the protein-ligand 
complex in the spectra. Due to the relatively small size of the ligands, only ligands bound to the 
monomer could be discretely resolved. For compounds 6 and 11, a small degree of non-specific 
binding was observed, as revealed by the presence of doubly-bound EcCoaB monomer species, 
which could either represent non-specific binding, or possibly two fragments binding at the same 
time to the active site. The mass shifts observed in the spectra were consistent with the molecular 
weights of the ligands (Table S1). For example, binding of ligand 11 (406 Da) to the EcCoaB 
monomer shifted the 9+ state by m/z = 48 (expected m/z shift = 45) and the 10+ state by m/z = 
44 (expected m/z shift = 41). 











4  355 42 39 38 36 
5  355 43 39 38 36 
6 355 43 39 37 36 
9  264 32 29 28 26 
11 406 48 45 44 41 
To validate the screening hits, they were tested for EcCoaBC inhibitory activity using an enzymatic 
assay. In this assay (performed by Dr. Jeannine Hess, Abell research group) the production of 
pyrophosphate that occurs concomitantly with the first half-reaction catalyzed by EcCoaB (the 
formation of 4’-phosphopantothenoyl-CMP) was monitored. As EcCoaB was used as a surrogate 
for the bifunctional EcCoaBC in the MS studies, EcCoaBC (16 nM) was used in the enzymatic assay 
to ensure that the inhibitors identified were biologically relevant. Ligands were tested at a 
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concentration of 1 mM, in the presence of CTP, PPan and L-cysteine at 125, 125 and 500 μM, 
respectively. The initial sulfonamide fragment 1 showed the weakest EcCoaBC inhibitory activity 
of 6 ± 3%, while the most potent compound was the naphthalene analogue 11, which inhibited 
EcCoaBC activity by 92% ± 5 (Table 4.4).  
Table 4.4 EcCoaBC inhibition activity of compounds at 1 mM as measured by an enzymatic assay. 
Compound
  
Structure % inhibition of 
EcCoaBC at 1 mM 
Native MS hit 
1 
 
6 ± 3 No 
2 
 
15 ± 4 No 
3 
 
21 ± 4 No 
4 
 
34 ± 4 Yes 
5 
 
83 ± 5 Yes 
6 
 





28 ± 8 No 
8 
 
13 ± 2 No 
9 
 
29 ± 5 Yes 
10 
 
25 ± 5 No 
11 
 
92  ± 5 Yes 
Pleasingly, there was good agreement between the results of the native MS assay and the 
biochemical assay. The five native MS hits (compounds 4, 5, 6, 9 and 11) were also the five most 
active compounds in the biochemical assay, with an average EcCoaBC inhibition of 57% at 1 mM 
(range of 29 to 92%) (Figure 4.15). Conversely, the compounds that failed to bind in native MS 
(compounds 1, 2, 3, 7, 8 and 10) showed the lowest activity in the biochemical assay, on average 
inhibiting activity by 18% (range of 6 to 28%). Taken together, these results validate the use of 




Figure 4.15 Inhibition of the PPCS activity of EcCoaBC by compounds 1–11 at 1 mM as measured by an 
enzymatic assay. EcCoaBC, CTP, phosphopantothenate and L-cysteine were present in the assay at 
concentrations of 16 nM, 125 µM, 125 µM and 500 µM, respectively. Native MS hits (4, 5, 6, 9 and 11) 
inhibited enzymatic activity by an average of 57%. Native MS misses (1, 2, 3, 7, 8 and 10) inhibited 
enzymatic activity by an average of 18%. The error bars represent the standard deviation of three 
experiments. 
However, it should be noted that the native MS screening was performed on the EcCoaB domain, 
while the enzyme inhibition studies were performed with the more biologically relevant EcCoaBC 
protein. This difference could account for why the correlation between MS screening hits and 
inhibition potency is not clear in all cases. For example, compound 7 and 9 inhibited the PPCS 
activity of EcCoaBC to similar extents (28 ± 8 and 29 ± 5% inhibition, respectively), but only 
compound 9 was a hit in the native MS assay.  
In future work, native MS could be used to derive binding affinities for the inhibitors identified 
here (as was done for CTP) and the correlation between MS-determined binding affinities for 
EcCoaB and inhibitory activity against EcCoaBC explored. Moreover, CIU IM-MS could be used to 




Native MS was used to study the interactions by between the EcCoaB domain and its ligands. Our 
data show that EcCoaB dimer formation is promoted by CTP, but not ATP, which is consistent 
with previous structural and biochemical data. A similar native nESI-IM-MS-based analysis of 
EcCoaBC will be important for understanding how the EcCoaB interactions observed contribute 
to the oligomeric interactions of dodecameric EcCoaBC, to which the CoaC domain (which CoaB 
is fused with) will also contribute. 
Additionally in this study, native MS was applied for screening a small library of fragment-sized 
sulfonamide compounds against E. coli CoaB, and the hit compounds were validated using a 
biochemical assay. Good agreement was observed between the native MS binding studies with 
EcCoaB and the enzyme inhibition assays performed with EcCoaBC. The active sulfonamide 
compounds represent a new class of small-molecule, non-mimetic inhibitors of CoaBC, a recently 
validated antimicrobial target. This study thus highlights the utility and versatility of native MS 
both for structural biology and for drug discovery.  
4.3. Experimental 
4.3.1. Materials and methods 
All chemicals were of reagent grade quality or better, obtained from commercial suppliers and 
used without further purification. Phosphopantothenate[203] and the fragment-sized sulfonamide 
2-11 compounds were synthesized by group members Dr. Jeannine Hess and Robert Starley. 
Unless otherwise stated, reactions were conducted under positive pressure of a dry nitrogen 
atmosphere. Anhydrous solvents were purchased directly from commercial sources and used 
without further purification. Analytical thin layer chromatography (TLC) was performed using 
Merck glass-backed silica (Kieselgel 60 F254 0.25 mm) plates. Compounds were visualized using 
shortwave (254 nm) ultraviolet light. Flash column chromatography was performed using an 
Isolera Spektra One/Four purification system and the appropriately sized Biotage SNAP column 
containing KP-silica gel (50 μm). Solvents are reported as volume/volume eluent mixtures. 
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Reactions were monitored by TLC and LCMS to determine consumption of starting materials. 
Nuclear magnetic resonance (NMR) spectra were recorded at 300 K unless otherwise stated, 
using either a Bruker 400 MHz AVANCE III HD Smart Probe, 400 MHz QNP cryoprobe, or 500 MHz 
DCH cryoprobe spectrometer. All spectra were recorded in the deuterated solvent indicated. 
Data are reported as chemical shift in parts per million (δ ppm) relative to the residual protonated 
solvent resonance peak. The relative integral, multiplicity and coupling constants (J Hz) of peaks 
has been provided where possible. Liquid chromatography mass spectrometry (LCMS) was 
carried out using an AQUITY UPLC H-class system (Waters, Manchester UK). Samples were run 
using a gradient of water (1−5%) (+0.1% formic acid) in acetonitrile over a period of 4 min. High 
resolution mass spectra (HRMS) were recorded using a Waters Quadrapole-Time-of-Flight (Q-
Tof) spectrometer or an Orbitrap LCMS spectrometer attached to a Dionex Ultimate 3000 HPLC. 
The mass to charge ratio (m/z) of the molecular ion and difference from calculated mass (δ ppm) 
are quoted.  
4.3.2. Protein expression and purification 
4.3.2.1. EcCoaB overexpression and purification 
EcCoaB overexpression and purification was performed by group member Dr. Christina Spry. A 
pET-28b plasmid carrying the coding sequence for the CoaB domain of E. coli CoaBC was used. 
The plasmid encodes N- and C-terminally hexa-histidine-tagged EcCoaB 
(MGSSHHHHHHSSGLVPRGSHM-Pro182-Arg406-LEHHHHHH, CoaBC residues indicated).  E. coli 
BL21(DE3) cells transformed with the construct were grown in LB supplemented with 30 µg/mL 
kanamycin until an OD600 of approximately 0.6 was reached. Immediately thereafter 
overexpression was induced by the addition of 1 mM IPTG. After overnight incubation at 37 °C, 
the bacteria were harvested by centrifugation (4000 g, 15 min) and the cell pellet was stored at 
–20 °C.  The harvested cells were lyzed in 20 mM Tris, 500 mM NaCl, pH 8.0 containing one EDTA-
free cOmplete protease inhibitor cocktail tablet (Roche) per 50 mL lysate, using an EmulsiFlex-C5 
High Pressure Homogenizer (Avestin). The cells were passaged through the pressure cell three 
times at a pressure of 40 000 psi, after which the lysate was centrifuged at 35 000 g for 30 min. 
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For nickel-affinity chromatography, the clarified lysate was applied to a 5 mL HisTrap FF column 
(GE Healthcare) and, following washing with lysis buffer, the His-tagged protein was eluted using 
a linear gradient of imidazole (0–0.5 M). Elution was monitored at A280 and by SDS-PAGE analysis. 
Fractions containing EcCoaB were pooled and concentrated using a Vivaspin 20 centrifugal 
concentrator with a 10 kDa molecular weight cut-off before being subjected to gel filtration using 
a Superdex75 26/60 column (GE Healthcare) previously equilibrated with 20 mM Tris, 150 mM 
NaCl, pH 8.0. Gel filtration was performed at a flow rate of 2.5 mL/min and elution was again 
monitored at A280 and by SDS-PAGE analysis. Fractions containing purified His-tagged EcCoaB 
were pooled and concentrated as before, and aliquots of the concentrated protein were flash-
frozen in liquid N2 and stored at –80 °C. The identify and purity of EcCoaB was checked by 
denaturing LC-MS (Figure 4.2), which showed a mass for the protein that was identical with the 
theoretical mass of the protein without the N-terminal methionine (27942 Da). 
4.3.2.2. EcCoaBC overexpression and purification 
EcCoaBC overexpression and purification was performed by group member Dr. Christina Spry. E. 
coli CoaBC was overexpressed in E. coli BL21(DE3) cells from a codon-optimised pET-28a 
construct. Transformed cells were grown at 37 °C in LB culture medium containing 50 μg/mL 
kanamycin to an OD600 of approximately 0.5, then expression was induced with 500 M IPTG. 
The culture was incubated for a further 20 h at 20 °C, and the cells were pelleted by centrifugation 
(4000 g, 20 min). Cell pellets are frozen and stored at -80 °C. Cells were resuspended in lysis 
buffer [50 mM Hepes/Na (pH 7.4), 1 M NaCl, 25 mM imidazole, 1 tablet of Pierce Protease 
Inhibitor Tablet], and lysed by sonication for 3.5 min (10 s on/20 s off, amplitude 50%). Insoluble 
material was removed from the lysate by centrifugation at 30 000 g for 30 min at 4 °C. The 
supernatant was then loaded onto a 5 mL HisTrap FF column (GE Healthcare), which had been 
pre-equilibrated with lysis buffer. The column was further washed with lysis buffer, and then E. 
coli CoaBC was eluted from the column by increasing the imidazole concentration to 500 mM. 
The eluate was concentrated to ≤10 mL and injected onto a Superdex-200 Hiload 16/60 FPLC 
column (GE Healthcare) previously equilibrated with 50 mM Tris (pH 8.0), 250 mM NaCl, and 5 
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mM mercapto-ethanol. The purified protein was concentrated and aliquots were flash-frozen in 
liquid N2 and stored at −80 °C. 
4.3.3. Mass spectrometry 
Native nanoelectrospray ionization-ion mobility-mass spectrometry (nESI-IM-MS) spectra were 
recorded on a Synapt HDMS mass spectrometer (Waters, Manchester, UK) modified for studying 
high masses (32k quadrupole) and equipped with a traveling wave (TW) IM cell. EcCoaB was 
exchanged into 200 mM ammonium acetate (pH 7.0 unless otherwise stated) solution using 
Micro Bio-Spin 6 chromatography columns (Bio-Rad, UK). Protein samples were equilibrated at 
room temperature in the absence or presence of the indicated concentrations of ligands for at 
least 15 min before analysis. 2.5 μL of protein solution was injected into a gold-coated 
borosilicate emitter (Thermo Scientific, UK) for sampling. Typical conditions were capillary 
voltage 1.5 kV, cone voltage 50 V, trap collision voltage 20 V, trap DC bias 35 V, transfer collision 
voltage 20 V, source temperature 20 °C, backing pressure 3–4 mbar, trap pressure 3–4 × 10–2 
mbar, IM (N2) pressure 5–6 × 10–1 mbar and TOF pressure 7–8 × 10–7 mbar. For ion mobility 
experiments, the mass spectrometer was operated in mobility TOF mode using a wave velocity 
of 250 ms–1 and a wave height of 10 V. To effect collision-induced unfolding (CIU), the trap 
collision voltage was raised in 2 V increments from 10 to 80 V. Avidin, concanavalin A, alcohol 
dehydrogenase and pyruvate kinase were used as calibrants for CCS determination. All mass 
spectra were calibrated externally with cesium iodide (10 mg/mL). Data acquisition and 
processing were performed using MassLynx 4.1 (Waters) and DriftScope 2.5 (Waters). 
4.3.4. Kd determination 
The determination of dissociation constant (Kd) for the EcCoaB monomer-dimer equilibrium was 
determined using the procedure of Zenobi and co-workers,[193] which was based on earlier work 
by the group of Gabelica.[194] 
Briefly, the equilibrium association constant (Ka) relating the EcCoaB monomer (M) and dimer (D) 
concentration is described using equation 1, 
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 𝐾 =  [ ]
[ ]
=         (1) 
The response factors (RM and RD) governing the relationship between the concentrations of M 
and D and their relative ion intensities (IM and ID respectively) are described using equations 2 
and 3, 
  𝐼 = 𝑅 × [𝑀]       (2) 
 
 𝐼 = 𝑅 × [𝐷]       (3)  
Given a total EcCoaB monomer concentration of [M0], and setting the ratio of response factors 
of the dimer and monomer as R, the equations 3 and 4 can be derived, 
  𝑅 =         (4) 
  =        (5) 
After determination of IM and ID from the mass spectra, equation 5 can be solved for R and Ka by 
double-parametric non-linear curve fitting. Non-linear parameter uncertainties were estimated 
using a Monte Carlo method as described by Si and co-workers.[204] 
The proportion of ligand binding was estimated by considering the relative peak areas of 
unbound and bound states for each spectrum.[191] For example, the proportion of singly-bound 
monomer was calculated by dividing the relative intensity of singly-bound monomer by the total 
intensities of all monomeric species (unbound, singly-bound and doubly-bound). For this 
calculation, all charge states were taken into account. Additionally, the experimentally-
determined response factor of R = 1.8 was used as a parameter to determine the relative 
amounts of monomeric and dimeric EcCoaB species. 
149 
 
For determining the Kd value of the EcCoaB monomer binding to CTP, we first determined the 
proportion of unbound and singly-bound monomer in the presence of 50 μM CTP or ATP by 
consideration of the relative peak areas of all charge states of the monomer. We further made 
the assumptions that all ATP binding to the EcCoaB monomer is non-specific, and that the degree 
of non-specific binding by CTP to the protein would be identical to the degree of non-specific 
binding by ATP to the protein. Operating under that assumption, 24% of the 34% of CTP binding 
to the monomer was considered to be non-specific, leaving 10% of the monomer being 
specifically bound and 90% unbound. The corrected concentrations of unbound and singly-bound 
monomer were then calculated to be 15 μM and 1.6 μM respectively. Finally, the concentration 
of free CTP was estimated by subtracting the CTP concentration bound to protein (for both 
monomers and dimers, but corrected for non-specific binding) from the initial CTP concentration, 
which was 40.5 μM in this case. This gave a Kd value of 380 μM for the monomer-CTP complex. A 
similar method was used to calculate the Kd value for CTP binding to the EcCoaB dimer. 
4.3.5. Ion mobility calibration 
Calibration with ions of known CCS is required on a TWIM instrument because the analytical 
equations governing ion mobility are complex owing to the non-linear time- and space-varying 
dependence of the electric field.[76, 139] 
Briefly, the drift times (tD) (in ms) are corrected for mass-dependent flight time using equation 6, 
 𝑡′D = 𝑡D −
(m/z)        (6) 
where t′D is the corrected drift time of the calibrant ions, C is the "EDC (Enhanced Duty Cycle) 
delay coefficient” and is equal to 1.57, and m/z is the mass-to-charge ratio of the observed ion. 
The calibrant CCS (Ω) values are then corrected for both ion charge state (z) and reduced mass 
(μ) according to equation 7, 
 Ω′ =  Ω
(  × ( / ))
        (7) 
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where Ω′ is the corrected CCS value and μ is the reduced mass of the ion-N2 collision complex. 
Next, ln (tD′) is plotted against ln (Ω′) and the slope (X) of the graph is determined. A new 
corrected drift time (t′′D) is then calculated using equation 8, 
 𝑡′′D = 𝑡′Dx × 𝑧 × (1/μ)      (8) 
Finally, Ω is re-plotted against t′′D to generate a linear calibration plot that can then be used to 
determine CCS values for analyte ions.  
Unless otherwise stated, all CCS values are quoted as N2 values. PULSAR[53] was used to perform 
CCS calibration,[76] generate CIU unfolding plots and calculate CIU50 values. As algorithms for CCS 
calculation from X-ray crystal structures are parameterized for helium collision gas,[139] 
theoretical CCS(He) values were first determined using the projection approximation (PA) 
algorithm implemented in DriftScope, and then converted to theoretical CCS(N2) values as 
described by Bush et al.[79] However, the PA algorithm, which functions by finding the average 
projection (or “shadow”) of an ion onto a defined plane, generally underestimates CCS values for 
biomolecules because it does not take into the account of the greater gas slow-down effect for 
cavities as well as protein charge which affects ionization of neutral gas molecules.[139] To account 
for this, an empirically-determined scaling factor of 1.14 is introduced.[61]  Thus, the “corrected” 
theoretical CCS value (CCScalc) was calculated using equation 9, 
 𝐶𝐶𝑆 = 1.14 ×  𝐶𝐶𝑆  × ( )      (9) 
where CCSPA is the CCS calculated from the X-ray crystal structure using the PA algorithm, Mexp is 
the experimental mass of the protein and MPDB is the mass calculated from the crystal structure. 
In the case of the EcCoaB dimer, CCSPA was determined to be 3482 Å2 from the reported X-ray 
crystal structure (PDB: 1U7U),[184] and Mexp and MPDB were 27942 and 24834 Da, respectively. 
Thus, CCScalc was calculated to be 4258 Å2. 
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4.3.6. Inorganic pyrophosphatase-purine nucleoside phosphorylase PNP-PPIase assay  
The assay was performed by group member Dr. Jeannine Hess. PPCS activity was monitored by 
the method of Webb[205] using the commercially available EnzCheck pyrophosphate assay kit (E-
6645) (Life Technologies). The assay couples production of pyrophosphate to the phosphorolysis 
of 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG), which can be monitored by 
measuring absorbance at 360 nm. Reactions were performed at 25 ˚C in the wells of a 96-well 
plate (Greiner), in a final volume of 150 µL. The final composition of reactions was 16 nM 
EcCoaBC, 125 µM CTP, 125 µM 4’-phosphopantothenate, 500 µM L-cysteine, 0.03 U/mL inorganic 
pyrophosphatase, 1 U/mL purine nucleoside phosphorylase, 200 µM MESG, 100 mM Tris, pH 7.6, 
1 mM MgCl2, 1 mM TCEP, and 1 mM of test compound (initially dissolved to 50 mM in DMSO) or 
an equivalent concentration of DMSO (2%, v/v). Initially, 100 mM Tris, pH 7.6, 1 mM MgCl2, 1 mM 
TCEP with CTP, 4’-phosphopantothenate, L-cysteine, MESG and the test compound/DMSO, each 
at twice the final concentration, in a final volume of 75 µL, was added in triplicate to the wells of 
a 96-well plate, and the plate was pre-incubated at 25 ˚C for 10 min.  A 100 mM Tris, pH 7.6, 1 
mM MgCl2, 1 mM TCEP solution containing EcCoaBC, inorganic pyrophosphatase and purine 
nucleoside phosphorylase, each at twice the final concentration, was also prepared and similarly 
pre-incubated at 25 ˚C for 10 min.  Reactions were subsequently initiated by the addition of 75 
µL of the enzyme solution to each well, and enzyme activity was immediately monitored by 
measuring absorbance at 360 nm at 20 s intervals over 30 min in a ClarioStar microplate reader 
(BMG Labtech). Assays were performed in triplicate, and included wells without 4’-
phosphopantothenate, which served as “no reaction” controls, as well as wells containing 2% 
(v/v) DMSO instead of test compound, which served as “uninhibited” controls. Initial reaction 
rates were determined from the linear portion of the time courses. To convert the reaction rates 
measured in the presence of each test compound to a percentage inhibition, the average rate 
determined for the “no reaction” wells was first subtracted from all initial rates. Thereafter the 
background-corrected rates obtained for the wells containing test compound were subtracted 
from the average of the background-corrected uninhibited controls, and then the resulting 
difference in rate divided by the average of the uninhibited control. 
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5. Investigation of the Aurora A-TPX2 interaction and its targeting 
by small molecules using native mass spectrometry 
5.1. Introduction 
Aurora A (AurA) is a Ser/Thr kinase that plays important roles in mitosis and cytokinesis.[148] 
During mitosis, Aurora A associates with the centrosome and the spindle microtubules to control 
centrosome maturation and spindle assembly. However, the overexpression of AurA has been 
linked with a range of solid and hematological tumors as well as with aneuploidy, defective 
mitotic spindles, and resistance to apoptosis.[165] Consequently, AurA has been considered to be 
an attractive target for the development of anticancer agents.[206]  
Like other Ser/Thr kinases, AurA is activated by phosphorylation of a threonine residue (T288) in 
its activation loop. AurA can also be activated by binding with its protein binding partner, 
targeting protein for Xklp2 (TPX2), in multiple ways.[207] First, TPX2 localizes AurA to the mitotic 
spindle. Secondly, TPX2 stabilizes the active conformation of AurA by protecting the key 
phospho-T288 in the kinase activation loop from protein phosphatase 1. Thirdly, TPX2 increases 
the stability of AurA by protecting it from proteasomal degradation during early mitosis. TPX2 is 
often overexpressed in many cancers alongside AurA. 
Despite being 747 amino acid residues in length, only residues 1–43 of TPX2 (TPX21–43) are 
sufficient for the binding and activation of AurA. Interestingly, TPX2 binds to AurA in two distinct 
stretches, TPX7–21 and TPX30–43 that are connected by a flexible, non-structured linker that cannot 
be observed in the X-ray crystal structure (Figure 5.1). The “upstream” TPX7–21 region adopts an 
extended conformation that fits within a hydrophobic groove in the N-lobe of AurA. Meanwhile, 
the “downstream” TPX30–43 region forms an α-helix that binds to AurA between the N-lobe and 




Figure 5.1 X-ray crystal structure of AurA122–403 and TPX21–43 showing the protein-protein interaction 
binding regions (PDB code: 1OL5). Reproduced with permission from Bayliss et al.[208]  
Kern and co-workers have recently shown that T288 phosphorylation and TPX2 binding results in 
comparable increases in the catalytic activity of dephosphorylated AurA.[45] Moreover, they 
surprisingly showed that dephosphorylated AurA is in the active conformation when bound to 
TPX2, suggesting that TPX2 is sufficient for AurA activation even in the absence of T288 
phosphorylation. The addition of TPX2 to phosphorylated AurA resulted in a further two-fold 
increase in catalytic activity.  
The majority of AurA inhibitors reported in the literature target the ATP-binding site, with the 
clinically-profiled alisertib (MLN8237, Millennium Pharmaceuticals)[209] (Table 5.1) being among 
the most well-known. JNJ7706621, a classical “Type 1” ATP-competitive kinase inhibitor, has also 
been reported to display potent but non-selective activity against AurA.[210] However, the high 
degree of structural conservation in the active site of all the members of the human kinome[211] 
makes the development of selective ATP-competitive inhibitors of kinases, including AurA, a 
particularly difficult challenge. 
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Table  5.1 AurA ligands used in this study. KD values for JF218, JF004 and JF025 were determined 
by ITC by Abell group members. 




40 nM[212]  ATP 
JNJ7706621 
 
IC50 = 11 nM[210] ATP (Type 1) 
JF218  
 
0.79 µM Allosteric 
JF004 
 
49 µM Allosteric 
JF025 
 
537 µM Allosteric 
Targeting the AurA-TPX2 protein-protein interaction is an alternative approach to blocking AurA 
activity. Disruption of the AurA-TPX2 interaction has been shown to impair kinase activity, 
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resulting in the mislocalization of Aurora A, mitotic defects, and cell cycle arrest.[213] Moreover, 
since the TPX2-binding site of AurA is much less highly conserved than the ATP-binding site, 
inhibitors that target TPX2 binding could potentially show improved selectivity for AurA over 
other kinases, thereby reducing off-target effects.  
The Abell research group had a significant interest in developing compounds that target the 
AurA-TPX2 protein-protein interaction via binding to the TPX2 binding site of AurA. 
Representative examples of the in-house allosteric AurA inhibitors, JF218, JF004 and JF025 
investigated in this work are shown in Table 5.1. The aim of this section of the project was to 
apply native MS methods to study the AurA-TPX2 interaction and to further validate the 
mechanism of action of the compounds developed. 
5.2. Results and discussion 
5.2.1. Expression and purification of AurA and TPX2 
In this project, AurA mutants (Table 5.2) were expressed in E. coli  BL21(DE3) cells following a 
general protocol utilized by the research group of Dr. Marko Hyvönen (Department of 
Biochemistry). The precise monitoring of these mutants and control of their phosphorylation 
status had not previously been investigated. The culture medium for AurA protein expression as 
well as all purification and storage buffers contained 1 mM ATP, as AurA was thought to be 
unstable without the presence of ATP bound to the active site (Hyvönen group, personal 
communication).  
Table 5.2 List of AurA mutants used in this study. 
Mutant Description 
AurA-A AurA126–390 containing kinase domain with T287A mutation and non-
cleavable C-terminus His6-tag. Expressed in this study. 
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AurA-B/AurA-B′ AurA126–391 containing kinase domain with T287A mutation and TEV-
cleavable N-terminus His6-tag. AurA-B′ is the cleaved version of AurA-B. 
Expressed in this study. 
AurA-C/AurA-C′ AurA123–401 containing kinase domain with T287A/T288D double 
mutation and TEV-cleavable N-terminal His6-tag. Constitutively active. 
AurA-C′ is the cleaved version of AurA-C. Expressed in this study. 
AurA-D AurA125–403 containing kinase domain with D274N mutation. Catalytically 
dead. Provided by collaborator Maxim Rossman from the Hyvönen 
group. 
The AurA construct first employed was the AurA mutant containing the kinase domain, a T287A 
mutation and a non-cleavable C-terminus His6-tag (AurA-A). The T287A mutation was chosen 
because although phosphorylation at T287 is often observed in vitro, this does not appear to have 
an effect on catalytic activity.[214] Reducing the number of phosphorylation sites from two to one 
was thought to be advantageous for MS because then the presence of phosphorylation at the 
critical T288 residue can be unambiguously identified by a +80 Da m/z shift from the 
unphosphorylated protein in the mass spectrum. The construct also contains the λ-phosphatase 
gene, which when co-expressed dephosphorylates AurA and reduces its toxicity to the bacterial 
cells. However, initial attempts at the expression of AurA-A were unsuccessful, leading to the 
isolation of either a defective protein (incorrect mass) or the correct protein but in very low 
yields. This was attributed to the fact that AurA is highly toxic to E. coli cells, which exerts selective 
pressure on bacteria to develop mutations in the enzyme or to eject the plasmid altogether. To 
ameliorate the toxicity issue, a number of modifications to the general procedure were 
investigated (Table 5.3).[215]  




The expression culture is inoculated 
directly from colonies on an agar 
plate instead of from a starter 
culture.  
The selection of plasmid-containing cells is more stringent on 
antibiotic-containing agar plates than in liquid culture media. 
Induction with a lower IPTG 
concentration (100 μM instead of 
400 μM). 
Cells induced using low IPTG concentrations have more 
metabolic control over the toxicity of the expressed protein. 
Induce at 37 °C for 3 h instead of 20 
°C overnight. 
A shorter induction period reduces the time over which the 
selection pressure of the toxic protein acts. 
A second dosage of ampicillin (50 
μg/mL) is added just before 
induction. 
The ampicillin initially present in the medium may be 
hydrolyzed by β-lactamases by the time the culture reaches 
OD600 = 0.4. Adding a second dosage of ampicillin before 
induction ensures that only cells that still retain the plasmid will 
survive during the expression period.  
Using these modifications, yields of ca. 1 mg/L of purified AurA-A was obtained. Due to the very 
low sample consumption requirements of nanoESI-MS, further optimization of the protein 
expression and purification procedure was not performed.  
The AurA-A protein was initially purified by affinity chromatography using a nickel Sepharose 
resin in a gravity flow column, and then further purified by size-exclusion chromatography. 
However, although sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) analysis of the 
purified product showed the presence of only a single band, mass determination by high-
resolution LC-MS showed that four AurA species were actually present (Figure 5.2). The masses 
of the four species corresponded to phosphorylated AurA-A (31834 Da), unphosphorylated 
AurA-A (31754 Da), phosphorylated and demethioninylated AurA-A (31702 Da) and 
unphosphorylated and demethioninylated AurA-A (31623 Da). The presence of these four 
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species was attributed to sporadic cleavage of the N-terminal methionine residue[216] and/or 
phosphorylation.  
 
Figure 5.2 Deconvoluted high-resolution LC-MS of AurA-A. 
This heterogeneity led to difficulties in the subsequent interpretation of native MS data. 
Consequently, the alternative AurA construct, AurA-B, was explored. Like AurA-A, this construct 
also contains the T287A mutation, but differs in the fact that the His6-tag is located at the N-
terminus and is cleavable by the tobacco etch virus (TEV) protease. After cleavage, the N-
terminus begins with a glycine residue rather than a methionine residue, so sporadic 
demethioninylation would be avoided. Under the optimal conditions, AurA-B was purified in 
yields of approximately 1–2 mg/L of culture. LC-MS analysis of the uncleaved product showed 
the presence of two major species differing by 80 Da, which suggests that one of the two species 
is phosphorylated while the other is unphosphorylated. However, both masses were 156 Da 
larger than the expected mass as given by the protein sequence. Nevertheless, the protein 
sample was subjected to digestion by TEV protease and the LC-MS spectrum of the cleaved 
product (AurA-B′) showed the correct masses of 32,045 and 32,125 Da for the unphosphorylated 
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and phosphorylated enzyme, respectively. This suggested that the source of the +156 Da shift in 
the uncleaved protein may have been part of the N-terminal tag that was removed. 
While cleaved AurA-B′ was comprised of fewer protein species than purified AurA-A (two instead 
of four), it was still not a homogeneous sample. Therefore, efforts were made to purify and 
process AurA-B′ using various means in order to obtain a homogeneous sample. First, the crude 
TEV digest containing unphosphorylated and monophosphorylated AurA-B′ was subjected to 
nickel column chromatography to remove the excised His6-tag and TEV enzyme, which also 
contains a polyhistidine tag. To our surprise, the eluted AurA-B′ was found to contain a mixture 
of monophosphorylated and diphosphorylated species. This was attributed to the presence of 
ATP in the elution and storage buffers, allowing AurA-B′ to phosphorylate itself in vitro. The 
subsequent addition of λ-phosphatase failed to remove all the phosphate groups from AurA-B′, 
even when the potent AurA inhibitor alisertib was present.  
The above results suggested that the presence of 1 mM ATP in the bacterial culture medium as 
well as in all of the purification and storage buffers for AurA strongly promoted 
autophosphorylation, making it difficult to isolate the enzyme in the unphosphorylated state. 
Therefore, ATP was replaced with ADP in the culture medium as well as in all subsequent buffers, 
which was something that had not previously been attempted. The rationale was that ADP, being 
similar in size to ATP, could also bind to the active site of AurA and stabilize the enzyme but 
without promoting its autophosphorylation activity. Gratifyingly, this modification led to the 




Figure 5.3 Expression of AurA-B′ in the presence of ADP (lower panel) instead of ATP (upper panel) favors 
the formation of unphosphorylated enzyme, but which still phosphorylates itself over time. Phosphate 
groups are represented schematically as purple circles. 
However, the unphosphorylated AurA-B′ still slowly converted into the monophosphorylated 
form over time. This was attributed to the presence of ATP in commercial ADP stocks,[217] and 
was confirmed in this study by native MS (Figure 5.4). Even the small amount of ATP in the 
solution was sufficient to activate the autophosphorylation activity of AurA-B′. The 
contaminating ATP could potentially be removed by incubation with hexokinase and glucose,[217] 




Figure 5.4 Native MS of (a) ATP and (b) ADP solutions. ATP and ADP are indicated by orange circles and 
purple diamonds respectively (only z = 1 states annotated), and the bolded numerals represent the number 
of Na+ ions attached. Dimers and trimers of ATP and ADP are presumed to be non-specific.  
 A sample containing a mixture of monophosphorylated and diphosphorylated AurA-B′ was 
subjected to phosphopeptide analysis using LC/MS-MS with tryptic digestion (performed by the 
Cambridge Centre for Proteomics) to locate the position of the phosphorylation site. As expected, 
99% of the phosphate groups were located at the critical T288 residue, while other serine and 
threonine residues were occasionally phosphorylated (Figure 5.5). The presence of other 
phosphorylation sites could explain the observation of doubly phosphorylated AurA-B′ when the 
protein was expressed and purified in an abundance of ATP.  
162 
 
Figure 5.5 Sequence of AurA-B′ with phosphorylation sites underlined. The critical T288 residue is also 
shown in bold, and contains 99% of phosphorylation. 
Subsequently, a third AurA construct, AurA-C, was investigated. This construct contains the 
T287A/T288D double mutation as well as a N-terminal His6-tag cleavable by TEV protease. Since 
the Asp288 residue is a functional mimic of phosphorylated Thr288, this mutant is constitutively 
active. As a result, AurA-C is even more highly toxic to E. coli cells, as its catalytic activity is not 
abrogated in the presence of λ-phosphatase. Moreover, due to its lack of phosphorylation sites 
at both positions 287 and 288, AurA-C is expected to give only one protein species after cleavage 
of the N-terminal His6-tag. 
AurA-C was expressed in low yields of approximately 1 mg/L of culture. LC-MS analysis of the 
uncleaved sample showed two major clusters of protein peaks, which was consistent with the 
two bands that were observed on the SDS-PAGE gel. The higher-mass cluster contained three 
major peaks corresponding to phosphorylated AurA-C, unphosphorylated AurA-C and 
unphosphorylated and demethioninylated AurA-C. Meanwhile, the lower-mass cluster was 
thought to be comprised of truncated versions of the protein. Fortunately, cleavage with TEV 
resulted in a protein sample that formed only a single band on the SDS-PAGE gel, suggesting that 
the truncations were located in the N-terminal tag. LC-MS analysis revealed the presence of the 
desired protein species (AurA-C′) at 32,278 Da (Figure 5.6). Unfortunately, similar to what was 
observed with AurA-B′, AurA-C′ also autophosphorylated itself over time even when expressed, 
purified and stored in ADP. As previously discussed, this could be accounted for by the presence 
of ATP in the ADP stock. Since AurA-C′ contains both T287A and T288D mutations, this indicates 







monophosphorylated and diphosphorylated species observed. At present, the biological 
significance of phosphorylation of AurA at sites other than T287 and T288 is unknown. 
 
Figure 5.6 Deconvoluted high-resolution LC-MS analysis of unphosphorylated AurA-C′ after TEV cleavage 
(lower panel) and a mixture of unphosphorylated, monophosphorylated and diphosphorylated AurA-C′ 
after further purification and storage for 72 h (upper panel).  
TPX2 was expressed as a GB1 fusion protein in E. coli BL21(DE3) cells to maintain solubility during 
protein expression. Cleavage of the GB1 tag using TEV protease releases a 48-residue fragment 
containing the active binding region TPX27–43, which could be isolated simply by passing through 
a 10 kDa molecular weight cut-off (MWCO) filter. The purity of TPX27–43 was sufficient for use in 






Figure 5.7 High-resolution LC-MS of the mixture of TPX27 –43 (5.2 kDa) and the cleaved GB1 tag (11.1 kDa) 
(upper panel), which could be passed through a 10 kDa MWCO filter to isolate TPX27–43 (lower panel). 
Charge states for TPX27–43 and the cleaved GB1 tag are indicated with purple stars and orange circles, 
respectively. 
5.2.2. Native MS of the AurA-TPX2 interaction 
The interaction between AurA and TPX2 was studied by native MS. In native MS, protein samples 
must first be exchanged into a volatile buffer such as NH4OAc, since non-volatile salts can lead to 
suppression of ionization and extensive adduct formation. However, it was noticed that AurA-B′ 
was prone to covalent dimer formation when buffer-exchanged into NH4OAc (Figure 5.7). This 
was thought to be due to disulfide bridge formation at Cys290, as mutating that position 
suppressed dimer formation in experiments performed by the Hyvönen group. It was found that 
dimer formation could also be suppressed by the addition of 1 mM of β-mercaptoethanol in the 





Figure 5.7 Deconvoluted high-resolution LC-MS of AurA-B′ before (lower panel) and after (upper panel) 
buffer exchange into ammonium acetate buffer. 
Undesirable dimer formation was observed with TPX27–43 due to its abundance of Cys residues. 
Hence, β-mercaptoethanol could also be added to storage buffers for TPX27–43 as well as to the 
NH4OAc solution just before electrospray. 
As described above, AurA-A, AurA-B′ and AurA-C′ were expressed in a mixture of variously 
phosphorylated states due to the propensity of the enzyme to phosphorylate itself. This 
increased the difficulty of peak assignment because peaks of different phosphorylation states, 
each already broad due to the adduction of weakly-bound solvent or other adducts in native MS, 
often overlapped with each other. The only exception was AurA-D, bearing a D274N mutation 
that makes it catalytically dead, which was isolated by the Hyvönen group in a completely 
homogeneous state. This allowed the distinguishing of ADP-bound and ATP-bound (Δm/z = 8) 




Figure 5.8 Deconvoluted LC-MS spectrum of AurA-D, showing near-complete homogeneity (left), and 
native MS of AurA-D showing the discrimination of various small molecule-bound species of the 10+ charge 
state (right).  
Next, AurA-C′ and TPX27–43 were incubated together and their native mass spectrum was 
recorded (Figure 5.9). An obvious shift in the signals of AurA-C′ (32.2 kDa) was observed upon 
addition of TPX27–43 (5.2 kDa), due to the formation of the non-covalent AurA-C′·TPX27–43 
complex (37.4 kDa). The relatively low charge states of both free AurA-C′ (9+ and 10+) and the 
AurA-C′·TPX27–43 complex (10+ and 11+) suggested that both species were in the folded 
conformation. Interestingly, despite the strong (ca. 6 nM using a fluorescence polarization assay 
performed by our collaborator Tomasso Moschetti in the Hyvönen group) binding affinity 
between AurA and TPX27–43, a small amount of both unbound AurA-C′ and unbound TPX27–43 
were observed in the native mass spectrum. This suggests that one or both of the binding 
partners were in the incorrect conformation to form the AurA-TPX2 complex in solution. To our 




Figure 5.9 Native MS of AurA-C′ (10 µM) and TPX27–43 (20 µM) in 200 mM NH4OAc containing 5% DMSO. 
AurA-C′ and TPX27–43 are depicted as blue ovals and yellow crescents, respectively. 
A collision-induced dissociation experiment was performed on the AurA-TPX2 complex by raising 
the collision voltage within the trap region of the mass spectrometer (Figure 5.10). As the 
collision energy was increased, the signals for AurA-B′ and the AurA-B′-TPX27–43 became sharper 
due to dissociation of weakly bound solvent or other adduct molecules from the protein. As the 
collision energy reached 120 V, free TPX2 degraded or otherwise became unobservable. 
However, even at the highest collision voltage of 150 V, where degradation of the protein 
backbone was observed to begin and where the protein has already long unfolded (unfolding 
begins at ca. 60 V as observed by CIU-MS, data not shown), the AurA-B′-TPX27–43 complex still 





Figure 5.10 Native MS of AurA-B′ (10 µM) and TPX27–43 (20 µM) in 200 mM NH4OAc containing 1% DMSO. 
AurA-B′ and TPX27–43 are depicted as blue ovals and yellow crescents, respectively. An unknown small-
molecule impurity is indicated as a blue star (see below). 
Because of the strong binding affinity between AurA and TPX27–43, it was thought that this 
protein-protein interaction would be too strong to disrupt using fragment-sized molecules. 
Therefore, weaker-binding TPX phage display mutants (“M3” and “M6”) (Table 5.4) were 
obtained from the Hyvönen group and tested for their binding to AurA using native MS.  
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Table 5.4 Sequence of TPX7–43 and TPX2 mutants M3 and M6. Residues 7–43 of TPX2 are underlined. 
Mutations are shown in bold font. Binding affinities (KD) for AurA were determined by a fluorescence 
polarization assay by the Hyvönen group. 
Construct KD Sequence 



















However, no binding at all was observed between AurA-B′ with M3 (data not shown) or with M6 





Figure 5.11 Native MS of AurA-B′ (15 µM), M6 (30 µM) and their combination in 200 mM NH4OAc. No 
binding between AurA-B′ and M6 was observed. 
It was also observed that there was a small-molecule impurity of around 300 Da that was bound 
to both of our TPX-2 and AurA protein preparations (lowest panel in Figure 5.10). Several efforts 
were made to identify the nature of this impurity. The impurity showed apparently high binding 
affinity to AurA, as a sizable proportion of AurA-B′ remained bound by this impurity even after 
multiple overnight washes with NH4OAc buffer. The impurity also dissociated from AurA-B′ at 
much higher collision energies (ca. 100 V) than required for ADP/ATP or AurA inhibitors (ca. 60 
V). Denaturing AurA-B′ or AurA-C′ with 50% acetonitrile/1% formic acid resulted in the release 
of a host of small molecules with masses between 200 and 300 Da (Figure 5.12), some of which 
could be assigned to polyethylene glycol (PEG) or plasticizers, which are common contaminants 
in biochemical laboratories. The Hyvönen group have also observed that AurA is very “sticky” and 




Figure 5.12 Native MS of partially denatured AurA-B′ in 50% 200 mM NH4OAc: 49% acetonitrile: 1% formic 
acid. Both folded and unfolded forms of AurA-B′ could be seen. Inset: expansion of region between 200 to 
400 m/z. The small molecules observed were assigned as follows: 239 (PEG [A5B+H]+), 261 (PEG [A5B+Na]+), 
283 (PEG [A6B+H]+) and 299 (unknown). 
Because both AurA and TPX27–43 are large relative to the small molecule impurities, the disruption 
of the AurA-TPX27–43 complex by small molecules should be obvious in native MS regardless of 
whether or not impurities were also bound to AurA or TPX27–43. Hence, no further efforts were 
made to isolate and characterize the impurities or to further purify the proteins. 
5.2.3. Screening AurA inhibitors by native MS 
The in-house and commercial inhibitors were tested against AurA by native MS. The spectra 
showed that these inhibitors could bind with the various AurA mutants, however, spectra were 
complicated by the presence of the small-molecule impurity and therefore protein-ligand peaks 
could not be assigned with certainty (data not shown). We therefore turned to the more 
important issue of whether or not native MS could be used to monitor the disruption of the AurA-
TPX2 protein-protein interaction by small molecules. At the onset of this study, only a few 
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examples of screening protein-protein interaction disrupters by native MS had been reported in 
the literature.[218] 
Native MS spectra for AurA-C′ and TPX27–43 were obtained in the absence or presence of the 
classical Type 1 kinase inhibitor, JNJ7706621 (IC50 = 11 nM[210]), or our in-house AurA-TPX2 
disrupter, JF218 (KD = 0.79 µM as determined by ITC) (Figure 5.13). The results showed that 
JNJ7706621 was unable to disrupt the AurA-C′-TPX27–43 complex as expected. Instead, a ternary 
AurA-C′·TPX27–43·JNJ7706621 complex was observed, which could presumably form by the 
inhibitor binding to the active site of AurA which is unoccluded in the AurA-TPX2 complex. In 
contrast, JF218 greatly diminished the intensity of the signals belonging to the AurA-C′·TPX27–43 
complex, while signals for free AurA-C′ appeared. This suggests that JF218 was able to disrupt 
the AurA-C′·TPX27–43 complex in solution by binding to the TPX2 site of the kinase, thereby 
displacing TPX2 and generating free AurA species that could be detected in the gas-phase. The 
native MS data is consistent with the results determined in a fluorescence polarization assay and 




Figure 5.13 Native MS of AurA-C′ (6 µM), TPX27–43 (6 µM) in the absence (lower panel) or presence of 
JNJ7706621 (30 µM) (middle panel) or JF218 (30 µM) (upper panel) in 200 mM NH4OAc containing 5% 
DMSO. 
Subsequently, a panel of in-house allosteric inhibitors with various affinities for AurA were tested 
for their ability to disrupt the AurA-TPX2 interaction by native MS (Figure 5.14). Gratifyingly, the 
order of disruption of the AurA-B′-TPX7– 43 complex in native MS followed the order of binding 
affinities of the molecules to AurA. The weakest AurA ligand, JF025 (KD = 537 µM) barely showed 
any disruption of the protein-protein interaction in native MS, while for the strongest ligand 




Figure 5.13 Native MS of AurA-B′ (10 µM), TPX27–43 (20 µM) in the absence or presence of JF218, JF004 
and JF025 (top to bottom) in 200 mM NH4OAc containing 1% DMSO. 
Since it had not been possible to detect the binding of TPX2 mutants to AurA by native MS, an 
alternative method was investigated to destabilize the AurA-TPX2 interaction to see if weaker 
ligands could be tested as protein-protein interaction disruptors by native MS. The collision 
energy within the trap and transfer regions of the mass spectrometer was raised in order to 
destabilize the AurA-B′-TPX7–43 complex in the gas phase. However, this did not significantly 
change the ease at which the ligands dissociated the AurA-TPX2 complex (Figure 5.14). This result 
can be explained by the reasoning that disruption of the AurA-TPX2 complex by small-molecule 




Figure 5.14 The proportion of AurA-B′ that is bound by TPX-2 as a function of total trap and transfer 
voltage in the absence of presence of 100 µM of JF218, JF004 or JF025.  
5.2.4. Summary 
The expression of AurA was generally low-yielding due to the toxicity of most AurA variants to E. 
coli, despite several modifications to the procedure to improve yield. Moreover, isolating AurA 
in a homogeneous form proved to be difficult due to the propensity of AurA to phosphorylate 
itself. Replacing ATP in the buffer with ADP reduced but did not eliminate autophosphorylation, 
owing to the presence of contaminating ATP in the ADP stock solutions. Additionally, it was 
discovered that reducing agent needed to be added to the NH4OAc solution after buffer exchange 
in order to prevent covalent association of AurA or TPX2 via disulfide bridge formation. 
The native MS experiments provided important validation of the mechanism of action of the 
group’s in-house AurA inhibitors. The results indicated that these inhibitors could disrupt the 
AurA-TPX2 complex, producing free AurA species that could be detected in the gas phase. 
Significantly, the rank order of binding affinities of AurA inhibitors determined by ITC was in 
agreement with the degree of disruption of the AurA-TPX2 interaction as observed by native MS. 
As expected, ATP-competitive inhibitors did not disrupt the AurA-TPX2 complex in native MS. 
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Future work might involve the use of IM-MS (with or without CIU) to investigate the effect that 
different kinds of inhibitors have on AurA conformation and stability against unfolding. 
5.3. Experimental 
5.3.1. Materials and methods 
All chemicals were of reagent grade quality or better, obtained from commercial suppliers and 
used without further purification. JF218, JF004 and JF025 were synthesized by group member Dr 
Jamy Feng and their binding affinities were measured using ITC by Abell group members. 
Plasmids, AurA-D and TPX2 mutants (M3 and M6) were provided by the Hyvönen group.  
5.3.2. Protein expression and purification 
5.3.2.1. Aurora A protein and expression and purification 
In this project, AurA-A and AurA-B were expressed in E. coli BL21(DE3) cells transformed with 
the expression vector (pHAT4) carrying the AurA gene and the ampicillin resistance gene using 
standard molecular biology techniques. The AurA-C plasmid contained an additional kanamycin 
resistance gene. Cells scraped from a fresh transformation were incubated in 2×YT medium 
containing 100 µg/mL ampicillin (for AurA-C, the medium also contained 50 μg/mL kanamycin) 
until OD600 of approximately 0.4–0.5 was reached. Cells were incubated at 4 °C for 30 min and 
then at 22 °C for 30 min. A second dose of ampicillin (50 µg/mL) was added before expression 
was induced with 100 µM IPTG. Cells were incubated at 37 °C for 3 h. The bacteria were harvested 
by centrifugation (4000 g, 20 min), washed with 50 mM Hepes pH 7.4, 500 mM NaCl, and then 
centrifuged again (4000 g, 20 min). The pellet was resuspended in lysis buffer containing 50 mM 
Hepes pH 7.4, 1 M NaCl, 100 mM Mg(OAc)2, 1mM ATP, 25 mM imidazole, one tablet of protease 
inhibitors (cOmplete Protease Inhibitor Cocktails, Roche), 500 µL of 2 mg/mL DNase I per 50 mL 
lysate. Cells were lyzed by sonication using 10 s pulses of 50% amplitude at intervals of 30 s each 
with a total sonication time of 3.5 min. The lysate was centrifuged at 30 000 g for 30 min at 4 °C, 
then clarified by filtration through a 0.45 μM syringe filter.  
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For nickel-affinity chromatography, the clarified lysate was loaded onto a gravity flow column 
containing 5 mL Ni Sepharose High Performance (GE Healthcare). The column was washed with 
50 mM Hepes pH 7.4, 500 mM NaCl, 100 mM Mg(OAc)2, 1 mM ATP, 40 mM imidazole, 5 mM β-
mercaptoethanol, then eluted with 50 mM Hepes pH 7.4, 500 mM NaCl, 100 mM Mg(OAc)2, 1 
mM ATP, 600 mM imidazole, 5 mM β-mercaptoethanol. Elution was monitored by SDS-PAGE 
analysis. Fractions containing AurA were pooled and concentrated using a Vivaspin 20 centrifugal 
concentrator with a 10 kDa molecular weight cut-off before being subjected to gel filtration using 
a Superdex75 16/60 column (GE Healthcare) previously equilibrated with 50 mM Hepes pH 7.4, 
50 mM NaCl, 100 mM Mg(OAc)2, 1 mM ATP, 5 mM β-mercaptoethanol. Gel filtration was 
performed at a flow rate of 1 mL/min and elution was again monitored at A280 and by SDS-PAGE 
analysis. Fractions containing purified AurA were pooled and concentrated as before.  
To cleave the N-His6 tag (for AurA-B and AurA-C), ProTEV (10 U per 100 μg of AurA) (Promega) 
was added in 1× ProTEV buffer (Promega) containing 1 mM DTT and the mixture was incubated 
at 4 °C overnight. The cleavage reaction was monitored by SDS-PAGE analysis. After completion 
of reaction, the solution was passed through a nickel column as before and elution was 
monitored by SDS-PAGE analysis (the cleaved AurA is eluted in the low-imidazole wash). Fractions 
containing cleaved AurA were pooled and concentrated before being subjected to gel filtration 
purification as before. Aliquots of the concentrated protein were flash-frozen in liquid N2 and 
stored at –80 °C.  
5.3.2.2. TPX2 protein and expression and purification 
TPX27–43 was expressed in this project as a GB1 fusion protein in E. coli BL21(DE3) cells 
transformed with the expression vector carrying the TPX2 fusion gene and the ampicillin 
resistance gene using standard molecular biology techniques. Cells scraped from a fresh 
transformation were incubated in LB medium containing 100 µg/mL ampicillin until OD600 of 
approximately 0.4–0.5 was reached. Expression was induced with 400 µM IPTG, and cells were 
incubated at 20 °C overnight. The bacteria were harvested by centrifugation (4000 g, 20 min), 
washed with 50 mM Tris-HCl pH 8.0, 150 mM NaCl, and then centrifuged again (4000 g, 20 min). 
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The pellet was resuspended in lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 
mM Mg(OAc)2, one tablet of protease inhibitors (cOmplete Protease Inhibitor Cocktails, Roche), 
500 µl of 2 mg/mL DNase I per 50 mL lysate. Cells were lyzed by sonication using 10 s pulses of 
50% amplitude at intervals of 30 s each with a total sonication time of 3.5 min. The lysate was 
centrifuged at 30 000 g for 30 min at 4 °C, then clarified by filtration through a 0.45 μM syringe 
filter.  
For nickel-affinity chromatography, the clarified lysate was loaded onto a gravity flow column 
containing 5 mL Ni Sepharose High Performance (GE Healthcare). The column was washed with 
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 20 mM imidazole, 5 mM β-mercaptoethanol, then eluted 
with 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 500 mM imidazole, 5 mM β-mercaptoethanol. Elution 
was monitored by SDS-PAGE analysis. Fractions containing the TPX2 fusion protein were pooled 
and concentrated using a Vivaspin 20 centrifugal concentrator with a 10 kDa molecular weight 
cut-off before being subjected to gel filtration using a Superdex75 16/60 column (GE Healthcare) 
previously equilibrated with 50 mM Hepes pH 7.4, 50 mM NaCl, 1 mM β-mercaptoethanol. Gel 
filtration was performed at a flow rate of 1 mL/min and elution was again monitored at A280 and 
by SDS-PAGE analysis. Fractions containing purified TPX2 fusion protein were pooled and 
concentrated as before.  
To cleave the GB1 tag, ProTEV (2U per 100 μg of TPX2 fusion protein) (Promega) was added in 1× 
ProTEV buffer (Promega) containing 1 mM DTT and the mixture was incubated at 4 °C overnight. 
The cleavage reaction was monitored by SDS-PAGE analysis. After completion of reaction, the 
solution was passed through a 10 kDa MWCO filter and the filtrate was aliquoted, flash-frozen in 
liquid N2 and stored at –80 °C.  
5.3.3. Mass spectrometry 
Native nanoelectrospray ionization-ion mobility-mass spectrometry (nESI-IM-MS) spectra were 
recorded on a Synapt HDMS mass spectrometer (Waters, Manchester, UK) modified for studying 
high masses (32k quadrupole) and equipped with a traveling wave (TW) IM cell. AurA was 
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exchanged into 200 mM NH4OAc (pH 7.0) using Micro Bio-Spin 6 chromatography columns (Bio-
Rad, UK). 1 mM β-mercaptoethanol was sometimes added to prevent protein dimerization. 2.5 
μL of protein solution was injected into a gold-coated borosilicate emitter (Thermo Scientific, UK) 
for sampling. Typical conditions were capillary voltage 1.5 kV, cone voltage 50 V, trap collision 
voltage 20 V, trap DC bias 35 V, transfer collision voltage 20 V, source temperature 20 °C, backing 
pressure 3–4 mbar, trap pressure 3–4 × 10–2 mbar, IM (N2) pressure 5–6 × 10–1 mbar and TOF 
pressure 7–8 × 10–7 mbar. All mass spectra were calibrated externally with cesium iodide (10 
mg/mL). Data acquisition and processing were performed using MassLynx 4.1 (Waters) and 
DriftScope 2.5 (Waters). 
High-resolution liquid chromatography mass spectrometry (LC-MS) was performed on a Xevo G2-
S Q-TOF UPLC instrument (Waters) coupled to an Acquity UPLC system. Samples were eluted 
through an Acquity UPLC BEH300 C4 column (1.7 μm, 2.1 × 50 mm) using a gradient of 95% 
Solvent A for 5.21 min, 100% Solvent B for 1 min, and 100% Solvent A for 1 min, where Solvent A 
= H2O with 0.1% formic acid and Solvent B = 95% MeCN/5% H2O containing 0.01% formic acid. A 
flow rate of 0.2 mL min−1 was used and the total run time was 7.29 minutes. The electrospray 
source was operated with a capillary voltage of 2.0 kV and a cone voltage of 40 V. Nitrogen was 
used as the desolvation gas at a total flow of 850 L h−1. Data acquisition and processing was 
performed using MassLynx 4.1 (Waters) with deconvoluted mass spectra reconstructed from the 









6. Conclusions and outlook 
At the onset of this project, native mass spectrometry was still an emergent technique in 
fragment-based drug discovery, and indeed only a handful of studies on the use of native MS for 
any type of ligand screening had been reported up to that time. Few researchers had employed 
native MS to investigate the disruption of protein-protein interactions by small molecules, and 
none had used this technique for the investigation of protein-DNA inhibition. Mass spectrometry 
also did not feature in our own group’s well-established biophysical cascade for fragment 
screening. 
Native MS has now gained increasing acceptance in drug discovery because of the orthogonal 
information that it can provide regarding biomolecular structure and conformation, although it 
is still far from mainstream use. One limitation that has historically hindered the wider adoption 
of native MS for drug screening is its low throughput. Without automation capability, a typical 
native MS experiment in this project required (after optimization) about 10 min to carry out, from 
sample loading to the acquisition of a suitable spectrum. An early study (2012) in the literature 
used the Advion Triversa NanoMate, a microfluidic chip-based sample injection and liquid 
handling robot, to screen a ligand library at a rate of about 1.5 min per sample.[63] Today, 
ultrahigh-throughput workflows have been developed that can analyze multiple samples per 
second, such as the SCIEX ECHO MS System employing acoustic ejection mass spectrometry 
(AEMS)[219] or AstraZeneca’s acoustic mist ionisation mass spectrometry (AMI-MS) platform.[220] 
However, these setups are expensive and would likely only be of interest to pharmaceutical 
companies or large academic groups dedicated to drug discovery. The use of automated 
platforms for fragment screening also requires that the protein target is well-characterized, 
homogenous, and robust. 
This project was the first to use native MS to screen ligands against a protein-DNA interaction 
(EthR-DNA), and also confirmed the applicability of native MS to investigate inhibition of a 
protein-protein interaction (AurA-TPX2). There are several advantages to screening ligands 
against a protein-DNA or a protein-protein complex rather than against the isolated protein 
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partners. Firstly, measuring the disruption of the complex means that the experiment is a 
functional assay rather than purely a binding one. Ligands may bind to a protein without 
disrupting its interactions with its partners, thus resulting in false positives if only the single 
protein target is screened. In this project, screening of fragments against the EthR-DNA complex 
by native MS identified hits with higher in vitro activity compared to differential scanning 
fluorimetry (DSF) screening against EthR alone. The second advantage is that the disruption of a 
biomolecular complex is nearly always unambiguous, whereas binding of a ligand to a single 
protein target can be complicated by heterogeneity of the protein sample, leading to poorly 
resolved and broad signals in the native mass spectrum that cannot be definitively assigned as 
protein-ligand peaks. This was observed in this project where AurA was expressed in a mixture 
of unphosphorylated and phosphorylated states, as well as sometimes methionylated and 
demethionylated states as well. Additionally, both AurA and EthR samples that were expressed 
in this project often contained bound but unidentifiable small molecules even in their supposed 
apo states, further complicating the analysis of putative protein-ligand interactions. Finally, these 
issues are also exacerbated by the low molecular weight of fragments, as these produce only 
small m/z shifts upon binding, especially if the protein is large. However, there are also drawbacks 
to screening against a protein-protein or protein-DNA complex. Since quaternary interactions can 
be strong, the screened ligands must be sufficiently potent to disrupt the complex in solution for 
their activity to be detected by native MS. This issue is especially pronounced for fragments which 
generally have weak binding affinities due to their small sizes. To overcome this, the quaternary 
interactions within the complex can be weakened to make them easier to disrupt by fragments, 
such as through mutagenesis of key interface residues, or by using only a partial (but still 
functional) complex. The latter approach was successfully employed in this project where we 
screened fragments against the partial EthR4-DNAR31 complex rather than the full-length EthR6-
DNA62 complex. Finally, it should be noted that not all targets will have pharmacologically 
relevant protein-protein or protein-DNA interactions that can be screened against, and even for 




Another general consideration for fragment screening by native MS are the concentrations of 
protein and ligand employed. Since fragments are weakly binding (typically Kd > 100 μM), higher 
concentrations of ligand must be used to ensure that the binding event is detectable. In this 
project, fragments concentrations of up to 1 mM were used for screening. However, the use of 
high concentrations of ligand can introduce other concerns. First, since ligands are typically 
dissolved as stock solutions in DMSO, using high ligand concentrations would necessarily increase 
the DMSO content in the final sample as well. For example, adding a compound to a final 
concentration of 1 mM from a standard 100 mM stock solution would result in a 1% (v/v) DMSO 
solution, which is probably tolerated in most cases. However, for compounds that are only 
soluble up to 10 mM in DMSO, adding it at 1 mM would create a 10% (v/v) DMSO solution. As 
shown in this project, such high DMSO concentrations can have significant effects on the 
conformation and stability of proteins. Therefore, each protein target should be tested for 
stability and robustness in DMSO before screening with ligands is carried out. In this context, IM-
MS (including CIU) can be used to illuminate subtle differences in protein conformation and 
stability induced by DMSO that may not be detectable using solution techniques. Secondly, high 
concentrations of ligand can lead to non-specific binding that may complicate the interpretation 
of ligand binding results, notwithstanding the number of different approaches that have been 
proposed to allow for this. On the other hand, protein concentrations should be kept as low as 
possible (typically <10 μM) in order to prevent non-specific protein-protein interactions, but still 
high enough to maintain sufficient signal intensity. Again, the concentration of protein should be 
optimized for each target before embarking on a fragment screening campaign. 
Towards the future, there are several avenues along which this project could be pursued further. 
Our study has provided evidence that DMSO can modulate protein size and stability through the 
dual effect of shifting charge state distributions as well as acting at the level of individual charge 
states. However, the exact mechanisms by which DMSO achieves this are still unclear. More 
careful control of experimental parameters to ensure stringent reproducibility could allow peak 
widths to be analyzed for the degree of DMSO adduction under different activating conditions. 
Using smaller proteins (such as lysozyme or myoglobin) coupled with high-resolution mass 
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spectrometers (such as an Orbitrap) might even allow such adducts to be resolved down to the 
single-molecule level. This information could help in understanding the role that DMSO plays in 
the fine balance between evaporative cooling and collisional heating as the protein ions travel 
through the various stages of the mass spectrometer. Additionally, the use of mass spectrometry 
coupled with gas-phase circular dichroism or optical/infrared spectroscopy could allow the 
effects of DMSO on protein structure and stability to be studied from a different angle, 
complementing the ion mobility results. 
In the EthR study, several open lines of investigation could not be further explored due to time 
constraints. This study was notable because it provided evidence that six subunits of EthR bound 
to its operator DNA, instead of eight subunits as had been previously reported based on SPR. Our 
data also revealed significant heterogeneity in the nature of the complexes formed, which could 
account for why no X-ray crystal structure of the EthR-DNA complex has yet been reported. The 
ability to simultaneously resolve and characterize multiple complexes from a heterogeneous 
mixture is one of the most distinctive advantages of native MS over other bioanalytical 
techniques. As the exact binding mode of EthR to DNA was (and still is) unknown, preliminary 
experiments were conducted that aimed to narrow down the precise binding sites on DNA by 
using oligonucleotides of different length, and/or with specific base sequences scrambled. 
Although some initial progress was made on this front (e.g. the scrambling of some base 
sequences weakened EthR binding more than at other sequences), the campaign proved to be 
quite tedious due to the sheer number of different DNA lengths and sequences that could 
potentially be tested. IM-MS measurements were also performed that revealed CCS values of 
6687 and 8259 Å for the EthR4-DNA62 and EthR6-DNA62 complexes respectively. However, the 
relatively low resolution of this technique meant that these measurements were not too useful 
in deducing the arrangement of EthR subunits within the complex. It is envisioned that other 
techniques, such as cryo-electron microscopy or in silico molecular modeling, might be needed 
to further elucidate the structural characteristics of this interaction. Towards the end of this 
project, the discovery of an EthR analogue (termed “EthR2”) was reported in the literature as a 
potential anti-tubercular target.[221] I expressed and purified this protein in high yield from a 
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plasmid designed by our Biochemistry collaborators, and preliminary native MS results suggested 
that EthR2 bound to DNA as a mixture of dimers and tetramers. Just like EthR, no X-ray crystal 
structure of the EthR2-DNA complex has yet been reported, presumably due to this 
heterogeneity. It would be interesting to use native MS to further characterize this interaction, 
and to see whether fragments could be screened against this complex in similar fashion to what 
was achieved with EthR. 
On the CoA front, this study has demonstrated that the dimeric E. coli CoaB construct could be 
an effective surrogate for the native CoaBC dodecamer for ligand screening by native MS. In 
addition to what was described in this thesis, I also successfully recorded the native mass spectra 
for both M. tuberculosis and M. smegmatis CoaBC dodecamers after extensive optimization, 
providing clear evidence for their oligomeric status at a time when the X-ray crystal structure of 
these complexes had not yet been resolved to a sufficient degree.[222] CID experiments showed 
that the dissociation of these dodecamers followed the asymmetric charge partitioning pathway, 
with the M. tuberculosis CoaBC dodecamer (547 kDa) centered around the 59+ charge state 
dissociating into a “stripped” undecamer (502 kDa) centered around 34+ and a highly-charged 
monomer (46 kDa) centered around 25+. It would be worthwhile to further explore the 
interactions and stability of this large multiprotein complex under various conditions, including 
in the presence of natural substrates or small molecule inhibitors. 
Finally, there are several ways that the Aurora A project could be advanced further, 
notwithstanding the difficulties in obtaining homogeneous protein samples that were also free 
of contaminants. CIU could be employed to investigate the stability of different AurA mutants, as 
well as to distinguish between inhibitors with different mechanisms, similar to how CIU was 
previously used to profile Type I and Type II inhibitors of Abl kinase.[196] Preliminary results 
revealed minor differences in the CIU fingerprints of AurA mutants with dasatinib and alisertib 
(Type I inhibitors), imatinib (Type II inhibitor), or AurkinA and JF218 (TPX2 site binders). Statistical 
analysis (e.g. χ2 correlation) would be needed to quantify these smaller differences that are not 
immediately apparent by eye. Meanwhile, the screening of small molecules against the AurA-
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TPX2 protein-protein interaction could be investigated further. This study failed to sufficiently 
weaken the AurA-TPX2 interaction for fragment screening, but further testing of both AurA 
and/or TPX2 mutants may yield complexes that are weak enough to be disrupted by fragments. 
Overall, native MS deserves more attention in drug discovery workflows, including fragment-
based drug discovery. It provides a wealth of information (such as data on protein conformation, 
stability and stoichiometry) that are orthogonal to other biophysical techniques, and can also 
tackle, or least recognize, cases of protein heterogeneity that may not be detectable using other 
techniques. However, mass spectrometry systems capable of performing more advanced 
analyses (such as IM-MS) are still expensive and require specialized personnel. It is hopeful that 
in the future, continual advances in technology and engineering could drive miniaturization and 
automation of mass spectrometry to such an extent that benchtop mass spectrometers capable 
of diverse functions (e.g. automated ligand screening and/or recording of CIU fingerprints) could 
become routinely used by non-specialist groups. At the theoretical level, there is room for 
improvement in our knowledge of ionization mechanisms, as well as in our understanding of how 
closely gas-phase observations correlate with solution or in vivo conditions. Further demystifying 
the exact processes and events that occur between ionization and detection would be important 
for native MS to gain wider acceptance as an essential technique for drug discovery, similar to 
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